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Abstract 
 
Peroxisomes are dynamic and multifunctional organelles, which are essential 
for human health and development. They are remarkably diverse, with functions 
that vary significantly between cells and organisms, and can dramatically 
change their size, shape and dynamics in response to cellular cues. In the past 
few years, several studies have significantly increased our understanding of the 
basic principles that enable peroxisome biogenesis and degradation, as well as 
their pivotal role in cellular signalling and homeostasis. However, several of 
these processes are still poorly understood. In this thesis we initially studied the 
peroxisome targeting mechanism of a group of C-terminally anchored 
membrane proteins, known as tail-anchored (TA) proteins. In order to 
investigate the molecular signals that enable TA protein targeting to cellular 
organelles, we analysed the physicochemical properties of a cohort of TA 
proteins both in silico and in vivo, and show that a combination of 
transmembrane domain (TMD) hydrophobicity and C-terminal tail charge 
determines organelle-specific targeting. Focusing on peroxisomes, we 
demonstrate that a balance between TMD hydrophobicity and high positive tail 
charge directs TA proteins to this organelle, and enables binding to the 
peroxisomal chaperone PEX19. These results allowed us to create a 
bioinformatical tool to predict the targeting of uncharacterised TA proteins and 
further develop our understanding of the molecular mechanisms involved in the 
targeting of this protein group. From our initial TA protein screen, we identified 
the TA protein MIRO1 at peroxisomes and looked at its role in the regulation of 
peroxisome motility. We show that endogenous MIRO1 localises to 
mitochondria and peroxisomes, and that dual targeting depends on the C-
terminal tail. MIRO1 expression significantly increased peroxisome motility in 
several cell lines, and revealed a role for motility in peroxisome dynamics, by 
inducing organelle proliferation and elongation. These results reveal a new 
molecular complex at peroxisomes and provide us with a tool to further dissect 
the role of motility on peroxisome function.  
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1.1. Peroxisomes 
Peroxisomes are dynamic and multifunctional organelles present in virtually all 
eukaryotic cells. They were initially described by Rhodin in 1954 as spherical 
and oval microbodies (Rhodin, 1954) and later characterized and renamed by 
Christian de Duve and his group, who identified several enzymes responsible 
for hydrogen peroxide metabolism (Baudhuin et al., 1964; De Duve and 
Baudhuin, 1966). Peroxisomes are bound by a single membrane and are 
usually found as spherical or rod-like shapes (0.1 to 0.5 µm in diameter), but 
can also form elongated tubular structures and networks (Figure 1.1) (Schrader 
et al., 2000). Their number can range from just a few organelles in yeast cells to 
several hundred in mammalian hepatocytes (Yan et al., 2005).  
Peroxisomes are involved in numerous essential cellular processes, such as 
lipid and reactive oxygen species (ROS) metabolism (see below). 
Consequently, defects in genes coding for peroxisomal proteins lead to several 
peroxisomal disorders with varying degrees of severity (reviewed in Waterham 
et al., 2016). Although the severity of the pathology can in some cases be 
associated to defects in specific proteins, patients with different mutations in the 
same protein can present very different phenotypes. For example, mutations in 
PEX16, an essential protein for peroxisome biogenesis, tipically lead to the 
development of Zellwegger syndrome and premature death within the first year 
after birth. However, several patients with mutations in this protein have been 
recently identified which present milder phenotypes, surviving for several years 
(Ebberink et al., 2010).  
Patients born with peroxisomal disorders generally present mild to very severe 
neurodevelopmental defects, organ specific pathologies particularly affecting 
the liver and kidneys, as well as sight and hearing impairments (Berger et al., 
2016; Braverman et al., 2013; Waterham et al., 2016). Due to the genetic 
component of these disorders, to this date no cure has been identified for any of 
the peroxisome spectrum disorders. However, symptom management and 
controlled diets (particularly regarding the ingestion of lipids) have enabled 
improvements in the quality of life of these patients (Klouwer et a., 2015). 
Additionally, due to their roles in cellular metabolism and redox status, 
peroxisomal dysfunction contributes to aging, cancer and several 
17 
neurodegenerative disorders, such as Alzheimer’s and Parkinson’s disease 
(Fransen et al., 2013; Lizard et al., 2012; Titorenko and Terlecky, 2011). 
 
1.1.1. Peroxisomal functions 
Peroxisomes harbour a vast array of metabolic functions that vary according to 
species, cell type, developmental stage and environmental conditions (Hu et al., 
2012; Islinger et al., 2010; Pieuchot and Jedd, 2012; Smith and Aitchison, 
2013). In most organisms peroxisomes play an essential role in lipid and ROS 
metabolism (Smith and Aitchison, 2013). In mammals, peroxisomes are 
responsible for three key pathways in lipid metabolism: fatty acid α-oxidation,  
 
Figure 1.1 – Microscopic views of peroxisomes. (A-B) Electron micrographs 
of peroxisomes from regenerating rat liver. (A) Tubular peroxisome next to a 
lysosome (LYS) and in close association with the ER. Magnification: x85,000. 
(B) Regular spherical peroxisome with attached smaller one (arrows), and in 
close association with the ER. Magnification: x135,000. (C-D) Highly purified rat 
liver peroxisomes (Po) associating with taxol-stabilised microtubules (MT) from 
bovine brain (MT). Bars: 0.2 µm (C), 0.5 µm (D). (E-F) Human skin fibroblasts 
stained against PEX14 (peroxisomal marker) and Hoechst (DNA/nucleus). (E) 
Control fibroblast; (F) ΔPEX5 patient fibroblast with membrane ghosts. Scale 
bar 20 µm. ((A-B) from (Fahimi et al., 1993), (C-D) from (Schrader et al., 2003). 
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β-oxidation and ether phospholipid biosynthesis (Lodhi and Semenkovich, 
2014; Wanders et al., 2010).   These   processes   are   performed   in   close 
association with mitochondria and the ER, which are responsible for later steps 
in these pathways (Wanders et al., 2016). As a result of these and other 
peroxisomal metabolic functions, several types of reactive oxygen and nitrogen 
species (ROS/RNS) are produced (e.g. H2O2, O2• ̅  and NO•) (Bonekamp et al., 
2009; Fransen et al., 2012; Nordgren and Fransen, 2014). To balance out the 
production of ROS/RNS, and help maintain the cellular redox state, 
peroxisomes also possess several antioxidant enzymes, such as catalase, 
peroxiredoxin 5 and superoxide dismutase 1 (Antonenkov et al., 2010; Fransen 
et al., 2012). Additionally, mammalian peroxisomes are also responsible for 
other anabolic and catabolic reactions such as glyoxylate detoxification, purine 
catabolism, bile acid and docosahexaenoic acid synthesis, and amino acid 
degradation (Wanders and Waterham, 2006).  
Recently, peroxisomes have been identified as essential signalling platforms, 
playing key roles in antiviral signalling and ROS-dependent regulation of 
mTORC1 signalling (reviewed in Mast et al., 2015; Tripathi and Walker, 2016). 
In a breakthrough study, Dixit and colleagues reported the dual targeting of the 
mitochondrial antiviral signalling (MAVS) protein to peroxisomes and 
mitochondria, and its ability to induce different signalling cascades at each 
organelle in response to viral RNA recognition by RIG-I-like receptors (Dixit et 
al., 2010; Odendall et al., 2014). The peroxisomal targeting of MAVS was 
recently confirmed by other groups. However, the authors were unable to find 
any differences in the signalling cascades activated at each organelle (Bender 
et al., 2015). Additionally, the ataxia telangiectasia mutated (ATM) protein and 
the tuberous sclerosis complex (TSC) have been found at the peroxisomal 
membrane, where they can upregulate autophagy (and pexophagy) by 
repressing mTORC1 signalling, in response to increases in ROS (Zhang et al., 
2013, 2015b). Despite the novelty and potential impact of these studies on our 
understanding of peroxisome function, further studies will be needed to confirm 
these results, in particular due to the contradicting nature of some of the 
published data. For example, whereas the authors point to an increase in 
peroxisome degradation in response to ROS, other studies have shown the 
opposite effect, with the same stimulus leading to peroxisome proliferation 
(Delmaghani et al., 2015). Furthermore, the mechanism by which TSC proteins 
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and ATM are targeted to peroxisomes was poorly characterised and should be 
further investigated.   
 
1.1.2. Peroxisomal biogenesis 
Peroxisome formation and maintenance are dependent on a unique set of 
proteins known as peroxins (Just and Kunau, 2014). Several of these proteins 
are conserved from yeast to plants and mammals (Smith and Aitchison, 2013), 
and mutations in their genes lead to peroxisome biogenesis disorders, such as 
Zellweger syndrome (Waterham and Ebberink, 2012). Peroxins are involved in 
targeting, membrane insertion and import of peroxisomal proteins, membrane 
biogenesis and regulation of peroxisome proliferation. Mutation or deletion of a 
single peroxin can lead to the complete absence of peroxisomes (i.e. PEX3, 
PEX16 and PEX19) (Ghaedi et al., 2000; Honsho et al., 1998; Matsuzono et al., 
1999; Muntau et al., 2000), or to the formation of empty organelles known as 
membrane “ghosts” (e.g. PEX5, PEX6, PEX14) (Figure 1.1 F) (Dodt et al., 
1995; Fukuda et al., 1996; Shimozawa et al., 2004). 
 
1.1.2.1. Matrix protein import 
Peroxisomal matrix proteins are synthesised in the cytosol and transported to 
the organelle by the shuttling receptors PEX5 and PEX7 (Braverman et al., 
1998; Dodt and Gould, 1996; Otera et al., 1998), which recognize peroxisomal 
targeting signal 1 and 2 (PTS1/PTS2) sequences in matrix proteins (Rehling et 
al., 1996; Terlecky et al., 1995). These receptors and bound proteins are 
transported across the peroxisomal membrane by interacting with membrane 
peroxins (PEX14 and PEX13) to form import channels (Emmanouilidis et al., 
2016; Gould et al., 1996; Meinecke et al., 2016; Schliebs et al., 1999). 
Interestingly, these channels are capable of importing completely folded, co-
factor bound and even oligomeric proteins (Erdmann and Schliebs, 2005; Léon 
et al., 2006; McNew and Goodman, 1994). This characteristics enable the 
import of peroxisomal matrix proteins that lack PTS signals, by a process known 
as piggybacking (reviewed in Thoms, 2015). For example, the cytosolic protein 
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SOD1 lacks a PTS sequence, but by forming a hetero-oligomer with CCS 
(PTS1-bearing protein), it can be imported to peroxisomes. 
Following cargo release, PEX5 and PEX7 are recycled back to the cytosol for 
further rounds of import, via an ubiquitin-dependent pathway which relies on 
PEX2, PEX10 and PEX12 for receptor ubiquitination, and the AAA ATPases 
PEX1 and PEX6, in association with PEX26 for receptor export (reviewed in 
Francisco et al., 2014; Platta et al., 2016). 
 
1.1.2.2. Membrane protein import 
Peroxisome membrane proteins (PMPs) can be synthesised in the cytosol and 
inserted directly into peroxisomes, or travel to this organelle via the ER 
(reviewed in Giannopoulou et al 2016). These proteins contain one or more 
membrane peroxisome targeting signals (mPTS), formed by a PEX19 binding 
motif and a transmembrane domain (TMD) (Halbach et al., 2006; Jones et al., 
2001). PMPs are recognised and targeted to peroxisomes by the cytosolic 
chaperone PEX19, which maintains them in a stable and import competent 
conformation, and keeps them from aggregating (Fang et al., 2004; Shibata et 
al., 2004). The PMP-PEX19 complex docks at the peroxisomal membrane by 
interacting with PEX3 to insert newly formed proteins (Figure 1.4) (Fang et al., 
2004; Fujiki et al., 2006; Giannopoulou et al., 2016). An additional membrane 
protein, PEX16, has been shown to regulate the insertion of PEX3 into 
peroxisomal (and ER) membranes and might play a similar role for other PMPs 
(Kim and Mullen, 2013; Kim et al., 2006; Matsuzaki and Fujiki, 2008), but its 
functions in mammalian peroxisomes are still poorly understood. 
Interestingly, in mammalian cells both PEX3 and PEX16 have been shown to 
target peroxisomes either directly (Jones et al., 2004; Matsuzaki and Fujiki, 
2008), or indirectly via the ER (Kim et al., 2006; Toro et al., 2009). The latter 
pathway has been strongly associated with the de novo formation of 
peroxisomes from ER-derived pre-peroxisomal vesicles (see below). Several 
other PMPs have been detected in the ER in different organisms (reviewed in 
Mayerhofer, 2016), but the physiological role of this targeting is still poorly 
understood. 
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1.1.2.3. Theories of peroxisome biogenesis 
In comparison to other organelles, the mechanism of peroxisome biogenesis is 
still a matter of debate, confronting a classical view of peroxisome generation by 
growth and division and the more recent de novo formation from the ER. In 
brief, according to the growth and division model, peroxisomes form by 
importing newly synthesized proteins from the cytosol and lipids from other 
organelles such as the ER and lipid droplets, in a multistep pathway that leads 
to their elongation, constriction and fission (Figure 1.2) (Fujiki et al., 2014; 
Schrader et al., 2016). In contrast, the de novo synthesis model states that 
several peroxins, in particular PEX3 and PEX16, are initially inserted in the ER, 
and subsequently segregate to specialized ER exit sites, leading to the 
formation of pre-peroxisomal vesicles (Agrawal and Subramani, 2013; Dimitrov 
et al., 2013). These vesicles have been suggested to i) mature into functional 
peroxisomes, ii) fuse into pre-existing peroxisomes, and iii) fuse with other pre-
peroxisomal vesicles to form mature peroxisomes (Agrawal et al., 2011; Kim et 
al., 2006; Toro et al., 2009; van der Zand et al., 2012).  
Despite the lack of evidence for peroxisome (or pre-peroxisomal) membrane 
fusion, several groups have been able to show that PEX3, an essential protein 
for peroxisome biogenesis, is targeted to the ER. Understanding the role of this 
protein in the ER should further help us comprehend peroxisome formation and 
establish a clear model for organelle biogenesis. Furthermore, understanding 
how peroxisomes receive lipids for membrane formation (vesicles and/or 
membrane tethering) should further clarify the events leading to their formation. 
In view of this, a combined model where both pathways operate simultaneously 
serving complementary purposes, with different contributions depending on the 
cellular state and organism, is the most current view of peroxisome biogenesis 
(Agrawal and Subramani, 2016; Hettema et al., 2014; Hua and Kim, 2016). 
 
1.1.3. Peroxisome dynamics 
Peroxisomes respond to fluctuations in the cellular nutritional and environmental 
states by changing their number, position, morphology and function (Figure 1.2) 
(Kaur and Hu, 2009; Schrader et al., 2012b). To do so, several signalling 
pathways are activated which fine tune the expression of specific peroxisomal 
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proteins or that activate/inhibit peroxisome associated proteins (Mast et al., 
2015; Schrader et al., 2012b, 2016). 
 
1.1.3.1. Proliferation 
In mammalian cells, peroxisome proliferation can be upregulated by several 
nutritional and environmental cues, such as increases in free fatty acids and 
growth factors, hypoxia and cold exposure (Figure 1.2)  (Bagattin et al., 2010; 
Delmaghani et al., 2015; Laurenti et al., 2011; Schrader et al., 1998a). These 
stimuli induce an increase in the number and size of peroxisomes, and 
alterations in the expression of several peroxisomal proteins, in order to 
increase their metabolic activity (Bagattin et al., 2010; Diano et al., 2011; 
Gurvitz and Rottensteiner, 2006). Potentially, an increase in peroxisome 
number/size could also facilitate interactions with other organelles by increasing 
the available surface area and facilitate metabolism. 
The most studied pathway of peroxisome proliferation in mammals is mediated 
by a family of ligand-activated transcription factors known as peroxisome 
proliferator activated receptors (PPARs) (Rakhshandehroo et al., 2010; 
Schrader et al., 2012b; Wang, 2010). These transcription factors are typically 
activated by lipid-ligands and regulate the expression of genes associated with 
lipid metabolism and adipocyte differentiation (Kliewer et al., 1992; Reddy et al., 
1986). Additional pathways independent of PPARs have also been described 
and it is likely that yet unknown mechanisms contribute to the regulation of 
peroxisome proliferation (Gondcaille et al., 2005; Li and Gould, 2002; Sexton et 
al., 2010). 
 
1.1.3.2. Division 
Peroxisome division allows cells to balance the formation of new peroxisomes 
with the degradation of damaged or excessive organelles. Peroxisomes divide 
in a multistep process that involves membrane elongation, constriction and final 
membrane fission to form new organelles (Figure 1.2) (reviewed in Honsho et 
al., 2016; Schrader et al., 2016). Interestingly, several of the proteins involved in 
peroxisomal division are also targeted to mi tochondria and regulate  
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Figure 1.2 – Model of peroxisome dynamics and interactions in 
mammalian cells. Intra- and extracellular signals such as free fatty acids, 
growth factors and ROS can induce peroxisomal proliferation by activating 
and/or inducing the nuclear targeting of transcription factors. For example, free 
fatty acids induce targeting of PPARs and their binding partner retinoid-X-
receptor (RXR) to the nucleus, where they bind peroxisome proliferator 
response elements (PPRE). These elements are present on peroxisomal genes 
encoding proteins involved in β-oxidation and peroxisome proliferation. New 
peroxisomes form by growth and division in a multi-step pathway that starts with 
the import of membrane lipids, likely from the ER and lipid droplets, and newly 
synthesized proteins from the cytosol and the ER (presumably by vesicular 
transport). Peroxisome membrane elongation and remodelling is regulated by 
PEX11 proteins, in particular PEX11β. Following elongation, membranes are 
constricted by a mechanism still unknown, and divide in a process mediated by 
DLP1, FIS1 and MFF, and likely regulated by GDAP1. In order to maintain a 
homogenous population, peroxisomes move through the microtubule 
cytoskeleton, and excess peroxisomes (or damaged) are removed by 
macropexophagy. Other pathways such as 15-LOX-mediated autolysis and 
LON-protease mediated degradation of matrix proteins have also been 
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described. Peroxisomes share close functional relationship with mitochondria 
and the ER, but have also been shown to interact with lipid droplets, lysosomes 
and other peroxisomes (Schrader et al., 2015b). Recently, a vesicular 
mitochondria-to-peroxisome trafficking route has been described, but the role of 
these mitochondria-derived vesicles (MDVs) in peroxisome function remains 
unknown. Adapted from (Islinger et al., 2012b). 
 
mitochondrial division (Figure 1.3) (Gandre-Babbe and van der Bliek, 2008; 
Huber et al., 2013; Koch et al., 2003, 2005). 
Peroxisome elongation is regulated by the Pex11 family of proteins across 
several species (Koch et al., 2010; Williams and van der Klei, 2014), with three 
proteins present in mammals: PEX11α, PEX11β and PEX11γ (Schrader et al., 
1998b; Tanaka et al., 2003). The best characterised of these, PEX11β, has 
been shown to induce membrane deformation due to its strong affinity to 
membrane lipids (Itoyama et al., 2012; Schrader et al., 2012a) and its N-
terminal amphipathic helix (Opaliński et al., 2011; Yoshida et al., 2015). 
Additionally, PEX11β dimerization might contribute to maintain membrane 
tubulation by creating a stable curvature, similarly to BAR domain proteins 
(Daumke et al., 2014), and play a role in membrane constriction (Yoshida et al., 
2015).  
Peroxisomal fission is mediated by the dynamin-like protein DLP1, a large 
cytosolic GTPase which forms oligomeric helixes around constriction sites and 
induces fission (Bui and Shaw, 2013; Li and Gould, 2003; Mears et al., 2011). 
DLP1 is recruited to peroxisomes by the tail-anchored (TA) proteins FIS1 and 
MFF, which facilitate oligomerisation of DLP1 (Otera et al., 2010; Yoon et al., 
2003). Recently, the mitochondrial TA protein GDAP1 has also been shown to 
dually target peroxisomes and mitochondria, and to regulate organelle division 
(Huber et al., 2013). Interestingly, PEX11β interacts with FIS1 and MFF on the 
membrane (Kobayashi et al., 2007; Koch and Brocard, 2012), and is able to 
activate DLP1 due to its GTPase activating protein (GAP) activity (Williams et 
al., 2015). 
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Figure 1.3 – Schematic view of peroxisomal and mitochondrial 
cooperation and cross-talk. Peroxisomes (left) and mitochondria (right) in 
mammals share several functions such as fatty acid β-oxidation (β-Ox), ROS 
metabolism and heat production. As a result, altered homeostasis in either 
organelle affects the other. Peroxisome and mitochondria share several 
proteins of their division machinery (e.g., DLP1, MFF, FIS1, GDAP1), as well as 
MAVS, a protein required for antiviral signalling. Furthermore, a novel trafficking 
pathways from mitochondria to peroxisomes (and lysosomes) involving 
mitochondria-derived vesicles (MDVs) has been reported. Cat - catalase; 
VLCFA, LCFA, MCFA, very long-chain, long-chain and medium-chain fatty 
acids; RC, respiratory chain. From (Schrader et al., 2015a). 
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1.1.3.3. Degradation 
The major process for peroxisome degradation in mammalian cells is 
pexophagy, a form of autophagy that selectively targets peroxisomes (Figure 
1.2) (reviewed in Honsho et al., 2016; Nordgren et al., 2013). Additional 
mechanisms include LON-protease dependent degradation of matrix proteins 
and 15-lipoxygenase-mediated autolysis (Yokota et al., 2001, 2008).  
Pexophagy allows cells to remove excessive or damaged peroxisomes to 
maintain organelle homeostasis, and can be induced by cellular stresses such 
as altered redox state and hypoxia (Iwata et al., 2006; Walter et al., 2014; 
Zhang et al., 2015b). The majority of peroxisomes in mammalian cells are 
degraded by macropexophagy, a process in which a double membrane 
structure, the autophagosome, grows and engulfs the target peroxisome and 
delivers it to lysosomes for recycling (Iwata et al., 2006; Mizushima and 
Komatsu, 2011). Organelles tagged for degradation are recognised by specific 
autophagy adaptors that form a bridge between the organelle and the growing 
autophagosomal membrane (Behrends and Fulda, 2012). Two of these 
adaptors, NBR1 and p62, can recognize ubiquitinated proteins at the 
peroxisomal membrane, but their physiological targets are still unknown 
(Deosaran et al., 2013; Kim et al., 2008).  
Recently, two groups have reported the ubiquitination of PEX5 as a trigger for 
pexophagy. Nordgren and colleagues showed that by expressing an export-
incompetent version of PEX5 (EGFP-tagged), this protein became mono-
ubiquitinated at the membrane and triggered pexophagy (Nordgren et al., 
2015). The second group reported a role for ATM kinase in the phosphorylation 
of PEX5 in response to intracellular ROS. This phosphorylation induced the 
mono-ubiquitination of PEX5 (at a different residue from the previous group), 
and its recognition by p62, triggering pexophagy (Zhang et al., 2015b). 
However, further studies will be necessary to confirm these results, has other 
groups have shown that increases in intracellular ROS induce peroxisome 
proliferation instead of degradation (Delmaghani et al., 2015, Diano et al. 2011). 
Additionally, the TA protein ACBD5 has also been suggested to induce 
pexophagy in mammalian cells but its role is less well characterised (Nazarko et 
al., 2014). 
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1.1.3.4. Motility 
Eukaryotic cells strictly regulate the movement and distribution of their 
organelles in order to guarantee their optimal activity and inheritance during the 
cell cycle (Jongsma et al., 2015). Whereas in yeast and plant cells peroxisomes 
predominantly move along actin filaments by interacting with myosin motors 
(Fagarasanu et al., 2010; Sparkes and Gao, 2014), in mammalian cells they 
have been shown to move along microtubules via kinesin and dynein motors 
(Figure 1.1, 1.2) (Neuhaus et al., 2016; Schrader et al., 2003). 
In mammalian cells, two main populations of peroxisomes can be observed by 
live-cell imaging: the majority of peroxisomes (85-95%) exhibit slow oscillatory 
movement, whereas the remaining 5-15% display fast, directional, and 
microtubule-dependent movement (Bharti et al., 2011; Rapp et al., 1996; 
Schrader et al., 2000; Wiemer et al., 1997). This low percentage of directed 
movement appears to be sufficient to maintain a homogeneous peroxisomal 
distribution at minimum energy expenditure, as calculated using modelling 
approaches (Bonekamp et al., 2012).  
Earlier studies analysed peroxisome motility after treatment with several 
microtubule and actin depolymerising drugs such as nocodazole, vinblastine 
and cytochalasins (Huber et al., 1997; Schrader et al., 1996; Wiemer et al., 
1997). Whereas nocodazole and vinblastine completely abrogated fast and 
directed peroxisome motility, actin depolymerising drugs had no clear effects on 
this organelle. Interestingly, in cells treated with nocodazole, peroxisomes were 
still able to elongate, suggesting that peroxisome motility is not essential for 
organelle division (Schrader et al., 1996, 1998b). Additional treatments such as 
ATP and GTP depletion, or changes in the intracellular calcium pool, showed 
that long-range peroxisome movement is a regulated and energy dependent 
process (Huber et al., 1997). 
Peroxisomes move both towards and away from the cell centre, in a dynein and 
kinesin dependent manner (Dietrich et al., 2013; Kural et al., 2005; Schrader et 
al., 2003). Strikingly, little is known about the recruiting factors for these motors 
in mammalian cells. Recently, Bharti et al. proposed a new role for PEX14 in 
the regulation of peroxisome motility by binding directly to tubulin (Bharti et al., 
2011). The authors suggest that this interaction is necessary to regulate 
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peroxisome motility and that this protein anchors peroxisomes to microtubules. 
Similarly, Dietrich and co-workers propose an interaction between the AAA 
ATPase PEX1 and the unconventional kinesin KIFC3, which may function in the 
tethering of peroxisomes to microtubules (Dietrich et al., 2013). The authors 
also suggest that this minus-end directed motor might regulate or disrupt the 
activity of the dynein complex in peroxisome motility. Additional roles for 
peroxins in motility regulation have also been described in yeast, where PEX3 
and PEX19 interact with myosin motors (Chang et al., 2009; Otzen et al., 2012). 
So far, the correlation between peroxisome motility and function in mammalian 
cells remains elusive. Mammalian peroxisomes are generally homogeneously 
distributed in the cytosol, which might facilitate interaction with other organelles 
and distribution during the cell cylcle. However, peroxisomal disorder patients 
with larger and less abundant peroxisomes, present clustering of this organelle 
close to the nucleus (Nguyen et al., 2006). This suggestes a connection 
between peroxisome metabolism and/or biogenesis with organelle motility.  
 
1.1.4. Interactions with other organelles 
Peroxisomes exert their functions as part of an intracellular network that 
enables their communication with other organelles such as mitochondria, ER 
and lipid droplets (Schrader et al., 2013, 2015b; Shai et al., 2015). These 
connections can form through contact sites for protein-protein and lipid 
interactions, by exchange of vesicles between organelles (e.g. mitochondria 
derived vesicles), and through signalling pathways and metabolite diffusion 
(Ivashchenko et al., 2011; Neuspiel et al., 2008; Raychaudhuri and Prinz, 
2008).  
Peroxisomes share a particularly close connection with mitochondria, 
cooperating in β-oxidation and ROS degradation, coordinating the cellular 
antiviral responses, and sharing several membrane proteins (Figure 1.3) 
(reviewed in Schrader et al., 2015a). Interestingly, several of these proteins are 
TA proteins (e.g. FIS1, MFF, GDAP1 and MAVS) (Dixit et al., 2010; Gandre-
Babbe and van der Bliek, 2008; Huber et al., 2013; Koch et al., 2005) (see 1.2). 
As a result of this close interaction, homeostatic changes in either organelle can 
closely affect the other, and mutations in shared proteins are the foundation of a 
29 
new group of mitochondrial-peroxisomal disorders (Koch et al., 2016; López-
Erauskin et al., 2013; Schrader et al., 2014; Shamseldin et al., 2012; Waterham 
et al., 2007). 
 
1.2. Tail-anchored (TA) membrane proteins 
TA proteins are a heterogeneous group of integral membrane proteins found in 
all intracellular organelles which are characterised by their topology. TA proteins 
have a single hydrophobic TMD located near the C-terminus, that anchors them 
to the lipid bilayer, and a short C-terminal polar tail that protrudes into the 
organelle matrix (Borgese et al., 2003). The N-terminal part of the protein faces 
the cytosol and includes the functional domains, which can be involved in 
several functions such as vesicular trafficking, apoptosis, signal transduction 
and redox reactions (Borgese and Fasana, 2011). TA proteins are found across 
all three domains of life (Borgese and Righi, 2010), and several screening 
approaches have shown their abundance in animals, plants and fungi (Beilharz 
et al., 2003; Kalbfleisch et al., 2007; Kriechbaumer et al., 2009).  
Because of their structure, the TMD of TA proteins only emerges from the 
ribosome at the end of translation. As a result, TA proteins require post-
translational mechanisms for sorting and membrane insertion (Borgese and 
Fasana, 2011; Kutay et al., 1993). Additionally, TA proteins lack traditional 
signal sequences that allow the recognition and sorting by cytosolic 
chaperones. Instead, the physicochemical properties of their TMD, such as 
length and hydrophobicity, and the charge of flanking amino acids, appear to 
regulate targeting to each organelle (Beilharz et al., 2003; Borgese et al., 2007; 
Kuroda et al., 1998; Marty et al., 2014). Furthermore, some of these proteins 
are targeted to more than one organelle, raising the possibility of competitive 
binding pathways for TA proteins (Borgese and Fasana, 2011). 
 
1.2.1. Targeting and insertion of TA proteins  
Post-translational sorting and insertion of TA proteins to each organelle requires 
distinct mechanisms (Figure 1.4) (reviewed in Borgese and Fasana, 2011). 
Although some TA proteins have the ability to spontaneously integrate into the 
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ER and outer mitochondrial membrane (Brambillasca et al., 2005; Kemper et 
al., 2008; Setoguchi et al., 2006), most TA proteins are recognized by cytosolic 
chaperones and form complexes with membrane receptors.  
 
 
 
 
Figure 1.4 – Trafficking and membrane insertion of TA proteins. After 
translation, TA proteins are initially targeted to peroxisomes, mitochondria or the 
ER. Golgi and plasma membrane (PM) proteins are first inserted in the ER and 
reach their final destination by a vesicular pathway. ER TA proteins are targeted 
and inserted by the TRC pathway. The BAG6/TRC35/UBL4A sorting complex 
(not shown) delivers ER TA proteins to dimeric, ATP bound TRC40. TRC40 
interacts with WRB and CAML at the ER membrane, and releases its substrate 
after ATP hydrolysis. ATP binding recycles TRC40 back to the cytosol for 
another round of import. Peroxisomal TA proteins are bound by the cytosolic 
chaperone PEX19 and delivered to peroxisomes by its interaction with PEX3, in 
an ATP-independent manner (Yagita et al, 2013). 
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1.2.1.1. ER and the TRC/GET pathway 
Several pathways have been implicated in the targeting and insertion of ER TA 
proteins, including the SRP-mediated co-translational pathway and a 
HSC70/HSP40-mediated mechanism (Rabu et al., 2009). However, the majority 
of ER TA proteins appear to be sorted by the TMD-recognition complex (TRC) 
pathway in mammals, which has been extensively characterised for the past 
few years (Figure 1.4) (reviewed in Denic et al., 2013; Hegde and Keenan, 
2011). Numerous insights into this pathway have been obtained from the study 
of the homologous mechanism in yeast (GET pathway) where the crystal 
structure of several components has been characterised (Chartron et al., 2012). 
In this pathway, a TMD recognition complex composed by BAG6, UBL4A and 
TRC35 binds newly translated proteins at the ribosome and delivers them to the 
cytosolic ATPase TRC40 (yeast Get3) (Leznicki et al., 2010; Mariappan et al., 
2010; Stefanovic and Hegde, 2007). ER TA proteins are characterised by highly 
hydrophobic TMDs which enable their interaction with BAG6 and TRC40 
(Borgese et al., 2007; Brodsky, 2010). TRC40 forms homodimers that cycle 
between open and closed conformations, depending on their bound nucleotide. 
In its ATP-bound state, TRC40 acquires a closed conformation which enables 
the formation of a hydrophobic groove that interacts with substrate TMDs. 
(Favaloro et al., 2008; Mariappan et al., 2011; Mateja et al., 2009; Schuldiner et 
al., 2008; Stefanovic and Hegde, 2007). ATP hydrolysis appears to promote 
binding of TRC40 to the ER membrane receptors WRB and CAML, which tether 
and mediate the insertion of the TMD in the membrane (Vilardi and Lorenz, 
2011; Yamamoto and Sakisaka, 2012).  
Interestingly, the TMD recognition complex could be playing additional roles in 
the sorting of TA proteins, namely in the degradation of misfolded proteins or 
the sorting of TA proteins to other organelles by interacting with different 
chaperones (Hegde and Keenan, 2011; Kawahara et al., 2013).  
 
1.2.1.2. Mitochondria  
Despite the numerous mitochondrial TA proteins identified, their targeting and 
membrane insertion is still poorly understood (Borgese and Fasana, 2011). 
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Mitochondrial TA proteins have moderately hydrophobic TMDs in comparison 
with ER proteins, and are usually flanked by positive charges on one or both 
sides (Borgese et al., 2001, 2003; Horie et al., 2002).  
Due to the moderate hydrophobicity of their TMD, some mitochondrial proteins 
spontaneously translocate across membranes in vitro, in the absence of both 
cytosolic and membrane proteins (e.g. cytochrome b5) (Brambillasca et al., 
2005; Colombo et al., 2009; Kemper et al., 2008). Owing to their propensity to 
aggregate in the cytosol, it is unlikely that many proteins follow this pathway. 
However, no cytosolic chaperones have yet been shown to interact with and 
stabilise these proteins.   
A role for the translocase of the outer mitochondrial membrane (TOM) complex 
has been proposed for the membrane insertion of BCL2 and BAX (Bellot et al., 
2007; Motz et al., 2002). Conversely, insertion of BAK, BCL-XL and OMP25 is 
independent of this pathway (Setoguchi et al., 2006), suggesting that multiple 
pathways might be involved in the insertion of mitochondrial TA proteins. 
Lastly, a role for the membrane lipid composition has also been proposed both 
in yeast and mammals, with changes in ergosterol and cholesterol content, 
respectively, affecting the ability of some proteins to translocate the membrane 
(Brambillasca et al., 2005; Kemper et al., 2008; Krumpe et al., 2012). 
 
1.2.1.3. Peroxisomes and the PEX19 pathway 
Similarly to mitochondria, peroxisomal TA proteins possess moderately 
hydrophobic TMDs and have a positively charged C-terminal polar region (Chen 
et al., 2014a; Delille and Schrader, 2008; Yagita et al., 2013). However, studies 
on this system have been hampered by the lack of described peroxisomal TA 
proteins, and have focused mainly on PEX26 and its yeast counterpart Pex15, 
which are responsible for the anchoring of Pex1 and Pex6 to the peroxisomal 
membrane (Birschmann et al., 2003; Matsumoto et al., 2003). Whereas yeast 
Pex15 appears to be indirectly targeted to peroxisomes via the ER (Buentzel et 
al., 2015; Elgersma et al., 1997; Schuldiner et al., 2008; van der Zand et al., 
2010), human PEX26 follows a direct pathway relying on PEX19 and PEX3 for 
targeting and membrane insertion (Figure 1.4) (Buentzel et al., 2015; Halbach 
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et al., 2006; Yagita et al., 2013) (see 1.1.2.2). Two recent publications have 
further characterized this targeting by using semi-permeabilized cells (Yagita et 
al., 2013) and a cell-free system (Chen et al., 2014a), in human and 
Neurospora crassa cells, respectively. In both, PEX26 is bound and stabilized 
by PEX19, and delivered to the peroxisomal membrane where it forms a ternary 
complex with PEX3. This process is TRC40/GET3 independent in both 
systems. Furthermore, Chen and co-workers have also shed some light on the 
mechanistic functions of PEX19 and PEX3 in the filamentous fungus N. crassa, 
describing a new amphipathic domain in PEX19 that is required for TA protein 
TMD insertion, and a hydrophobic surface on PEX3 that is also required for the 
insertion of cargo protein TMDs (Chen et al., 2014a). Additionally, dually 
targeted TA proteins FIS1 and GDAP1 have also been shown to interact with 
PEX19 and are likely to follow the same direct pathway for peroxisomal 
insertion (Delille and Schrader, 2008; Huber et al., 2013). 
 
1.2.2. Mistargeting and degradation 
In addition to specific targeting pathways for TA proteins, new machinery has 
been described for the degradation of mistargeted proteins. Two pathways have 
recently been proposed, one for ER proteins and a second for mitochondrial 
proteins (Boname et al., 2014; Chen et al., 2014b; Okreglak and Walter, 2014). 
The signal peptide peptidase (SPP) protein is an aspartyl protease that cleaves 
the TMD of ER-resident proteins, releasing the cytosolic fragment of the 
substrate for proteasomal degradation (Golde et al., 2009; Loureiro et al., 
2006). This type of protease can only cleave ER proteins with cytosolic N-
terminal domains, such as TA proteins. By altering the availability of SPP, 
Boname and colleagues were able to show that HMOX1, CYTB5, RAMP4 and 
RAMP4-2 are specifically cleaved by this protein (Boname et al., 2014). An 
additional TA protein, UBE2J1, was not cleaved by SPP, pointing to the 
presence of multiple degradation pathways for ER TA proteins. 
A second pathway is mediated by the AAA ATPase ATAD1 (Msp1 in yeast), a 
membrane-bound protein which is dually targeted to mitochondria and 
peroxisomes (Chen et al., 2014b; Okreglak and Walter, 2014). In two 
concurrent publications, Msp1 was shown to bind Pex15 and promote its 
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degradation when mistargeted to mitochondria. This interaction was particularly 
evident when an ATPase mutant of Msp1 was expressed, which locked target 
proteins at the membrane and inhibited their turnover. Similar results were 
obtained with the human homolog ATAD1, suggesting that this function is 
conserved (Chen et al., 2014b). Additionally, Msp1/ATAD1 were also shown to 
bind and degrade mitochondrially mistargeted Gos1/GOS28 (homologous Golgi 
resident TA proteins) (Chen et al., 2014b). However, how these proteins are 
recognised and removed is still unknown. A possible pathway would be through 
the ubiquitination of residues that are otherwise shielded by interacting partners 
at the correct membrane. This ubiquitination would then allow the recognition of 
target proteins, similarly to the mechanism of p97 (Cdc48 in yeast) AAA 
ATPase (Stolz et al., 2011; Tanaka et al., 2010). Lastly, a role for these proteins 
on peroxisomes is still unknown, as no mistargeted TA proteins were analysed 
in this organelle. 
 
1.3. MIRO proteins 
Miro proteins are TA proteins localized on the outer mitochondrial membrane 
and highly conserved across eukaryotes (Reis et al., 2009; Vlahou et al., 2011). 
The human proteins, MIRO1 and MIRO2, have a similar structure and share 
60% similarity (Figure 1.5 A) (Fransson et al., 2003). Due to their structure and 
GTPase domain sequence, these proteins have been identified as a new family 
within the superfamily of small Ras GTPases (Reis et al., 2009; Wennerberg 
and Der, 2004). Unlike other Ras GTPases, Miro proteins are anchored to the 
membrane by a TMD instead of post-translational lipid moieties, and possess 
two GTPase domains, making these proteins significantly bigger than other 
members of this family (Wennerberg and Der, 2004). The first GTPase domain 
has sequence similarities to Rho GTPases, which lead to their original 
classification within the Rho family (Fransson et al., 2003), but the absence of 
an insert domain and a CAAX-motif (which are typical of Rho GTPases) lead to 
their re-classification as a distinct family. The second GTPase domain is only 
distantly related to the Ras superfamily (Klosowiak et al., 2013).  
Ras GTPases regulate several cellular processes such as cell proliferation, 
morphology and apoptosis (Goitre et al., 2014). These molecular switches  
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Figure 1.5 – Schematic representation of mammalian MIRO and the 
mitochondrial trafficking complex. (A) Structure of mammalian MIRO protein, 
with two GTPase domains flanking two calcium binding EF-hand motifs, and 
two “hidden” EF-motifs. (B) The TA proteins MIRO1 and MIRO2 enable 
mitochondrial motility by forming a motility complex. MIRO binds directly with 
Kinesin-1 (also known as kinesin heavy chain or KIF5) and TRAK1/TRAK2 to 
promote anterograde motility, and with dynein via the interaction of p150 with 
TRAK proteins. TRAK proteins interact and can be post-translationally modified 
by OGT. ((B) adapted from (Devine et al., 2016). 
 
change from on/off states depending on their binding to GTP/GDP, respectively. 
Additionally, Ras GTPases are strictly regulated by guanine nucleotide 
exchange factors (GEFs) and GTPase activating proteins (GAPs), which 
exchange GDP for GTP (GEF) or induce GTP hydrolysis (GAP). Despite Miro’s 
classification within this superfamily, little is known about its GTP hydrolysis 
activity and protein regulation. Thus far, a study on the yeast orthologue, Gem1, 
has shown that both GTPase domains are capable of GTP hydrolysis, and that 
this activity is not affected by the calcium binding capacity of the EF-hand motifs 
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(Koshiba et al., 2011). Furthermore, the Vibrio cholera protein VopE has been 
shown to interact with human MIRO1 and MIRO2, and increase the hydrolytic 
activity of the GTPase domains, switching the proteins to an off state due to its 
GAP activity (Suzuki et al., 2014). This inhibits mitochondrial clustering near the 
nucleus during bacterial infection and is proposed to inhibit MAVS-dependent 
signalling, delaying an immune response.  
 
1.3.1. Genes and functions 
As previously mentioned, Miro genes are conserved in almost all eukaryotic 
genomes (Vlahou et al., 2011), suggesting their presence in early eukaryotic 
evolution. Miro’s domain architecture is mostly conserved across species, with a 
few exceptions present in trypanosomatid flagellates and ciliates (Vlahou et al., 
2011), and it typically contains two GTPase domains separated by two calcium-
binding EF-hand motifs, and a C-terminal TMD and short tail. Two additional 
hidden EF-hand motifs were identified by structural analysis of the Drosophila 
orthologue dMiro (Figure 1.5 A) (Klosowiak et al., 2013), forming a pair with the 
canonical domains. Yet, these hidden motifs are unlikely to bind Ca2+ due their 
altered loop structure and lack of negatively charged residues. Miro proteins are 
targeted to mitochondria in all studied species and play roles in mitochondrial 
dynamics and homeostasis (reviewed in Yamaoka and Hara-Nishimura, 2014). 
However, specific functions have evolved for different organisms, adding layers 
of complexity to the understanding of the function of these proteins.  
 
1.3.1.1. Mitochondrial motility 
Human MIRO1 and MIRO2 were initially described by Fransson and colleagues 
as new Rho GTPases involved in mitochondrial homeostasis and apoptosis 
(Fransson et al., 2003). Expression of these proteins severely altered 
mitochondrial distribution in COS-7 cells, leading to several phenotypes such as 
mitochondrial elongation and collapse of the mitochondrial network, as well as 
an increase in cell death with the expression of mutated proteins (Fransson et 
al., 2003, 2006). Concurrently, studies on the Drosophila orthologue, dMiro, 
showed that the absence of this protein lead to mitochondrial accumulation in 
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neuronal cell bodies, whereas protein expression induced an accumulation of 
mitochondria in synapses, pointing to a role of dMiro in anterograde 
mitochondrial movement (Guo et al., 2005). Subsequent studies showed that 
the kinesin-interacting protein Milton forms a complex with dMiro, and that this 
complex is responsible for mitochondrial anterograde and retrograde transport 
in Drosophila (Glater et al., 2006).  
The homologous complex was later described in mammalian cells, where 
MIRO1 interacts with TRAK1 and TRAK2 (orthologues of Milton) and both 
kinesin and dynein motors (Figure 1.5 B) (Fransson et al., 2006; MacAskill et 
al., 2009b; Saotome et al., 2008; van Spronsen et al., 2013; Wang and 
Schwarz, 2009). Additionally, due to its calcium binding motifs, MIRO1 has 
been proposed to inhibit mitochondrial motility in active synapses, where 
glutamate signalling induces high intracellular calcium concentrations (MacAskill 
et al., 2009b; Wang and Schwarz, 2009), and to regulate mitochondrial Ca2+ 
storage in response to cytosolic fluctuations (Chang et al., 2011). In contrast, 
experiments performed using a MIRO1 knockout (KO) mouse model challenged 
the role of this protein in calcium sensing (Nguyen et al., 2014). In this study, 
the authors did not observe changes in mitochondrial calcium uptake between 
control and KO cells (unlike what had been proposed in (Chang et al., 2011)). 
Additionally, mitochondria motility in mouse embryonic fibroblasts (MEFs) and 
cortical neurons of wild-type (WT) and KO mice was similarly affected by 
changes in intracellular calcium, arguing against a role for this protein in 
calcium-dependent motility control. A similar result using WT and a calcium 
mutant of MIRO1 had been previously shown in cardiomyocytes (Saotome et 
al., 2008). Interestingly, Nguyen and colleagues also observed changes in the 
mitochondrial retrograde motility instead of the expected effects in anterograde 
motility. Whereas this is in conflict with evidence obtained from protein silencing 
and overexpression experiments, it should be noted that several studies have 
also shown a role for MIRO1 in retrograde movement (Morlino et al., 2014; 
Russo et al., 2009; van Spronsen et al., 2013).  
Interestingly, the regulation of mitochondrial motility by the MIRO1/TRAK 
complex is in contrast with the frequently suggested model of organelle motility 
– the tug-of-war. According to this model, membrane bound opposition motors 
push the organelle in both directions, with the resulting speed and direction 
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relaying on the strength and number of attached motors. In the absence of one 
motor, a shift towards the opposite direction should be observed (Hendricks et 
al., 2010). When considering the existing data on MIRO1-regulated motility, a 
more complex system emerges. Here, MIRO1 functions as a regulator of both 
plus and minus end directed motility in response to cellular cues such as 
calcium concentration and GTP/GDP availability. As both kinesin and dynein 
motors are part of the same complex, a system where different signals can 
activate/inhibit one or both motors should be considered (Hancock, 2014). 
Additionally, due to its role in mitochondrial motility, MIRO1 has been implicated 
in the transport of mitochondria via tunnelling nanotubes (Ahmad et al., 2014). 
Using both an in vitro model of rotenone-induce mitochondrial damage, and in 
vivo models of asthma and airway injury, Ahmad et al. showed that high levels 
of MIRO1 improve mitochondrial transfer from healthy mesenchymal stem cells 
to epithelial cells containing damaged mitochondria. This process lead to a 
decrease in epithelial cell apoptosis and decreased the inflammatory response 
to airway damage, suggesting that MIRO1 could be targeted for therapeutic 
approaches.  
 
1.3.1.2. Gem1 and mitochondrial dynamics 
Whereas mammalian MIRO proteins seem to play a key role in mitochondrial 
microtubule-dependent motility, a reciprocal function in yeast was not expected, 
as mitochondria move through the actin cytoskeleton in this organism (Boldogh 
and Pon, 2007). Initial studies on the yeast orthologue Gem1 revealed changes 
in the mitochondrial network in gem1Δ cells, with an increase in the number of 
cells presenting globular or collapsed tubular mitochondria (Frederick et al., 
2004). As these changes were not a result of defects in mitochondrial fission or 
fusion, Gem1 was proposed to regulate a new pathway in mitochondrial 
signalling and dynamics (Frederick et al., 2004). Double mutants of Gem1 and 
Mmr1, a yeast protein involved in mitochondrial inheritance, showed synthetic 
growth defects pointing to a possible role of Gem1 in mitochondrial inheritance 
(Frederick et al., 2008). In agreement with this, mutations in Gem1 GTPase 
domains strongly affected mitochondrial inheritance in budding yeast (Koshiba 
et al., 2011).  
39 
Recently, a role for Gem1 has been proposed in the regulation of the ER-
mitochondria tethering (ERMES) complex (Kornmann et al., 2009, 2011; Stroud 
et al., 2011). This structure has been suggested to regulate several processes 
such as mitochondrial division, inheritance, mitochondrial DNA replication and 
lipid transfer (Boldogh et al., 2004; Kornmann et al., 2011; Murley et al., 2013; 
Youngman et al., 2004). However, contradictory results suggest that Gem1 is 
not necessary for ERMES function and formation, and that this complex is not 
involved in lipid transfer nor mitochondrial inheritance (Nguyen et al., 2012).  
 
1.3.2. Interacting partners 
In order to regulate mitochondrial motility and function, MIRO1 and MIRO2 
interact with several other cytosolic and mitochondrial proteins, namely TRAK1 
and TRAK2 (Fransson et al., 2006), KIF5 (MacAskill et al., 2009b), Dynein 
complex (Morlino et al., 2014), PINK1 and PARKIN (Weihofen et al., 2009), 
MFN1 and MFN2 (Misko et al., 2010), HUMMR (Li et al., 2009), ARMC3 
(López-Doménech et al., 2012), VopE (Suzuki et al., 2014) and CENP-F 
(Kanfer et al., 2015). Some of these interactions have been well characterised 
and are described below. 
 
1.3.2.1. TRAK proteins and the motility complex 
As previously mentioned, TRAK1 and TRAK2, also known as OIP106 and 
GRIF-1/OIP98 respectively, form a complex with MIRO and motor proteins, 
enabling mitochondrial motility along microtubules (reviewed in Devine et al., 
2016). Both TRAK proteins were initially shown to interact directly with kinesin-1 
family proteins (KIF5A-C, also known as kinesin heavy chain (KHC)) (Brickley et 
al., 2005; Smith et al., 2006), and their overexpression in mammalian cells lead 
to similar phenotypes to that of MIRO proteins – elongated and collapsed 
mitochondrial networks in COS-7 cells, and reduced mitochondrial motility in 
cultured neurons (Brickley and Stephenson, 2011; Koutsopoulos et al., 2010; 
Wang and Schwarz, 2009). Their function is particularly well characterised in 
neuronal cells where these proteins appear to play complementary roles in 
axonal and dendritic mitochondrial motility (van Spronsen et al., 2013). TRAK1 
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is mostly axonal and interacts with both kinesin and dynein motors, whereas 
TRAK2 shows a more dendritic localisation and interacts preferentially with 
dynein motors. Both TRAK proteins also interact and are modified by the β O-
linked N-acetylglucosamine transferase (OGT) enzyme, which attaches 
monosaccharides to serine and threonine residues (Brickley et al., 2011; Iyer et 
al., 2003). Recently, Pekkurnaz et al. were able to show that OGT activity 
increases in response to higher glucose levels, leading to TRAK1 O-
glycosylation and consequent mitochondrial arrest, suggesting that neuronal 
mitochondrial motility is regulated in response to changes in nutrient availability 
(Pekkurnaz et al., 2014). 
The MIRO/TRAK complex also interacts with mitofusin 1 and 2 (MFN1/MFN2), 
two dynamin related GTPases that regulate mitochondrial fusion (Misko et al., 
2010). Although the function of this interaction is unknown, it should be noted 
that MFN2 has been shown to tether mitochondria to the ER (de Brito and 
Scorrano, 2008), and so, its interaction with MIRO could mimic the role of the 
ERMES complex in yeast. 
Lastly, some proteins have been shown to regulate mitochondrial motility by 
interacting with the MIRO-TRAK complex. For example, the hypoxia up-
regulated mitochondrial movement regulator (HUMMR) protein, which is up-
regulated by HIF-1α during hypoxic conditions, interacts with MIRO and TRAK 
proteins, increasing anterograde mitochondrial motility in neurons (Li et al., 
2009). Two other proteins, ALEX3 and ARMC10, interact with MIRO1-2, TRAK2 
and KIF5C and regulated mitochondrial motility in neurons (López-Doménech et 
al., 2012; Serrat et al., 2014). Despite the unknown function of these proteins, 
they belong to the Armcx family of proteins which is exclusive to Eutherian 
mammals, adding an extra layer of complexity to the regulation of mitochondrial 
motility in mammals. 
 
1.3.2.2. PINK1/PARKIN and mitochondrial degradation 
The PTEN-induced putative kinase (PINK1) and the ubiquitin ligase PARKIN 
are core regulators of the mitochondrial quality-control system, and are involved 
in the selective degradation of damaged mitochondria. PINK1 has been shown 
to phosphorylate PARKIN, recruiting it to the membrane of damaged 
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mitochondria, and increasing its ubiquitin ligase activity (Deas et al., 2011). Both 
PINK1 and PARKIN have been shown to interact with MIRO proteins (Wang et 
al., 2011; Weihofen et al., 2009). While PINK1 has been proposed to 
phosphorylate dMiro (Wang et al., 2011), ubiquitination by PARKIN appears to 
be more important for MIRO regulation, leading to its proteasomal degradation 
and consequent mitochondrial arrest (Birsa et al., 2014; Liu et al., 2012; Wang 
et al., 2011). This process may facilitate mitochondrial degradation by 
mitophagy by inhibiting mitochondrial motility and may be implicated in the 
pathology of familial Parkinson’s disease. 
 
1.3.2.3. CENP-F and cell cycle 
Recently, Kanfer et al. described a role for MIRO1 in mitochondrial distribution 
during the cell cycle (Kanfer et al., 2015). The authors show that MIRO1 
interacts with the centromeric protein F (CENP-F), a large microtubule binding 
protein which is recruited to mitochondria during cytokinesis, and that this 
interaction links mitochondria to microtubule growing tips, allowing their 
distribution to the cell periphery at the end of mitosis. How CENP-F drags 
mitochondria along growing microtubule tips is still unknown, but this interaction 
sheds some light on the regulation of mitochondrial distribution during the cell 
cycle. In another study, Lawrence and colleagues showed that disruption of 
MIRO1 and KIF5B using dominant negative mutants altered mitochondrial 
positioning during cytokinesis, pointing to a role for kinesin motors in this 
process (Lawrence et al., 2016). Further studies will be necessary to 
understand this process and to reveal the protein complexes responsible for 
mitochondrial distribution during the cell cycle.  
 
1.3.3. Miro and its role in disease 
Mitochondria play essential roles in energy production and calcium buffering. As 
a result, defects in their motility or in the maintenance of a healthy mitochondrial 
population are common hallmarks of several neurodegenerative disorders such 
as Alzheimer’s and Parkinson’s disease, amyotrophic lateral sclerosis (ALS) 
and spastic paraplegia (Mattson et al., 2008). Since MIRO proteins play an 
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essential role in mitochondrial motility and are involved in their ability to sense 
intracellular calcium shifts, defects in these proteins have been linked to ALS 
(Mórotz et al., 2012; Zhang et al., 2015a) and Parkinson’s disease (Liu et al., 
2012; Wang et al., 2011).  
Evidence of Miro’s role in neurodevelopment is particularly evident in animal 
models. Drosophila mutants expressing truncated versions of dMiro die 
prematurely and present movement defects during the larvae phase, with weak 
muscular capacity leading to paralysis (Guo et al., 2005). In neurons, 
mitochondria were shown to accumulate in the cell soma, and to be reduced or 
completely absent in axons and neuromuscular junctions, showing impaired 
anterograde mitochondrial transport. Curiously, mitochondria in these cells had 
no observable changes in structure and function (Guo et al., 2005). Absence of 
MIRO1 in mice is lethal at birth, as these animals are unable to breathe due to 
degeneration of specific motor neuron axons (Nguyen et al., 2014). Ex vivo 
analysis of neurons from these animals showed defects in retrograde axonal 
mitochondrial transport, without affecting respiratory and calcium buffering 
functions. A conditional KO mouse lacking neuronal MIRO1 was alive at birth 
but showed progressive symptoms of a motor neuron disorder similar to spastic 
paraplegia (Nguyen et al., 2014). Interestingly, the results from both animal 
models suggest that the pathology is caused by defects in mitochondrial motility 
(not function), and that this can be the primary cause of some neurological 
disorders.  
In line with these results, a link between MIRO and ALS has been recently 
proposed. Mórotz and colleagues have shown that expression of a mutated 
variant of VAPB (VAMP associated protein B), which is known to cause a 
familial form of ALS, alters mitochondrial anterograde motility by decreasing the 
ability of MIRO1 to interact with tubulin via kinesin motors (Mórotz et al., 2012). 
Additionally, analysis of patient and mouse model cells of ALS showed a 
significant reduction in MIRO1 expression (Zhang et al., 2015a). Interestingly, 
this reduction could also be induced by increasing glutamate levels both in vitro 
and in vivo, as glutamate toxicity is believed to strongly contribute to the 
pathology of ALS (Zhang et al., 2015a).  
 
43 
1.4. Objectives 
Peroxisomes play an essential role in human health and development. As such, 
the study of their functions, biogenesis and dynamics is essential to understand 
how cells and organisms work, and how to repair them in pathological 
conditions. 
This thesis aims to further develop our knowledge of the basic regulation of 
peroxisomes by addressing two main distinct points: how are tail-anchored 
proteins recognized and targeted to peroxisomes, and what’s the molecular 
machinery responsible for peroxisomal motility? 
In chapter 3, the targeting of TA proteins to peroxisomes is analysed. To do 
this, a bioinformatics approach was used to identify several physicochemical 
parameters that define the targeting signals of TA proteins. The two main 
factors identified, TMD hydrophobicity and tail charge, were then tested by 
mutating model TA proteins and analysing their localisation and ability to bind 
the peroxisomal chaperone PEX19. As a result, a bioinformatical tool was 
developed that allows us to predict the targeting of uncharacterised TA proteins 
and further develop our understanding of the molecular mechanisms involved in 
the targeting of this protein group. 
In chapter 4, the targeting and function of a specific TA protein, MIRO1, was 
characterised. To do so, the cellular localisation of MIRO1 was established 
using imaging and biochemical methods. As MIRO1 was identified on 
peroxisomes, its function at this organelle was investigated using several 
MIRO1 mutants, as well as live-cell imaging techniques coupled with a 
bioimaging analysis of whole cell motility data. As a result, MIRO1 was shown 
to regulate peroxisomal motility, allowing us to use it as a tool to further dissect 
the role of motility on peroxisome dynamics. Subsequently, we demonstrated 
that the application of a directed motor force may play a role in the formation of 
new peroxisomes.  
In chapter 5, the localisation and function of the MIRO1 interacting partner 
TRAK1 was briefly analysed. This was performed by expressing this protein in 
conjunction with MIRO1, and by analysing the effects of its mutation in a patient 
cell line. As a result, TRAK1 presented no clear effects on peroxisomes and 
appears to play specific roles in mitochondrial distribution.  
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2.1. Chemicals 
All chemicals were purchased from Sigma-Aldrich (St Louis, USA), GE 
Healthcare (Buckinghamshire, UK), Merck Millipore (Darmstadt, Germany), 
ThermoFisher Scientific (Waltham, USA), and Roche (Basel, Switzerland). 
Restriction enzymes and other cloning reagents were from New England 
Biolabs (Ipswich, USA). Cell culture medium and additives were from Gibco, as 
part of ThermoFisher Scientific (Waltham, USA). 
 
2.2. Buffers and solutions 
General buffers and solutions are present in table 2.1. All buffers and solutions 
used for cell culture were sterilised by autoclaving or filtration prior to use.  
 
Table 2.1 – Buffers and solutions 
Buffers and solutions Recipe 
Blocking solution for IMF 1% (w/v) BSA in PBS 
Blocking solution for WB 5% (w/v) low-fat milk powder in TBS-T 
Chloroquine solution 60 mg/ml in deionized H2O 
Cross-linker solution 1 mM DSP 
DEAE-dextran solution 25 mg/ml in deionized H2O 
Fixative for IMF, pH 7.4 4% (w/v) Paraformaldehyde in PBS 
LB medium 2.5% (w/v) LB-Broth Miller 
LB plates 
2.5% (w/v) LB-Broth Miller 
1% (w/v) Agar 
Lysis buffer 
pH 7.5 
25 mM TrisHCl 
150 mM NaCl 
0,5 mM EDTA 
Add fresh: 0.5% (w/v) Triton X-100, 1 mM 
PMSF, 1 mini protease inhibitor cocktail 
(Roche) 
Mounting medium for IMF 
3 volumes Mowiol stock 
1 volume Propyl gallate stock 
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Mowiol stock 
12 g Mowiol 4-88 
40 ml PBS, stir over night 
+ 20 ml Glycerol, stir over night 
Centrifuge 1 hour, 15,000 rpm, 4°C 
Add sodium azide to the supernatant 
Phosphate buffered saline (PBS) 
pH 7.35 
140 mM NaCl 
2.5 mM KCl 
6.5 mM Na2HPO4 
1.5 mM K2HPO4 
Permeabilisation for IMF 0.2% (v/v) Triton X-100 in PBS 
Permeabilisation for IMF 
1 mg/ml Digitonin stock solution 
1:400 diluted in PBS 
Propyl gallate stock 
2.5% (w/v) Propyl gallate in PBS 
50% (v/v) Glycerol 
Laemmli loading buffer 
60 mM Tris, pH 6.8 
2% (w/v) SDS 
10% (v/v) Glycerol 
0.005% (w/v) Bromophenol blue 
20 mM DTT 
5% (v/v) β-Mercaptoethanol (fresh) 
SDS running buffer 
25 mM Tris 
190 mM Glycine 
0.1% (w/v) SDS 
Semidry blotting buffer 
48 mm Tris 
39 mM Glycine 
0.4% (w/v) SDS 
20% (v/v) Methanol 
50x TAE – Tris-Acetate-EDTA 
pH 8.0 
40 mM Tris 
20 mM Acetic acid 
1 mM EDTA 
TBS-T 
50 mM Tris, pH 7.5 
150 mM Sodium chloride 
0,05% Tween20 
Tris buffer separation gel, pH 8.8 2 M Tris in water 
Tris buffer stacking gel, pH 6.8 1 M Tris in water 
 
2.3. Cloning 
All expression plasmids were designed using Clone Manager 9 (Sci-Ed 
Software, USA) (Table 2.2), or kind offers from collaborators (Table 2.3). Primer 
synthesis (Table 2.4) and DNA sequencing were from Eurofins MWG Operon 
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(Ebersberg, Germany). Gene synthesis (Table 2.5) was performed by Genscript 
(Genscript, Piscataway, USA) or Eurofins (Eurofins Genomics, Ebersberg, 
Germany). 
Genes of interest were amplified by PCR from previously cloned plasmids or 
human cDNA obtained from cultured HepG2 cells. The latter was obtained by 
extracting total RNA from HepG2 cells using TRIZOL reagent and reverse 
transcribing it into cDNA. PCR conditions were adapted for each primer pair and 
optimized for KOD DNA polymerase activity, according to the manufacture’s 
protocol.  
DNA products from PCR and digestion reactions were run in agarose gels prior 
to purification. DNA electrophoresis was routinely performed in an agarose gel 
(1% agarose in 1x TAE buffer) stained with ethidium bromide (0.5 µg/ml). 
Separation was performed at 75 V for 45 to 60 minutes in TAE 1x buffer. DNA 
samples were mixed with 6x purple loading dye buffer and loaded to individual 
wells. A DNA ladder was also loaded to one well to compare band sizes. Digital 
images were taken using the BioDoc-It Imaging System (UVP, USA). Specific 
DNA bands were excised with a scalpel under UV light and purified using the 
NucleoSpin Extract II kit (Macherey-Nagel, Germany), following the 
manufacturer’s protocol 
DNA and vectors were digested with restriction enzymes (Table 2.2) following 
the manufacturer’s suggested buffers and additives (e.g. BSA) at 37°C, for 4h 
or overnight. Enzyme inactivation was performed at 65°C for 20 minutes. Upon 
digestion, samples were run in an agarose gel to remove unwanted DNA 
fragments. Vector DNA was dephosphorylated with antarctic phosphatase for 
40 minutes at 37°C, followed by enzyme inactivation for 20 minutes at 65°C. 
DNA concentration was determined using the Qubit2.0 fluorometer (Invitrogen, 
USA). 
For ligation, the molecule ratios between vector and insert were 1:3 and 1:5. To 
calculate the exact amount of DNA to be used, the following formula was used:  
𝑖𝑛𝑠𝑒𝑟𝑡 (𝑛𝑔) =
𝑣𝑒𝑐𝑡𝑜𝑟 (𝑛𝑔) × 𝑖𝑛𝑠𝑒𝑟𝑡 (𝑘𝑏)
𝑣𝑒𝑐𝑡𝑜𝑟 (𝑘𝑏)
 × 𝑟𝑎𝑡𝑖𝑜 
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Ligation was performed with T4 ligase at 4 or 16°C overnight, and control 
ligations were performed in parallel with the dephosphorylated vector.  
Plasmid amplification was performed in competent DH5α Escherichia coli 
following a standard heat shock protocol. For each plasmid, 50 µl of competent 
E.coli bacteria were mixed with 2 µl of ligation mixture and incubated for 30 
minutes on ice, followed by a 90 seconds heat shock at 42°C, and a short 
incubation on ice. For recovery, bacteria were incubated with 950 µl of LB 
medium for 45 minutes at 37°C with low agitation. Cells were centrifuged for 3 
minutes at 3000 rpm and the pellets were resuspended in 100 µl of LB medium. 
Cells were spread with the aid of glass beads on LB agar plates containing 
kanamycin (30 µg/ml) or ampicillin (100 µg/ml). Plates were incubated overnight 
at 37°C. 
Colonies were tested by DNA digestion following plasmid DNA isolation using 
the NucleoSpin Plasmid Miniprep kit (Macherey-Nagel, Germany). A single 
positive clone for each plasmid was selected and sequenced. For positive 
clones, DNA yield was increased by performing midi preparations using the 
NucleoBond Xtra Midi kit (Macherey-Nagel, Germany) according to the 
manufacturer’s protocol. 
 
Table 2.2 – Plasmids generated 
Name Template Primers Enzymes Vector 
Myc-FALDH-PO 
HepG2 
cDNA 
Myc-FALDH-XhoI-Fw 
Myc-FALDH-PO-BamHI-Rv 
XhoI 
BamHI 
pCMV-3b 
Myc-FALDH-ER 
HepG2 
cDNA 
Myc-FALDH-XhoI-Fw 
Myc-FALDH-ER-BamHI-Rv 
XhoI 
BamHI 
pCMV-3b 
GFP-FALDH-PO 
myc-
FALDH-PO 
GFP-FALDH-PO-XhoI-Fw 
GFP-FALDH-PO-BamHI-Rv 
XhoI 
BamHI 
pEGFP-C1 
GFP-FALDH-ER 
myc-
FALDH-ER 
GFP-FALDH-ER-XhoI-Fw 
GFP-FALDH-ER-BamHI-Rv 
XhoI 
BamHI 
pEGFP-C1 
Myc-ACBD4 
isoform2 
HepG2 
cDNA 
Myc-ACBD4 isoform 1 For 
Myc-ACBD4 isoform 2 Rev 
XhoI 
BamHI 
pCMV-3b 
Myc-ACBD5 
isoform1 
HepG2 
cDNA 
Myc-ACBD5 For 
Myc-ACBD5 Rev 
EcoRV 
XhoI 
pCMV-3b 
GFP-ACBD5 
isoform1 
myc-
rACBD5.1 
GFP-ACBD5.1-XhoI-Fw 
GFP-ACBD5.1-EcoRI-Rv 
XhoI 
EcoRI 
pEGFP-C1 
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GFP-ACBD5 
TMD+T 
WT 
Gene 
synthesis 
- 
EcoRI 
SacII 
pEGFP-C1 
GFP-ACBD5 
TMD+T 
Mut1 
Gene 
synthesis 
- 
EcoRI 
SacII 
pEGFP-C1 
GFP-ACBD5 
TMD+T 
Mut2 
Gene 
synthesis 
- 
EcoRI 
SacII 
pEGFP-C1 
GFP-ACBD5 
TMD+T 
Mut3 
Gene 
synthesis 
- 
EcoRI 
SacII 
pEGFP-C1 
Myc-ATP5J2 
Gene 
synthesis 
- 
BamHI 
XhoI 
pcDNA3.1 
N-Myc 
Myc-PPP1R3F 
Gene 
synthesis 
- 
EcoRI 
XhoI 
pcDNA3.1 
N-Myc 
Myc-Miro1-Pex Myc-Miro1 
Myc-Miro1_AgeI_F 
Miro1_dTM_R 
AgeI 
BglII 
pAH26 
Myc-Miro1-PO Myc-Miro1 
Myc-Miro1_AgeI_F 
Miro1_EcoRI-R 
AgeI 
EcoRI 
pEGFP-
ACBD5 
TMD+T 
WT 
 
Table 2.3 – Plasmids used 
Plasmid Source 
GFP-BCL2 Kindly provided by R. Youle, NIH, Bethesda, USA 
GFP-BCL-XL Kindly provided by R. Youle, NIH, Bethesda, USA 
GFP-BAX Kindly provided by R. Youle, NIH, Bethesda, USA 
GFP-BAK Kindly provided by R. Youle, NIH, Bethesda, USA 
Myc-MIRO1 WT, V13, 
N18, KK, ΔTM 
Kindly provided by P. Aspenström, Karolinska Institute, 
Sweden 
Myc-MIRO2 WT 
kindly provided by P. Aspenström, Karolinska Institute, 
Sweden 
Myc-OMP25 Kindly provided by P. DeCamilli, Yale University, USA 
GFP-SEC61β Kindly provided by W.A. Prinz, NIH, Bethesda, USA 
Myc-VAPB Kindly provided by C. Miller, King’s College London, UK 
Myc-rACBD5.1 (Islinger et al., 2007) 
Flag-FIS1-WT and SR Kindly provided by N. Ishihara, Kurume University, Japan 
GFP-SKL (Koch et al., 2005) 
HA-Pex19 (Delille and Schrader, 2008) 
pAH26 (Halbach et al., 2006) 
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Table 2.4 – Primers for cloning and sequencing 
Name Sequence (5’ to 3’) 
GFP-ACBD5.1-XhoI-Fw 5’ CCGCTCGAGAAATGGCGGACACACGATCAG 3’ 
GFP-ACBD5.1-EcoRI-Rv 5’ CCGGAATTCCGTCAATTTAGTTTTCTTCTCCTTC 3’ 
Myc-FALDH-XhoI-Fw 5’ AATAAGGATCCATGGAGCTCGAAGTCCG 3’ 
Myc-FALDH-PO-BamHI-Rv 5’ AATAACTCGAGCAGACAGGGCTGGGTTTTGA 3’ 
Myc-FALDH-ER-BamHI-Rv 5’AATAACTCGAGGCACTAGGAGGTTGAACAGGA 3‘ 
GFP-FALDH-PO-XhoI-Fw 5’ CCGCTCGAGAAATGGAGCTCGAAGTCCGGC 3’ 
GFP-FALDH-PO-BamHI-Rv 5’ CGGGATCCCGTCATCTCTGCTTACTGGACC 3’ 
GFP-FALDH-ER-XhoI-Fw 5’ CCGCTCGAGAAATGGAGCTCGAAGTCCGGC 3’ 
GFP-FALDH-ER-BamHI-Rv 5’ CGGGATCCCGTCAGTAATATTCTGCCTTGACAA 3’ 
Myc-ACBD4 For 
5’ AAGGATCCATGGGCACCGAGAAAGAAAGCCCAGAGCC 
CGAC 3’ 
Myc-ACBD4 Rev 
5’ CTCTCGAGTCACCTCTTTTGGGTCCGAAACATTCGGAA 
GAGCC 3’ 
Myc-ACBD5 For 5’ AAAGGATCCATGCTCTTCCTCTCGTTTCATG 3’ 
Myc-ACBD5 Rev 5’ GTTCTCGAGTTATCAGTTCAGTTTTCTTCTCCTTCTTTG 3’ 
Myc-Miro1_AgeI_F 5’ GGAACCGGTCACCATGGAGCAGAAGCTGATC 3’ 
Miro1-dTM_R 5’ GGAAGATCTAAACGTGGAGCTCTTGGGGTC 3’ 
Miro1_EcoRI-R 5’ GCGGAATTCGAAAACGTGGAGCTCTTGAGGTC 3’ 
Miro1seqmid1 5’ CGCACAGAAAGCTGTTCTTCATCC 3’ 
Miro1seqmid2 5’ GACTGAGCAAGAGTCTCAAG 3’ 
pEGFPC1for 5’ GATCACTCTCGGCATGGAC 3’ 
pEGFPC1rev 5’ CATTTTATGTTTCAGGTTCAGGG 3’ 
pShuttleCMV-f 5’ GGTCTATATAAGCAGAGCTG 3’ 
CMVfor 5’ CGCAAATGGGCGGTAGGCGTG 3’ 
 
Table 2.5 – Gene synthesis 
Gene Sequence 
ACBD5 
TMD+T 
WT 
GCGGCGAATTCTCCTGGTGTGCTAACGTTTGCTATTATATGG 
CCTTTTATTGCTCAGTGGTTGGTGCATTTGTATTATCAAAGA 
AGGAGAAGAAAACTGAACTGAACCGCGGGC 
ACBD5 
TMD+T 
Mut1 
GCGGCGAATTCCCCTGGTGCATTAGCTTTTGCTATTATATGG 
CCTTTTATTGCTCAGTGGTTGGTGCATTTGTATTATCAAAGA 
GCCAGAGCCAAACTAAATTGAACCGCGGGC 
ACBD5 
TMD+T 
Mut2 
GCGGCGAATTCCCCTGGTGCATTAGCTTTTGCTATTATATGG 
CCTTTTATTGCTCAGTGGTTGGTGCATTTGTATTATCAAGCC 
GCCGCCGCCAAACTAAATTGAACCGCGGGC 
ACBD5 
TMD+T 
Mut3 
GCGGCGAATTCCCCTGGTCTGTTACTGTTTCTGATTATACTG 
CTGTTTATTCTGCTGCTGTTGGTGCTGTTGTATTATCAAAGA 
AGGAGAAGAAAACTAAATTGAACCGCGGGC 
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2.4. Cell culture and transfection 
Cell lines (Table 2.6) were routinely cultured in Dulbecco’s modified Eagle 
medium (DMEM) high glucose (4.5 g/L) supplemented with 10% FBS, 100 U/ml 
penicillin and 100 µg/ml streptomycin at 37°C with 5% CO2 and 95% humidity. 
HepG2 cells were cultured in similar conditions but with MEM medium. Mouse 
embryonic fibroblast (MEF) media was supplemented with β-mercaptoethanol at 
a final concentration of 50 µM to prevent the accumulation of oxygen radicals. 
Immortalised cells were maintained in culture for 30-40 passages and rimary 
cell lines for 10-15 passages. Cells were regularly monitored for alterations in 
cell  shape and proliferation.  
Cell passage was performed twice a week, after the cells reached confluence. 
Cells were washed once with PBS 1x and incubated for 5 minutes with 1.5 ml 
TrypLE Express at 37°C. Upon resuspension in medium, cells were centrifuged 
for 3 minutes at 1000 rpm to remove debris. Cell pellets were resuspended in 
10 ml of fresh medium and seeded at 1:10 to 1:5 dilution. Cells were routinely 
grown on 10ø cm dishes. For immunofluorescence, cells were seeded on round 
19ø mm glass coverslips 24 hours prior to transfection. When using HepG2 
cells, coverslips were coated with collagen prior to seeding. To ensure 
reproducibility between experiments, cell number was determined using a 
Neubauer counting chamber or a TC20™ Automated Cell Counter (Bio-Rad, 
USA).  
 
Table 2.6 – Cell lines 
Cell line Organism Tissue Cell type Morphology Source 
COS7 
Cercopithecus 
aethiops 
Kidney 
SV40 
transformed 
Fibroblast-
like 
ATCC 
(CRL-1651) 
HepG2 Homo sapiens Liver carcinoma Epithelial 
ATCC 
(HB-8065) 
C109 Homo sapiens Skin primary Fibroblast 
H. Waterham 
(University of 
Amsterdan, 
Netherlands) 
ΔPEX5 Homo sapiens Skin primary Fibroblast 
H. Waterham 
(University of 
Amsterdan, 
Netherlands) 
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ΔPEX14 Homo sapiens Skin primary Fibroblast 
M. Fransen (KU 
Leuven, 
Belgium) 
ΔPEX19 Homo sapiens Skin primary Fibroblast 
G. Dodt 
(University of 
Tübingen, 
Germany) 
MEF 
MIRO1 
+/+ and -/- 
Mus musculus  Embryo 
SV40 
transformed 
Fibroblast 
J. Shaw 
(University of 
Utah, USA) 
TRAK1 Homo sapiens Skin primary Fibroblast 
Yair Anikster 
(Sheba Medical 
Center, Israel) 
 
2.4.1. Cell freezing and thawing 
Stocks for each cell line were kept through cryopreservation in liquid nitrogen. 
Cell pellets from confluent dishes were prepared as described above and 
resuspended in freezing medium (DMEM supplemented with 20% FBS and 
10% DMSO). 1 ml aliquots were prepared in cryovials and frozen overnight at -
80°C, before being stored in a liquid nitrogen tank. For thawing, cells were 
quickly resuspended with pre-warmed culture medium and seeded in a 10ø cm 
dish. The culture medium was changed after a few hours (after cell adhesion) to 
remove debris and DMSO. 
 
2.4.2. Transfection methods 
Several transfection methods were used, depending on the cell line and 
experimental objective. COS-7 cells were routinely transfected with TurboFect 
for IMF and live-cell imaging, and with (DEAE)-dextran for WB and IPs. HepG2 
cells were transfected using Lipofectamine® 3000. Human skin fibroblasts and 
mouse embryonic fibroblasts were transfected by microporation. Transfection 
efficiency varied with method and cell line, and was optimised by adjusting cell 
number, plasmid concentration and transfection time. For each experiment, 
controls were performed with non-transfected cells and cells transfected without 
plasmid. For all transfection methods used, except microporation, cells were 
seeded in dishes or 19ø mm glass coverslips 24 hours prior to transfection. 
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2.4.2.1. TurboFect™ (ThermoFisher Scientific) 
For transfection, 4 µg of DNA and 6 µl of TurboFect were diluted in 400 µl of 
DMEM medium without FBS and antibiotics and incubated for 20 minutes. 
During incubation, the culture dish was washed once with PBS and fresh media 
(without FBS or antibiotics) was added. The DNA/TurboFect mixture was added 
drop-wise to the dish and incubated for 3 to 6 hours at 37 °C after which the 
cells were washed with PBS and incubated in fresh complete medium for 24/48 
hours. 
 
2.4.2.2. DEAE-dextran (Sigma-Aldrich) 
For transfection of 10ø cm dishes, 10 µg of DNA and 18 µl of DEAE-dextran 
were diluted in 1.5 ml of complete medium, and incubated at room temperature 
for 20 minutes. Cells were washed twice with PBS and incubated with the DNA-
DEAE-dextran mixture for 90 minutes, at 37ºC and 5% CO2. During incubation, 
the dishes were shaken every 15 minutes. After 90 minutes, the DNA-DEAE-
dextran mixture was removed and 10 ml of complete medium supplemented 
with 10 µl of chloroquine were added to the dishes for 3 hours. Lastly, the cells 
were washed 3 times with PBS and incubated with fresh medium for 24/48 
hours. To control the level of transfection, one coverslip was added to the 
dishes before seeding and prepared for immunofluorescence before cell lysis 
and collection. 
 
2.4.2.3. Lipofectamine® 3000 (ThermoFisher Scientific) 
Transfection protocols for lipofectamine were optimized for DNA and siRNA 
following the manufacturer’s protocol, and scaled up or down as necessary. For 
DNA transfection in a 6ø cm dish, one tube was prepared with 16.5 µl of 
lipofectamine diluted in 250 µl of Opti-MEM medium, and another with 11 µg of 
DNA and 22 µl of P3000 reagent in 250 µl of Opti-MEM medium, and mixed 
well. The DNA-P3000 mix was added to the diluted lipofectamine and incubated 
for 5 minutes. Lastly, the DNA-lipid mixture was added to the previously seeded 
cells and incubated for 24/48 hours. For silencing experiments (Table 2.7), 166 
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pmol or 332 pmol of siRNA was used instead of DNA, the P3000 reagent was 
excluded, and the cells were incubated for 72 hours. 
Table 2.7 – siRNA pools (Dharmacon, GE Healthcare) 
Gene Sequence 
siGENOME non-targeting pool 
D-001206 
5’ UAAGGCUAUGAAGAGAUAC 3’ 
5’ AUGUAUUGGCCUGUAUUAG 3’ 
5’ AUGAACGUGAAUUGCUCAA 3’ 
5’ UGGUUUACAUGUCGACUAA 3’ 
SiGENOME MIRO1 pool 
M-010365 
5’ GAACUCAACUUCUUUCAGA 3’ 
5’ GAACCAGUAUACAGAAAUA 3’ 
5’ GAACAUAUCAGAGCUCUUU 3’ 
5’ CAGAAUACCUUGCUUAAUC 3’ 
ON-TARGETplus MIRO1 pool 
L-010365 
5’ GCUUAAUCGUAGCUGCAAA 3’ 
5’ CCAGAGAGGGAGACACGAA 3’ 
5’ GCAAUUAGCAGAGGCGUUA 3’ 
5’ UGUGGAGUGUUCAGCGAAA 3’ 
 
2.4.2.4. Microporation  
Human and mouse fibroblasts were transfected using the Neon® Transfection 
System (ThermoFisher Scientific) following the manufacturer’s protocol. In 
short, cells dishes at 70-90% confluency were washed once with PBS and 
trypsinized using TrypLE Express as above. Trypsinized cells were 
resuspended in normal medium without antibiotics, and counted to determine 
cell density. The required amount of cells was centrifuged for 3 minutes at 1000 
rpm and the pellet washed with PBS. The cells were once again centrifuged and 
carefully resuspended in Buffer R. For each condition, the required number of 
cells was pre-mixed with the plasmid of interest and microporated using the 10 
or 100 µl Neon tip. Microporated cells were immediately seeded into plates with 
pre-warmed media without antibiotics and incubated for 24/48 hours. 
For each cell line, an optimization protocol was performed to select the most 
effective conditions (pulse voltage, pulse width, and pulse number). The 
following conditions were used: 
- C109, ΔPEX5, ΔPEX14 and TRAK1 patient fibroblasts: 1700 v, 20 ms, 1 
pulse 
- ΔPEX19 patient fibroblasts: 850 v, 30 ms, 2 pulse 
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- MEF MIRO1 +/+ and -/-: 1350 v, 30 ms, 1 pulse 
Cell number and plasmid concentration was optimized for each experimental 
set up, taking into consideration the dish/well size and time of incubation after 
transfection. 
 
2.4.3. Treatments 
To analyse the effects of microtubule depolymerisation, cells were treated 24 
hours after transfection with 10 µM of nocodazole, and incubated for 1 or 4 
hours before being fixed. Control cells were incubated with the same volume of 
DMSO as that used to dissolve nocodazole (maximum 0.1% v/v). 
To analyse the effects of calcium concentration on peroxisome motility, cells 
were treated with the calcium ionophore calcimycin (A23187). Prior to live-cell 
imaging, cells were treated with 10 µM of calcimycin and incubated for 10 
minutes. Control cells were incubated with the same volume of DMSO as that 
used to dissolve nocodazole (maximum 0.1% v/v). 
 
2.5. Immunofluorescence (IMF) 
Cells grown on glass coverslips were processed for IMF 24/48 hours after 
seeding or transfection, and 72h after silencing. Cells were routinely fixed for 20 
minutes with 4% paraformaldehyde (PFA), permeabilized with 0.2% triton X-100 
for 10 minutes and blocked with 1% BSA for 10 minutes. To visualise the 
microtubule network, cells were fixed for 10 minutes with 4% PFA followed by 5 
minutes with ice-cold methanol. In conditions where the protein of interest was 
extracted from the peroxisomal membrane by triton X-100, cells were 
permeabilized using a digitonin solution for 5 minutes. After blocking, cells were 
incubated with the primary antibody for 1 hour in a humid chamber (Table 2.8). 
This step was repeated for the secondary antibody, protected from light. 
Coverslips were washed with ddH2O to remove PBS and mounted with Mowiol 
medium on glass slides. All immunofluorescence steps were performed at room 
temperature and cells were washed three times with PBS between each 
individual step. 
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Table 2.8 – Primary and secondary antibodies.  
Antibodies Type 
Dilution 
Source 
IMF WB 
ACBD5 (HPA012145) mc ms 1:100 1:250 Sigma-Aldrich, Schnelldorf, Germany 
ATP synthase mc ms - 1:1000 Abcam, Cambridge, England 
BCL2 (PSI-3335) mc rb 1:100 1:1000 ProSci, San Diego, USA 
CATALASE pc ms 1:200 - Abcam, Cambridge, England 
CYCLOPHILLIN pc rb - 1:1000 Abcam, Cambridge, England 
FLAG  mc ms 1:500 - Sigma-Aldrich, Schnelldorf, Germany 
FLAG pc rb 1:750 1:1000 Sigma-Aldrich, Schnelldorf, Germany 
GAPDH mc rb - 1:5000 ProSci, San Diego, USA 
GFP (A11122) pc rb 1:200 1:1000 
Molecular Probes (ThermoFisher Scientific, 
Waltan, USA) 
HA mc ms - 1:1000 BioLegend, San Diego, USA 
MIRO1 (HPA010687) pc rb 1:100 1:250 Sigma-Aldrich, Schnelldorf, Germany 
MIRO1 (PSI-8027) pc rb 1:100 1:1000 ProSci, San Diego, USA 
Myc (Ab9106) mc rb 1:200 1:1000 Abcam, Cambridge, England 
Myc 9E10 mc ms 1:200 1:1000 Santa Cruz Biotechonology, Santa Cruz, USA 
PEX14 pc rb 1:1400 1:4000 
Kind gift from D.Crane Griffith University, 
Australia 
PDI mc ms 1:100 - Thermo Scientific, Waltham, USA 
PMP70 mc ms 1:500 1:5000 Sigma-Aldrich, Schnelldorf, Germany 
TOM20 (612278) mc ms 1:200 - 
BD Transduction Laboratories, San Diego, 
USA 
γ-TUBULIN mc ms 1:100 - Sigma-Aldrich, Schnelldorf, Germany 
AlexaFluor 488 IgG 
dk  
anti-rb 
1:400 - 
Molecular Probes (ThermoFisher Scientific, 
Waltan, USA) 
AlexaFluor 488 IgG 
dk  
anti-ms 
1:400 - 
Molecular Probes (ThermoFisher Scientific, 
Waltan, USA) 
AlexaFluor 594 IgG 
dk  
anti-rb 
1:1000 - 
Molecular Probes (ThermoFisher Scientific, 
Waltan, USA) 
AlexaFluor 594 IgG 
dk  
anti-ms 
1:1000 - 
Molecular Probes (ThermoFisher Scientific, 
Waltan, USA) 
TRITC IgG 
dk  
anti-ms 
1:100 - Dianova, Hamburg, Germany 
TRITC IgG 
dk  
anti-rb 
1:400 - Dianova, Hamburg, Germany 
HRP IgG 
gt  
anti-ms 
- 1:5000 Bio-Rad, Munich, Germany 
HRP IgG 
gt  
anti-rb 
- 1:5000 Bio-Rad, Munich, Germany 
Hoechst dye - 1:2000 - Polysciences, Inc., Eppelheim, Germany 
Abbreviations: IMF, immunofluorescence; WB, western blot; mc, monoclonal; pc, polyclonal; ms, 
mouse; rb, rabbit; gt, goat; dk, donkey; HRP, horseradish peroxidase. 
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2.6. Microscopy 
2.6.1. Epifluorescence and confocal microscopy 
Routine cell imaging was performed using an Olympus IX81 microscope 
equipped with an UPlanSApo 100x/1.40 oil objective (Olympus Optical, 
Hamburg, Germany). Digital images were taken with a CoolSNAP HQ2 CCD 
and adjusted for contrast and brightness using the Olympus Soft Imaging 
Viewer software (Olympus Soft Imaging Solutions GmbH) and MetaMorph 7 
(Molecular Devices, USA). 
Confocal images were obtained using a Zeiss LSM 510 inverted microscope 
equipped with a Plan Apochromat 63x/1.4 NA (oil/dic) objective (Carl Zeiss, 
Oberkochen, Germany), using the Argon 488nm and He 543nm laser lines. 
Digital images were adjusted for contrast and brightness using the Zeiss LSM 
Image Browser software (Carl Zeiss MircroImaging GmbH). 
Live-cell imaging data was collected using an Olympus IX81 microscope 
equipped with a Yokogawa CSUX1 spinning disk head, CoolSNAP HQ2 CCD 
camera, 60x/1.35 oil objective, and outfitted with a controlled temperature 
chamber and objective warmer. Digital images were taken and processed using 
VisiView software (Visitron Systems, Germany).  
 
2.6.2. Live-cell imaging 
For live-cell imaging, COS-7 cells and human fibroblasts were plated in 3,5ø cm 
glass bottom dishes (Cellvis, USA and MatTek, USA). Prior to image 
acquisition, a controlled-temperature chamber was set-up on the microscope 
stage at 37ºC, as well as an objective warmer. During image acquisition, cells 
were kept at 37ºC and in CO2–independent medium (HEPES buffered). For 
COS-7 cells, 500 stacks of 5 planes (0.5 µm thickness, 100ms exposure) were 
taken in a continuous stream. For human fibroblasts, 250 stacks of 9 planes 
(0.5 µm thickness, 100ms exposure) were taken in a continuous stream. All 
conditions and laser intensities were kept between experiments. For each 
condition analysed, a representative cell was selected and the acquired images 
were converted into a movie at 10x the original speed. Cells that moved during 
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the acquision process were removed from the datasets as these would affect 
the peroxisome motility measurements. 
 
2.7. Protein assays 
2.7.1. Cell lysis for protein assays 
Cell lysates were prepared for silencing experiments and immunoprecipitations. 
Routinely, cells were transfected in 6ø cm dishes and collected after 48/72 
hours. All lysis steps were performed at 4ºC or on ice, and all buffers were 
prepared fresh. For lysis, cells were washed with PBS, and 0.1-1 ml of lysis 
buffer was added to the plates. To remove all cells, a scraper was used and the 
cells were collected in an eppendorf tube. To improve lysis efficiency, cells were 
incubated in a rotating shaker for 15 minutes. Lysed cells were centrifuged at 
15,000 g for 15 minutes to remove debris and the supernatant was kept. Protein 
concentration was determined by Bradford assay (Bradford, 1976). 
 
2.7.2. Co-immunoprecipitation 
GFP, Myc or FLAG-tagged proteins and HA-tagged PEX19 were expressed in 
COS-7 cells. After 48 hours, cells were washed with PBS and incubated with 5 
ml of DSP cross-linker solution for 30 minutes, followed by quenching for 10 
minutes with 100 mM Tris (pH 7.4). After crosslinking, cells were lysed as 
described above and the supernatant was mixed with GFP-TRAP (ChromoTek) 
or Myc/FLAG-antibody coupled agarose beads, and incubated for 2 hours at 
4ºC. Beads were subsequently washed extensively with lysis buffer by quick 
centrifugations at 12,000 g and by incubating in a rotating shaker for 15 minutes 
at 4ºC. Bound protein was eluted with Laemmli buffer (GFP-TRAP) or 50 mM 
NaOH (agarose beads), and the eluted protein was denatured in Laemmli buffer 
for 10 minutes at 95ºC. Samples of lysate supernatant (before incubation with 
beads) were kept as “input”.   
The cross-linker DSP (dithiobis (succinimidyl propionate)) was used for PEX19 
interaction analysis due to the transient nature of the PEX19-TA protein 
interaction. This cross-linker was selected due to its short spacer (12.0 Å) and 
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cleavability. DSP has two identical reactive groups (activated esters) at each 
end of an 8-carbon spacer. These groups react with primary amines of proteins 
that are in very close proximity. The spacer is cleavable and the cross-link can 
be removed by reducing agents as those contained in SDS loading buffer. 
 
2.7.3. Subcellular fractionation (performed by Markus Islinger) 
Peroxisome purification from rat liver was performed as described (Islinger et 
al., 2012a). In brief, liver tissue was homogenized in homogenization buffer 
(HB; 250 mM sucrose, 5 mM MOPS, 1 mM EDTA, 2 mM PMSF, 1 mM DTT, 1 
mM ɛ-aminocaproic acid, 0.1% ethanol, pH 7.4) using an ice-cooled Potter-
Elvehjem tissue grinder (1 stroke/120 s). All further separation steps were 
performed at 4°C. The homogenate was cleared from cell debris and nuclei in 
an initial centrifugation step at 600 gav, 10 min. The resulting pellet was re-
homogenized and re-centrifuged applying the same conditions; both 
supernatants were pooled and comprise the initial post nuclear supernatant 
(PNS). Subsequently, PNS was centrifuged at 1,900 gav, 15 min to yield the 
pellet of heavy mitochondria (HM). The resulting supernatant was again 
centrifuged at 25,500 gav, 20 min resulting in the light mitochondrial pellet (LM). 
The corresponding supernatant was centrifuged an additional time at 100,000 
gav, 30 min to separate the microsomal pellet (MIC) from cytosol (CYT). To 
increase purity of the fractions, each pellet recovered was washed in 5 ml HB/g 
liver tissue and centrifuged using the same parameters. Highly purified 
peroxisomes were obtained from LM applying a sigmoidal Optiprep-gradient 
from 1.26 – 1.12 g/ml in a vertical type rotor at an integrated force of 1,256  
106 g min. In such a gradient highly purified peroxisomes form a distinct band at 
1.20 g/ml. 
 
2.7.4. Electrophoresis and Immunoblotting 
Standard 1D-SDS PolyAcrylamide Gel-Electrophoresis (SDS-PAGE) was 
performed with 10-12.5% separating and 4% stacking gels (Table 2.9). To mark 
protein size a pre-stained molecular weight marker (Precision Plus) was used 
and the sample running front was visualized by bromophenol blue added to the 
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loading buffer. Gels were conducted for 30 minutes at 80 V until the proteins 
entered the separating gel, and at 130 V for approximately 90 minutes, in 
chambers containing SDS running buffer.  
Protein transfer to nitrocellulose membranes was performed by semi-dry 
western blotting for 60 minutes at 14 V. After protein transfer, membranes were 
blocked with 5% low fat powdered milk in TBS-T for 1 hour. Membranes were 
incubated with the primary antibody diluted in TBS-T, overnight at 4°C on a 
shaker. After incubation, membranes were washed three times for 10 minutes 
with TBS-T. Incubation with the secondary antibody was performed for 90 
minutes at room temperature, after which membranes were washed three times 
for 10 minutes with TBS-T. For protein detection, membranes were incubated 
for 2 minutes with ECL and exposed to photographic film for 1 to 10 minutes in 
a light protected environment, and developed using a OPTIMAX film processor. 
 
Table 2.9 – Recipe for acrylamide gels 
 Separating Gel Stacking Gel 
10% 12.5% 4% 
30% Polyacrylamide 3.33 ml 4.17 ml 0.83 ml 
2 M Tris pH 8.8 1.86 ml 1.86 ml - 
1 M Tris pH 6.8 - - 0.63 ml 
20% SDS (0.1%) 50 µl 50 µl 25 µl 
dH2O 4.73 ml 3.89 ml 3.43 ml 
10% APS 30 µl 30 µl 40 µl 
TEMED 5 µl 5 µl 5 µl 
Total volume 10 ml 10 ml 5 ml 
 
2.8. Computational analysis 
2.8.1. Bioinformatics 
Data on human TA proteins was sourced from the literature. SNARE proteins 
were omitted as they have been previously shown to differ significantly from 
other ER TA proteins (Kalbfleisch et al., 2007). Protein sequences were 
obtained from the NCBI database (www.ncbi.nlm.nih.gov), all isoforms were 
analysed and those that lacked a C-terminal TMD were removed. Yeast TA 
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proteins were sourced from literature and by homology with human proteins. 
For each protein, the TMD and tail were predicted using the TMHMM server v. 
2.0 (Krogh et al., 2001). When no TMD was predicted but the protein had been 
characterized as a TA protein, the TMPred server (www.ch.embnet.org) was 
used, with a threshold score of 1500. As a measure for hydrophobicity, the 
Grand Average of Hydropathicity (GRAVY) of membrane spanning helices was 
calculated according to (Kyte and Doolittle, 1982), using the ProtParam server 
(Gasteiger et al., 2005) from ExPASy. Tail charge was calculated using the 
Protein Calculator v3.4 (Putnam Lab at The Scripps Research Institute, La 
Jolla, CA, USA), at pH7.0. PEX19-binding sites were analysed using the 
BLOCKS algorithm found at the PeroxisomeDB 2.0 (Schlüter et al., 2010). It 
should be noted that, due to the low number of know mPTS sequences, the 
reliability of the PEX19 predictor is low and this tool should be used with 
caution. 
 
2.8.2. TA protein classifier (performed by Doug McNeall) 
For the support vector machine (SVM) classifier (Cortes and Vapnik, 1995), we 
trained a SVM classifier with the [protein data] using the SVM application in 
package e1071 (Meyer et al., 2014), of the R statistical programming 
environment [R Core team, 2014] utilizing the LIBSVM library of Chang et al. 
(Chang and Lin, 2011). The SVM takes the training set of [Tail Charge, GRAVY 
and location in cell], and builds a statistical model to predict the probability of 
[location in cell], given any combination of [Tail Charge, GRAVY]. Initially, we 
restrict the training data to three unique classes, corresponding to [location in 
cell] – mitochondria (MITO), peroxisomes (PO) and endoplasmic reticulum 
(ER). This was used to calculate the targeting probability of a set of predicted 
human TA proteins previously published (Kalbfleisch et al., 2007). A fourth class 
– MITO and PO – was later added to calculate protein localisation probabilities. 
 
2.8.3. Peroxisome motility measurements (performed with Jeremy Metz) 
Peroxisomes were automatically detected and tracked using a customised in-
house algorithm. Briefly, each image was filtered using a scale-space Laplace 
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of Gaussian filtering approach (Lindeberg, 1998, 2013) over scales 
corresponding to the size range of peroxisomes. After filtering, a threshold was 
determined using the median absolute deviation as a robust estimator of the 
background level (Murtagh and Starck, 2000), and applied to the filter response 
to determine peroxisome positions. Once detected, peroxisomes were tracked 
using a global optimization subroutine (using a modified version of the Jonker-
Volgenant algorithm (Jonker and Volgenant, 1987)). For each peroxisome, each 
individual displacement between frames was tracked, giving instantaneous 
speeds. Tracking results were manually verified for accuracy. Whole cell 
peroxisome motility is represented by cumulative distribution functions (CDF) 
created from the total number of tracked movements. In a CDF plot, each 
individual point of the curve represents a peroxisome movement (instantaneous 
speed). These movements are organized by growing speed, generating an 
overview of the whole cell motility. For example, to quickly know the percentage 
of movements up to 0.1 µm/s, a line parallel to the Y axes can be drawn and the 
the value at which it intersects the graph is the % of movements. CDF plots 
presented in the results represent the total number of movements of all cells 
analysed for each group. Trajectories for the tracked peroxisomes were 
analysed by splitting their instantaneous speeds into two groups, using a cut-off 
for linear motion speed of 0.24 µm/s (Bonekamp et al., 2012). The relative 
populations of the two groups of peroxisome speeds was used as an indication 
of the amount of linear motion for each dataset, and compared against all 
trajectories to obtain a percentage of microtubule-dependent motility per cell.  
 
2.8.4. Quantification of peroxisome number 
The number of peroxisomes per cell was obtained from the motility analysis 
output, and determined by the detected peroxisomes from the first stack of each 
analysed cell.  
 
2.8.5. Peroxisome elongation measurements 
Peroxisome elongation lengths were obtained from live-cell imaging data and 
manually measured using MetaMorph 7. Each observed elongation was 
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measured at the longest point of extension. Kymographs were generated using 
ImageJ.  
 
2.9. Statistical analysis 
For the analysis of GRAVY, charge, tail length and PEX19 binding, scatter plots 
were created with GraphPad Prism 5 (GraphPad software Inc., USA). A one-
way ANOVA with post hoc Tukey test was used to determine statistical 
differences between groups. *p<0.05, **p<0.01, ***p<0.001. 
For quantitative analysis of the effect of MIRO1 expression on peroxisome 
distribution, motility and number, at least 3 independent experiments were 
carried out. Statistical analyses were performed using Microsoft Excel and 
GraphPad Prism 5 software. Data are presented as means ± SEM. Two-tailed 
unpaired t-tests and one-way ANOVA with post hoc Tukey tests were used to 
determine statistical differences against control values. * p<0.05, ** p<0.01, *** 
p<0.001. 
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Chapter 3 – Results 
 
Predicting the targeting of tail-anchored proteins 
to subcellular compartments in mammalian cells 
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3.1. Introduction 
TA proteins are a set of topologically grouped membrane proteins that possess 
a single TMD and a short tail at the C-terminus (Borgese et al., 2003). The TMD 
anchors the protein to the cytosolic side of several organelles, and allows the 
functional domains to exert their function in a semi-compartmentalized manner. 
These proteins can be targeted to mitochondria, peroxisomes, ER and 
intracellular compartments that are connected to the secretory pathway 
(Borgese et al., 2007), and are known to mediate essential biochemical 
processes such as protein import, apoptosis, signal transduction and antiviral 
signalling (Wattenberg and Lithgow, 2001). Furthermore, several TA proteins 
have a promiscuous targeting that allows them to go to more than one cellular 
membrane, meaning they are prone to affect several organelles when mutated 
(Schrader et al., 2014).  
Due to the proximity of the TMD to the C-terminus, this domain can only be 
recognised by cytosolic chaperones after leaving the ribosome, leading to the 
post-translational insertion of these proteins (Borgese and Fasana, 2011; Kutay 
et al., 1993). As a result, specific sorting machineries are required to recognize 
and target TA proteins. This is the case for the GET/TRC40 pathway (yeast and 
mammalian, respectively), which has been identified and extensively 
characterised in recent years (reviewed in Hegde and Keenan, 2011), and is 
responsible for the targeting and insertion of several ER TA proteins.  In 
addition, some studies have proposed a role for PEX19 and PEX3 in the sorting 
and insertion of the peroxisomal TA protein Pex15/PEX26 (yeast and 
mammalian, respectively) (Chen et al., 2014a; Halbach et al., 2006; Yagita et 
al., 2013). Lastly, less is known about sorting and insertion of mitochondrial TA 
proteins, with conflicting reports exploring the role of the TOM complex and the 
existence of an unassisted membrane insertion (Bellot et al., 2007; Kemper et 
al., 2008; Setoguchi et al., 2006), leaving open the possibility of an as yet 
unidentified molecular pathway. 
Targeting of TA proteins to cellular membranes has been strongly debated due 
to the absence of a consensus targeting signal (Beilharz et al., 2003; Borgese 
and Fasana, 2011; Marty et al., 2014). Several biochemical parameters, such 
as the TMD hydrophobicity and the charge of the amino acids flanking the TMD 
have been proposed to play a role (Borgese et al., 2007), but little information is 
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available on how these and other factors contribute to organelle targeting, in 
particular to peroxisomes.  
Peroxisomes are essential organelles for human health and development that 
play major roles in lipid and ROS metabolism. In the past few years, a growing 
number of proteins and functions have been identified in this organelle, 
showcasing their importance for cellular homeostasis (Smith and Aitchison, 
2013). Amongst these proteins are several TA proteins shared between 
mitochondria and peroxisomes (e.g. FIS1, MFF, GDAP1 and MAVS) (Dixit et 
al., 2010; Gandre-Babbe and van der Bliek, 2008; Huber et al., 2013; Koch et 
al., 2005), some of which have been associated with new disorders with 
combined defects in both peroxisomes and mitochondria (Huber et al., 2013; 
Shamseldin et al., 2012). 
In order to understand the targeting nuances of TA proteins, we started by re-
assessing the localisation of several known TA proteins in mammalian cells and 
found additional proteins that are targeted to multiple organelles. With the 
identification of new peroxisomal TA proteins we were able, for the first time, to 
distinguish these from other TA proteins and analyse the importance of tail 
charge for membrane targeting and PEX19 binding. We have found that 
peroxisomal targeting requires a highly positive charged tail, which can 
counteract strongly hydrophobic TMDs, and that this is directly related to the 
affinity of the proteins to the peroxisomal chaperone PEX19. Finally, we 
developed a prediction tool that allowed us to test the targeting of TA proteins, 
leading to the characterization of new proteins and the identification of a 
previously unknown peroxisomal TA protein.  
 
3.2. Results 
3.2.1. TA proteins have promiscuous targeting in mammalian cells 
In the past few years several TA proteins have been shown to target more than 
one organelle and exert similar but differently regulated functions depending on 
their target membrane (Dixit et al., 2010; Huber et al., 2013). This multiple 
targeting is not dependent on the expression of different isoforms from the 
same protein, indicating that the same sequence enables the targeting of a 
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protein to different membranes. To assess how extensive sharing of TA proteins 
between organelles is and to identify additional proteins at peroxisomes, we 
examined the localisation of a cohort of TA proteins (Figure 3.1). Expression of 
myc or GFP tagged proteins in COS-7 cells and colocalization with the 
peroxisomal marker PEX14 revealed that a subset of mitochondrial TA proteins 
had the ability to target both mitochondria and peroxisomes (Figure 3.1, Table 
3.1). These included the anti-apoptotic proteins BCL-XL and BCL2, the motor 
protein-adaptors MIRO1 and MIRO2, and OMP25 (Figure 3.1A, B). BCL2 and 
MIRO2 were additionally found at the ER, which had already been reported for 
BCL2 (Krajewski et al., 1993). Other members of the BCL2 family, the pro-
apoptotic proteins BAK and BAX, were only found at mitochondria when 
expressed in COS-7 cells (Figure 3.1C), and the ER TA proteins SEC61β, 
VAPB and FALDH isoform 2 (FALDH-ER in this study) were exclusively 
targeted to the ER (Figure 3.1D). Additionally, ACBD5 and FALDH isoform 1 
(FALDH-PO in this study) were targeted to peroxisomes (Figure 3.1E). Of note, 
these two proteins have been recently characterised as TA proteins by our 
group (data not shown), and add to the number of exclusively peroxisomal TA 
proteins. Interestingly, the two isoforms of FALDH expressed only differ in their 
C-terminal tail, pointing to a role of this sequence in the targeting to either 
peroxisomes or the ER (Figure 3.1D, E, Table 3.3) (Ashibe et al., 2007). 
To confirm the targeting of some of the tested proteins, antibodies were 
purchased to analyse endogenous localisation by IMF and WB of rat liver cell 
fractions. Of these, only a few were able to recognize the target protein in the 
conditions tested. To confirm our triple localisation of BCL2, an antibody against 
BCL2 was tested in COS-7 and HepG2 cells. To our surprise, this antibody 
showed a strong peroxisomal staining, some cytosolic staining, and no clear 
mitochondrial or ER localisation (Figure 3.2A). When tested on cells expressing 
GPF-BCL2, the antibody partially co-localised with the expressed protein. 
Despite the lack of a complete co-localisation, the BCL2 antibody was only able 
to recognise mitochondria when GFP-BCL2 was expressed. To test if the 
antibody was correctly recognizing BCL2, we stained cells expressing the GFP-
tagged protein and a clear co-localisation of both signals was observed (Figure 
3.2B). Additionally, this antibody recognized a band of 26 kDa in the cytosolic 
and the highly purified peroxisomal fractions of rat liver, which is the predicted 
size for BCL2 (Figure 3.2C). This could indicate that this antibody has a high 
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affinity for a specific isoform of BCL2 that is present in the cytosol and at 
peroxisomes in these cells. 
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Fig. 3.1 – Targeting survey of TA proteins in mammalian cells. Tagged TA 
proteins were expressed in COS-7 and processed for immunofluorescence 
using antibodies against myc and PEX14 (peroxisomal marker). Several of the 
tested proteins showed targeting to two (A) or three (B) organelles. In particular, 
GFP-BCL-XL, Myc-MIRO1 and GFP-OMP25, which have been previously 
identified in mitochondria, were also localised to peroxisomes (A), and Myc-
MIRO2 and GFP-BCL2 are additionally targeted to peroxisomes and the ER 
(B). Other proteins are exclusively targeted to (C) mitochondria (GFP-BAX, 
GFP-BAK), (D) ER (GFP-SEC61β, Myc-VAPB, Myc-FALDH-ER), and (E) 
peroxisomes (Myc-FALDH-PO, Myc-ACBD5). Arrows highlight regions of 
colocalization (A, B) or lack of colocalization (C, D) with peroxisomes. Higher 
magnification view of boxed regions (see overview) is shown. Bars, 20 µm 
(overview), 5 µm (overlay).  
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Fig. 3.2 – Endogenous BCL2 is peroxisomal and cytosolic. (A) Subcellular 
localization of endogenous BCL2 in HepG2 and COS-7 cells labelled with 
antibodies against BCL2 and PMP70 (peroxisomal marker). The recognised 
protein is present in peroxisomes and the cytosol. (B) GFP-BCL2 expressed in 
COS-7 cells and co-stained with antibodies against BCL2 and TOM20 
(mitochondrial marker). The anti-BCL2 antibody partially recognises the 
expressed protein in these cells. Higher magnification view of boxed regions 
(see overview) is shown. Bars, 20 µm (overview), 5 µm (overlay). (C) Detection 
of endogenous BCL2 in subcellular fractions isolated from rat liver. Equal 
amounts of protein were separated by SDS-PAGE and immunoblotted using 
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anti-ATP synthase α (mitochondrial marker), anti-GAPDH (cytosolic marker), 
anti-Cyclophilin (ER marker) and anti-PMP70 (peroxisomal marker) antibodies. 
Note that BCL2 is associated with the cytosolic fraction and the highly purified 
peroxisomal fraction. PNS – post nuclear supernatant. 
 
3.2.2. Targeting of TA proteins is strongly influenced by TMD 
hydrophobicity and tail charge  
As previously mentioned, the targeting information for sorting TA proteins to 
each organelle is generally localised to the C-terminus, in particular to the TMD 
and flanking amino acids (Borgese and Fasana, 2011). Additionally, instead of 
consisting of a conserved amino acid sequence, TA protein targeting seems to 
rely on physicochemical parameters such as TMD hydrophobicity and sequence 
charge (Beilharz et al., 2003; Borgese et al., 2007). To characterise the 
parameters that affect TA protein targeting, we started by assembling a list of 
known proteins from the literature and our own experimental findings (Table 
3.1). The final list contains a total of 50 proteins, distributed between the ER, 
mitochondria and peroxisomes, with some of them targeted to more than one 
organelle. Using this list, we searched the NCBI database for updated 
sequences and known isoforms. All isoforms were analysed for the presence of 
a TMD using TMHMM and TMpred, and the sequence and length of the TMD 
and tail of all proteins was annotated (Table 3.2). Any isoforms that did not fit 
the selected parameters were removed (see 2.8.1). Furthermore, we also 
selected the 10 and 20 amino acids before the TMD for analysis as these could 
potently affect chaperone binding (Table 3.3). For the obtained sequences we 
calculated the hydrophobicity of the TMD by using the grand average of 
hydropathy (GRAVY), and the tail charge (Table 3.4). Information on yeast TA 
proteins was also assembled in order to compare TMD hydrophobicity to human 
proteins (Table 3.5). 
Table 3.1 – Human TA proteins used in this study. 
Location Name Function Reference 
MITO 
MAOA Amine neurotransmitter metabolism (Kalbfleisch et al., 2007) 
MAOB Amine neurotransmitter metabolism (Kalbfleisch et al., 2007) 
CYB5B Electron carrier (Kalbfleisch et al., 2007) 
BAX* Apoptosis (Kalbfleisch et al., 2007) 
MTX1 Protein import (Kalbfleisch et al., 2007) 
TOMM5 Protein import (Kato and Mihara, 2008) 
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Location Name Function Reference 
MITO 
TOMM6 Protein import (Kato and Mihara, 2008) 
TOMM7 Protein import (Kalbfleisch et al., 2007) 
TOMM22 Protein import (Saeki et al., 2000) 
BAK1* Apoptosis (Youle and Strasser, 2008) 
MCL1 Apoptosis (Youle and Strasser, 2008) 
BCL2L13 Apoptosis (Youle and Strasser, 2008) 
BCL2L10 Apoptosis (Ke et al., 2001) 
BCL2L2 Apoptosis (Youle and Strasser, 2008) 
HRK Apoptosis (Youle and Strasser, 2008) 
GDAP1L1 Unknown (Niemann et al., 2014) 
PO 
ACBD5* Acyl-CoA binding (Islinger et al., 2007) 
PEX26 Protein important (probable) (Halbach et al., 2006) 
FALDH* Fatty aldehyde degradation - 
FAR1 Plasmalogen biosynthesis (Honsho et al., 2013) 
MITO/PO 
MIRO1* Organelle motility (Kalbfleisch et al., 2007) 
GDAP1 Organelle fission (Kalbfleisch et al., 2007) 
FIS1 Organelle fission (Kalbfleisch et al., 2007) 
MAVS Antiviral signalling (Kalbfleisch et al., 2007) 
MFF Organelle fission 
(Gandre-Babbe and van der 
Bliek, 2008) 
OMP25* Unknown (Kalbfleisch et al., 2007) 
BCL-XL* Apoptosis (Youle and Strasser, 2008) 
MITO/PO/ER 
MIRO2* Organelle motility (Kalbfleisch et al., 2007) 
BCL2* Apoptosis (Youle and Strasser, 2008) 
MITO/ER BNIP3 Apoptosis (Yasuda et al., 1998) 
ER 
BIK Apoptosis (Youle and Strasser, 2008) 
CYB5A Electron carrier (Kalbfleisch et al., 2007) 
HMOX1 Heme catabolism (Kalbfleisch et al., 2007) 
SEC61B* Protein import (Kalbfleisch et al., 2007) 
SEC61G Protein import (Kalbfleisch et al., 2007) 
FALDH* Fatty aldehyde degradation (Kalbfleisch et al., 2007) 
UBE2J1 Ubiquitination (Lenk et al., 2002) 
UBE2J2 Ubiquitination (Kalbfleisch et al., 2007) 
PTPN1 Cell signalling (Kalbfleisch et al., 2007) 
VAPA Vesicle trafficking (probable) (Kalbfleisch et al., 2007) 
VAPB* Vesicle trafficking (probable) (Borgese et al., 2007) 
SERP1 Protein interaction/regulation (Kalbfleisch et al., 2007) 
SLMAP Unknown (Kalbfleisch et al., 2007) 
PARP16 Unfolded protein response regulator (Jwa and Chang, 2012) 
CDKAL1 tRNA processing (Brambillasca et al., 2012) 
SMPD4 Sphingomyelin hydrolysis (Krut et al., 2006) 
USP19 Deubiquitination (Hassink et al., 2009) 
JPH1 ER/PM interaction (Takeshima et al., 2000) 
JPH2 ER/PM interaction (Takeshima et al., 2000) 
JPH3 ER/PM interaction (Takeshima et al., 2000) 
JPH4 ER/PM interaction (Takeshima et al., 2000) 
Note: references refer to the literature mined to acquire a comprehensive list of human 
TA proteins. * Proteins tested in this study.
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TMD hydrophobicity has been previously shown to correlate with TA protein 
targeting, particularly in yeast (Beilharz et al., 2003). In this system, ER proteins 
have highly hydrophobic TMDs (GRAVY > 1.75) in comparison with exclusively 
mitochondrial or peroxisomal proteins (Figure 3.3A). In humans, whereas a 
significant difference can still be found between ER and mitochondrial proteins, 
both sets show a much broader distribution of TMD hydrophobicity (Figure 3.3B, 
C). While this points to a role of TMD hydrophobicity in ER and mitochondrial 
protein targeting, no statistical differences were found between these groups 
and peroxisomes (Figure 3.3C). However, it should be noted that the number of 
analysed peroxisomal TA proteins is much lower than mitochondrial/ER 
proteins, and therefore small differences in TMD hydrophobicity might not be 
discernible. 
Another factor which has been proposed to regulate protein targeting is the tail 
charge (Borgese et al., 2007). As shown in figure 3.3D, peroxisomal TA proteins 
have a significantly higher positive tail charge than those targeted to the ER, 
mitochondria, or those shared by peroxisomes and mitochondria. Moreover, no 
significant differences were found in tail charge between mitochondrial and ER 
proteins.  
Other factors were also considered such as tail length, PEX19 binding, and 
charge and hydrophobicity of the residues prior to the TMD (Figure 3.3E-J). 
Although there was a significant difference between the mean peroxisomal tail 
length and that of other organelle specific TA proteins, a long tail does not seem 
to be a requirement for peroxisomal targeting, as shown by the case of ACBD5, 
which has a tail length comparable to the average of other groups. Additionally, 
as we now identified four TA proteins targeted to peroxisomes, we decided to 
look at the targeting prediction for binding of the peroxisomal chaperone PEX19 
(Schlüter et al., 2010). As a control, all the proteins in the list were also tested in 
the predictor. As shown in figure 3.3F, not all peroxisomal TA proteins have a 
predicted PEX19 binding site, and several non-peroxisomal proteins are 
predicted to have PEX19 binding sites, suggesting that the use of these tools 
alone is not sufficient to predict targeting. Finally, we analysed the residues 
prior to the TMD for both charge and hydrophobicity, but no significant 
differences were found between any of the groups (Figure 3.4G-J). 
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Fig. 3.3 – Comparison of the physicochemical parameters of TA proteins 
between different organelles. (A-B) Scatter plots depicting the TMD GRAVY 
plotted for each TA protein of known localization in yeast (S.cerevisiae) (A) and 
humans (B). Partition line at 1.75 GRAVY in yeast was defined has the 
intermediate value between the highest mitochondrial GRAVY and the lowest 
ER GRAVY. This line was overlapped with human plot to compare distribution 
of TMD hydrophobicity. Coloured regions represent: blue – mitochondria, green 
– peroxisomes, white – mitochondria and peroxisomes, salmon pink – ER. (C-J) 
Scatter plots of tail charge (C), TMD GRAVY (D), tail length (E), PEX19 binding 
(F), total charge within the 10 (G) and 20 (H) amino acids preceding the tail-
region, GRAVY within the 10 (I) and 20 (J) amino acids preceding the tail-
region. Whole samples range is shown, with mean values represented as 
horizontal lines in each sample. Dotted line in (F) indicates the cut-off value 
used to predict PEX19 binding (0.1) (Schlüter et al., 2007). Samples were 
compared using one-way ANOVA with post hoc Tukey test (** p < 0.01, *** p < 
0.001, ns - not significant). For all plots, mitochondrial TA proteins (MITO) are 
depicted in blue, peroxisomal (PO) are in green, shared (PO & MITO) are in 
white, and ER-TA proteins in salmon-pink.  
 
3.2.3. Alterations in tail charge and TMD hydrophobicity shift targeting 
between peroxisomes, mitochondria and the ER 
To analyse the effect of tail charge and TMD hydrophobicity on protein sorting, 
a GFP fusion protein was created by adding the TMD and tail of ACBD5 to the 
C-terminus of a GFP tag (Figure 3.4A). This construct, GFP-ACBD5TMD-T, was 
then mutated to have increasingly lower tail charge (Mut1 and Mut2) or a more 
hydrophobic TMD (Mut3). The wild type construct, with a TMD GRAVY of 1.2 
and a tail charge of 4.9 was strongly targeted to peroxisomes (Figure 3.4B), 
with some cells showing a dual targeting to peroxisomes and mitochondria (but 
never mitochondria alone). Mutation of two tail residues from arginine to 
alanine, decreasing the tail charge to 2.9 (Mut1), resulted in a re-targeting of the 
protein to mitochondria (Figure 3.4B). In these conditions, a significant number 
of cells also showed dual targeting to peroxisomes and mitochondria (Figure 
3.4B, C), but never peroxisomes only. Further lowering of the charge to 0.9 
shifted the targeting to the ER (Figure 3.4B), with some cells presenting a 
shared mitochondrial and ER targeting (Figure 3.4C). These results 
demonstrate that this region of the protein is sufficient for membrane insertion 
and specific organelle targeting, and that subtle changes in tail charge can 
easily shift targeting between organelles, in this case from peroxisomes to 
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mitochondria and finally to the ER. As the full ACBD5 protein is exclusively 
peroxisomal, other factors are likely at play to target some TA proteins to only 
one organelle, or to degrade mistargeted proteins. Following a similar approach, 
we tested the targeting of Flag-FIS1WT against a mutated version with a highly 
positive charged tail (Flag-FIS1SR) (Figure 3.5A) (Onoue et al., 2013). Flag-
FIS1WT (charge 1.9) was localised to both mitochondria and peroxisomes, 
whereas Flag-FIS1SR (charge 4.9) was predominantly targeted to peroxisomes, 
further strengthening the hypotheses that a high positive tail charge strongly 
promotes peroxisomal targeting. Although the Flag-FIS1WT construct had been 
previously described to localise to mitochondria only, in our experimental set up 
this protein was targeted to both mitochondria and peroxisomes. This is in 
agreement with previously published data on this protein (Koch et al., 2005). 
Since a high TMD hydrophobicity seems to promote ER targeting, we tested if 
peroxisomal proteins could be rerouted to this organelle by increasing TMD 
hydrophobicity but maintaining the high positive tail charge. For this, we 
mutated the TMD of GFP-ACBD5TMD-T and increased its GRAVY from 1.2 to 2.8 
(Figure 3.4A). This approach successfully shifted the targeting of this protein to 
the ER (Figure 3.4B), with some low levels of dual targeting to the ER and 
peroxisomes, suggesting that a balance between TMD hydrophobicity and tail 
charge is required for peroxisomal targeting. These results are in line with our 
observations of the targeting of both FALDH isoforms (Figure 3.1D, E). The two 
isoforms have a very hydrophobic TMD (2.5) and are identical with the 
exception of the tail sequence (Ashibe et al., 2007). The ER isoform possesses 
a negative charge whereas the peroxisomal isoform has a very high positive tail 
charge of 9.1 (Table 3.4), which in this case appears to override the TMD 
hydrophobicity, and promote peroxisome targeting.  
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Fig. 3.4 – Alterations in tail charge and TMD GRAVY redistribute GFP-
ACBD5TMD-TT to other organelles. (A) Overview of the domain structure of 
ACBD5 and ACBD5 GFP-TMD-Tail mutants (GFP-ACBD5TMD-T), their 
subcellular localisation, TMD GRAVY and tail charge. ACB, Acyl CoA binding 
domain; CC, predicted coiled coil region. (B) COS-7 cells were transfected with 
GFP-ACBD5TMD-T WT or GFP-ACBD5TMD-T tail mutants (Mut 1-3), and, where 
indicated, Myc-VAPB (ER marker). Fixed cells were labeled with antibodies 
against PEX14 (peroxisomal marker), TOM20 (mitochondrial marker), and Myc. 
GFP-ACBD5TMD-T WT was exclusively targeted to peroxisomes in most cells, 
whereas Mut1 was strongly targeted to mitochondria. In some cells, dual 
localisation of Mut1 to peroxisomes was observed (white arrows). GFP-
ACBD5TMD-T Mut2 and 3 were targeted to the ER and rarely showed dual 
targeting. Higher magnification view of boxed regions (see overview) is shown. 
Bars: 20 µm (overview), 5 µm (overlay). (C) Quantitative analysis of the 
subcellular localization of GFP-ACBD5TMD-T fusion proteins. The percentage of 
cells with peroxisomal (PO), mitochondrial (MITO), ER or shared localization is 
shown. Shared localization is as follows: WT/MUT1 – PO and MITO; MUT2 – 
MITO and ER; MUT3 – ER and PO. Values represent mean ± SEM of at least 
three independent experiments.  
 
Fig. 3.5 – Alterations in tail charge redirect FLAG-FIS1 to other organelles. 
(A) Overview of the domain structure of FIS1 and FLAG-FIS1 proteins (WT and 
SR), their subcellular localisation, TMD GRAVY and tail charge. TPR, 
Tetratricopeptide repeat domain. (D) COS-7 cells were transfected with FLAG-
FIS1 WT and SR. Fixed cells were labelled with antibodies against TOM20 
(mitochondrial marker) and FLAG. FLAG-FIS1 WT was dually targeted to 
peroxisomes and mitochondria in most cells. This targeting was shifted to 
peroxisomes in the SR mutant. Arrows point to peroxisome colocalization. 
Higher magnification view of boxed regions (see overview) is shown. Bars: 20 
µm (overview), 5 µm (overlay). (C) Quantitative analysis of the subcellular 
localization of FLAG-FIS1 WT and SR proteins. The percentage of cells with 
peroxisomal (PO), mitochondrial (MITO), ER or shared localization is shown. 
Shared localization is between mitochondria and peroxisomes. Values 
represent mean ± SEM of at least three independent experiments.  
 
3.2.4. TA proteins are targeted to peroxisomes via PEX19 
The peroxisomal chaperone PEX19 and the membrane protein PEX3 have 
been previously shown to interact with PEX26 and regulate its targeting and 
insertion in peroxisomes (Chen et al., 2014a; Halbach et al., 2006; Yagita et al., 
2013). Additionally, other TA proteins such as FIS1 and GDAP1 have also been 
shown to interact with PEX19 (Delille and Schrader, 2008; Huber et al., 2013). 
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To verify if ACBD5 and FALDH-PO also interact with PEX19, we co-expressed 
GFP-tagged versions of these proteins with HA-PEX19 in COS-7 cells, and 
performed co-immunoprecipitation experiments. As shown in figure 3.6A, HA-
PEX19 was co-immunoprecipitated with GPF-ACBD5 and GFP-FALDH-PO, 
supporting a role for this protein in the targeting of peroxisomal TA proteins. It 
should be noted that endogenous ACBD5 (60 kDa) and FALDH (55 kDa) 
generally run at a higher band size than expected, possibly due to post-
translational modifications Additionally, no interaction between FALDH-ER and 
PEX19 was found, pointing to the presence of a PEX19 binding site in the C-
terminal tail of FALDH-PO.  Next, we investigated the interaction of PEX19 with 
the GFP-ACBD5TMD-T fusion proteins, as altering the charge and hydrophobicity  
 
Fig. 3.6 – PEX19 affinity is a key determinant in targeting to the 
peroxisomal membrane. (A-B) Immunoblots (IB) of coimmunoprecipations 
from COS-7 cell lysates, expressing HA-PEX19 and various GFP fusions as 
indicated, using GFP-Trap. Cytosolic GFP was used as a control. (A) HA-
PEX19 was coimmunoprecipitated by GFP-ACBD5 and GFP-FALDH-PO, but 
not by GFP-FALDH-ER. (B) HA-PEX19 was coimmunoprecipitated with GFP-
ACBD5TMD-T WT but not by Mut1, Mut2 and Mut3. Input, 1% of total cell lysates; 
IP, immunoprecipitation. (C) Control and ΔPEX19 fibroblasts were transfected 
with GFP and FLAG fusions as indicated, fixed and labelled with antibodies 
against PEX14 (peroxisomal marker), TOM20 (mitochondril marker) and FLAG. 
In the absence of peroxisomes, all peroxisomal proteins were targeted to 
mitochondria. Higher magnification view of boxed regions (see top panel) is 
shown. Bars, 20 µm (top panel), 5 µm (lower panels). 
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of the tail and TMD should influence their binding. Our results show that 
whereas GFP-ACBD5TMD-T WT is bound by HA-PEX19, none of the mutant 
constructs is significantly associated with this chaperone (Figure 3.6B). We also 
analysed the targeting of GFP-FALDH-PO, GFP-ACBD5 and Flag-FIS1SR in 
cells lacking PEX19 (ΔPEX19 patient fibroblasts) (Figure 3.6C). Whereas in 
control fibroblasts the three proteins were targeted to peroxisomes, in ΔPEX19 
cells, which lack peroxisomes, all the tested proteins were targeted to 
mitochondria, suggesting that this might be the default pathway for peroxisomal 
TA proteins. Remarkably, even FALDH-PO was targeted to mitochondria 
instead of the ER, despite its high TMD hydrophobicity. 
 
3.2.5. Prediction of TA protein localisation in mammalian cells 
Having established the importance of tail charge and TMD hydrophobicity for 
protein targeting, we set out to create a targeting tool that would allow us to 
predict in silico the localisation of uncharacterized TA proteins. For this, a SVM 
classifier was trained using the TMD GRAVY, tail charge and cellular location of 
43 proteins from our dataset (Table 3.1). This classifier builds a statistical model 
that is able to predict the probability of a protein to be targeted to each 
organelle, using the TMD GRAVY and tail charge of that protein (Figure 3.7A). 
Three clusters (or regions of high class probability) of peroxisomal, 
mitochondrial and ER proteins can be clearly observed, with very few 
exceptions (i.e. mitochondrial TOMM22 clusters with ER). When using the 
highest probability class, the SVM misclassifies 9 of the 43 data points (21%) 
when used in an in-sample fashion. A more rigorous leave-one-out cross 
validation misclassifies 14 of the 43 data points (33%). Using this classifier, we 
tested a previously published list of TA proteins predicted in the human 
proteome (Kalbfleisch et al., 2007). For each entry, a probability of peroxisomal, 
mitochondrial and ER targeting was obtained (Appendix 1).The predicted 
localisation of three proteins was experimentally verified (Figure 3.7B). Of the 
tested proteins, ACBD4 was predicted and verified as a new peroxisomal 
protein (Figure 3.7B). This protein contains an acyl-CoA binding domain and 
belongs to the family of acyl-CoA binding proteins. Another protein which was 
also predicted to target peroxisomes is ATP5J2, a subunit of the mitochondrial 
ATP synthase complex. When expressed in COS-7 cells this protein shows a 
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dual targeting to peroxisomes and mitochondria (Figure 3.7B), and can induce 
some mitochondrial swelling. Finally we analysed the targeting of the predicted 
ER protein PPP1R3F, which is a regulatory subunit of protein phosphatase 
type-1 complexes. This was confirmed by expressing the myc-tagged protein in 
COS-7 cells. In the future, the localisation of these proteins should also be 
confirmed by analysing the localisation of the endogenous protein using 
antibodies. 
 
3.3. Discussion 
Regulated sorting of membrane proteins is a process that allows cells to strictly 
control the function of each individual compartment, whilst inhibiting the 
accumulation of hydrophobic and potently aggregated proteins in the cytosol 
(Mannini et al., 2014). A clear understanding of the basic signals that modulate 
this sorting would allow us, in principle, to predict the targeting of any given 
protein, and facilitate the understanding of protein function. TA proteins lack any 
identifiable consensus sequence that would allow their recognition by a 
targeting complex or chaperone, and have therefore been the object of intense 
research in the past few years (reviewed in Borgese and Fasana, 2011). Here, 
we have extended the existing information on TA protein localisation and 
characterized the targeting signals of peroxisomal TA proteins. Additionally, by 
taking advantage of the growing number of known TA proteins, we created a 
bioinformatic tool that allows us to predict membrane localisation. 
 
3.3.1. Where are TA proteins targeted too? 
TA proteins are targeted to several eukaryotic membranes, such as the ER and 
exocytic pathway, outer mitochondrial and chloroplast membrane, and 
peroxisomes (Borgese et al., 2007). While some proteins are exclusively 
targeted to one organelle, several have the ability to target two organelles, as 
exemplified by MFF, FIS1, GDAP1 and MAVS (Dixit et al., 2010; Gandre-Babbe 
and van der Bliek, 2008; Huber et al., 2013; Koch et al., 2005).  Our results 
show that more TA proteins have dual or even triple targeting (Figure 3.1, Table 
3.1), demonstrating that a thorough characterisation of these proteins is still 
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Fig. 3.7 – A combination of tail charge and TMD GRAVY allows prediction 
of organelle targeting for mammalian TA proteins. (A) SVM classifier plot 
showing clustering of TA proteins to different organelle locations based on TMD 
GRAVY and tail charge. Probability contours are as indicated. MITO, 
mitochondria; PO, peroxisomes; ER, endoplasmic reticulum; test – selected TA 
proteins (see B). (B) COS-7 cells were transfected with Myc fusions of ACBD4, 
ATP5J2, and PPP1R3F. Fixed cells were labelled with antibodies against 
PEX14 (peroxisomal marker), TOM20 (mitochondrial marker), PDI (ER marker) 
and Myc. Higher magnification view of boxed regions (see overview) is shown. 
Bars, 20 µm (overview), 5 µm (overlay). 
 
lacking. Discovery of a new cellular localisation for a protein could not only 
reveal new functions for an organelle, but uncover new layers of complexity for 
the regulation of that protein, with implications in pathological conditions. For 
example, the presence of BCL2-family proteins at peroxisomes could point to a 
previously unknown role of this organelle in apoptosis. Moreover, as the dually 
targeted proteins are both anti-apoptotic (BCL-XL and BCL2), this could point to 
a role of peroxisomes as signalling platforms during apoptotic stress. 
Yet, some caution should be taken when considering the results from our 
localisation experiments. As some of these proteins might have cell-type 
specific expression, their localisation in COS-7 might not be representative of 
their endogenous localisation. Additionally, as all of the proteins were 
overexpressed, some of the dual or triple targeting results could represent 
mistargeting to unspecific cellular membranes. For example, overexpression of 
ACBD5 (and FALDH-PO) led to mitochondrial targeting in some cells, even 
though endogenous ACBD5 has only been detected on peroxisomes (not 
shown). This could be overcome by analysing the localisation of the 
endogenous protein by IMF or WB of subcellular fractions. However, antibodies 
against the target proteins are not always available or working effectively. 
Despite our attempts to analyse several of these proteins, only a few of the 
available antibodies were functional in our set up. Interestingly, the antibody 
used against BCL2 showed a clear co-localisation with the peroxisomal marker 
PEX14 in IMF, as well as cytosolic staining, instead of the expected 
mitochondrial and ER staining (Figure 3.2). Similar results were obtained when 
analysing subcellular fractions of rat liver, where bands were found in the 
peroxisomal and cytosolic fractions. This could indicate that the antibody is 
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recognizing a protein isoform that is cytosolic and targeted to peroxisomes (or 
possibly two isoforms). 
 
3.3.2. How do TA proteins know where to go? 
Several studies have shown that targeting of TA proteins depends on several 
physicochemical parameters of their C-terminus, rather than a defined 
consensus sequence (Beilharz et al., 2003; Borgese et al., 2007; Kuroda et al., 
1998; Marty et al., 2014). Particularly, the hydrophobicity and length of the 
TMD, as well as the charge of the tail, seem to play key roles in targeting to the 
ER, mitochondria and peroxisomes (Horie et al., 2002; Mariappan et al., 2010; 
Yagita et al., 2013). While most of these studies use model proteins to test the 
effects of several mutations, additional biological input can be obtained by 
analysing larger groups of TA proteins (Borgese et al., 2007). Building on 
previous studies and taking advantage of the growing number of known TA 
proteins, we collected data on 50 proteins and re-analysed their 
physicochemical characteristics. In accordance with previous publications, the 
most relevant parameters for TA protein targeting were TMD hydrophobicity and 
tail charge (Figure 3.3). These two factors alone allowed us to cluster ER, 
mitochondrial and peroxisomal proteins, as show in our SVM classifier (Figure 
3.7).  
Our results show that exclusively peroxisomal TA proteins have a highly 
positive charged tail sequence when compared with proteins targeted to other 
organelles (Figure 3.3D). This characteristic was experimentally tested by 
gradually decreasing the tail charge in the GFP-ACBD5TMD-T fusion proteins 
(Figure 3.4), or increasing it as had been previously shown with Flag-FIS1SR 
(Figure 3.5) (Onoue et al., 2013). The initial shift in targeting to mitochondria 
and secondly to the ER is in agreement with previous data suggesting that a 
positively charged tail could significantly differentiate between mitochondrial and 
ER proteins (Borgese et al., 2007; Horie et al., 2002; Kuroda et al., 1998). 
Interestingly, while we do see this with the expressed proteins, our 
bioinformatics analysis doesn’t show any statistical differences between 
mitochondria and ER (Figure 3.3D), suggesting tail charge alone cannot be 
used to distinguish targeting to these two organelles.  
100 
TMD hydrophobicity has been previously shown to strongly correlate with TA 
protein targeting. Studies in yeast have shown a clear distinction between 
mitochondrial and ER proteins, with the former having a lower GRAVY than the 
latter (Figure 3.3A) (Beilharz et al., 2003). These results are frequently 
compared to TA proteins in humans, and are confirmed by our analysis (Figure 
3.3C). However, whereas a clear cut difference between mitochondrial and ER 
TMD hydrophobicity is seen in yeast (Figure 3.3A), an overlap between ER and 
mitochondrial TA proteins is observed with the human proteins (Figure 3.3B). 
This strongly suggests that this factor alone is also not sufficient to regulate 
targeting between these organelles. This is clearly exemplified by the two 
FALDH isoforms which have the same TMD GRAVY, and yet are targeted to 
distinct organelles, as a result of tail charge differences (Table 3.4). Curiously, 
peroxisomal TA proteins have a wide range of TMD hydrophobicity, leading to 
the assumption that this factor does not have a major role in peroxisomal 
targeting. However, when the GRAVY of GFP-ACBD5TMD-T was increased 
(Mut3), this protein was targeted to the ER (Figure 3.4A, B). Similar results have 
been shown in Neurospora crassa, where an increase in TMD hydrophobicity 
can shift the targeting of this protein to the ER (Chen et al., 2014a). These 
results suggest that a balance exists between TMD hydrophobicity and tail 
charge that determines the targeting of TA proteins. 
Finally, peroxisomal TA proteins also appear to have longer C-terminal tails 
(Figure 3.3E). Despite the significance of this result, we should note that only 4 
proteins were used for this analysis, and that this is not a pre-requisite for 
targeting since ACBD5, and the newly identified ACBD4, have short tails. 
Nonetheless, further testing could be performed by taking advantage of the 
FALDH isoforms. As these proteins have the same amino acid sequence apart 
from the tail segment, we could follow two approaches. On the one hand, we 
could mutate FALDH-ER to have the same charge as FALDH-PO, to 
understand if the long tail of FALDH-PO is necessary for peroxisomal targeting. 
On the other hand, we could gradually decrease the charge of FALDH-PO and 
see if a tail as long as 28 amino acids could be inserted in the ER. These 
approaches have recently been tested with PEX26 (Yagita et al., 2013). Using 
this model, the authors have shown that decreasing the tail charge or 
decreasing tail size while maintaining charge has the same effect, with PEX26 
being dually targeted to peroxisomes and mitochondria. 
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3.3.3. How are TA proteins targeted to peroxisomes? 
Previous studies have shown a role for import receptor/chaperone PEX19 in the 
targeting and insertion of peroxisomal TA proteins PEX26 (Pex15 in yeast) 
(Chen et al., 2014a; Halbach et al., 2006; Yagita et al., 2013) and FAR1 
(Honsho et al., 2013). This protein recognizes several peroxisomal membrane 
proteins (PMPs) through PEX19-binding sites, which contain several basic and 
hydrophobic residues near the TMD (Rottensteiner et al., 2004). Here, we show 
that ACBD5 and FALDH-PO interact with PEX19 (Figure 3.6A), strengthening 
the hypothesis that PEX19 is responsible for the targeting of TA proteins to 
peroxisomes. Additionally, PEX19 was able to bind GFP-ACBD5TMD-T WT, 
indicating that the targeting information of ACBD5 is located at its C-terminus. 
However, this interaction was lost when PEX19 was co-expressed with GFP-
ACBD5TMD-T mutants with altered TMD hydrophobicity or tail charge, implying 
that PEX19 loses affinity or is out-competed by other chaperones (e.g. TRC40) 
(Figure 3.6B). To test this, in vitro experiments were performed by collaborators 
using purified PEX19 and fluorescently labelled peptides for WT, Mut1 and 
Mut2 (unpublished data). These show similar affinities of PEX19 to WT and 
Mut1 fragments, and loss of affinity for Mut2, suggesting that the lack of 
interaction between PEX19 and Mut1 seen by co-immunoprecipitation could be 
due to competition with a yet unidentified mitochondrial chaperone, or 
differences in PEX19-Mut1 interaction stability between in vitro and in vivo 
experiments. Similar experiments should be performed using a recombinant 
version of the ER receptor TRC40, testing the binding of the protein to Mut2 and 
Mut3. 
Interestingly, in the absence of PEX19, and subsequently peroxisomes, 
ACBD5, FALDH-PO and FIS1-SR were targeted to mitochondria (Figure 3.6C). 
Whereas ACBD5 has a low TMD GRAVY, which is suitable for mitochondrial 
targeting, FALDH-PO has the same TMD GRAVY as its ER counterpart, 
suggesting that either the tail charge or the tail length of this protein inhibit 
binding by TRC40, and targeting to the ER. This supports a model where the 
mitochondrial pathway represents the default route for TA proteins, either by 
unassisted insertion (Pedrazzini et al., 1996) or by using a specific 
mitochondrial chaperone that is yet to be identified (Kemper et al., 2008). In 
favour of this, the recent identification on mitochondria of a degradation 
102 
pathway for mislocalised TA proteins, could represent an evolutionary 
mechanism to inhibit accumulation of peroxisomal (or other) TA proteins at this 
organelle (Chen et al., 2014b; Okreglak and Walter, 2014). As the protein 
responsible for this pathway (ATAD1) is also localised to peroxisomes, it would 
be interesting to see if it performs a similar function at this organelle. 
 
3.3.4. Can we predict TA protein targeting? 
TA proteins are present in all domains of life, including Archae and Bacteria 
(Borgese and Righi, 2010) and several bioinformatics studies have uncovered 
hundreds of potential new proteins in yeast, plants and mammals (Beilharz et 
al., 2003; Kalbfleisch et al., 2007; Kriechbaumer et al., 2009). Several of these 
proteins have been characterized and are linked to essential cellular processes. 
As there are still numerous uncharacterised proteins, a systematic analysis of 
their localisation would be a good starting point to find new functions.  
We started by looking at several biochemical parameters that could influence 
the targeting of these proteins (Figure 3.3) and using several approaches 
identified the TMD GRAVY and tail charge as the most relevant factors affecting 
targeting. Using this information we created a prediction tool that provides us 
with the probability of any given mammalian TA protein to be either 
mitochondrial, peroxisomal or ER (Figure 3.7A).  For these three major 
organelles, we were able to predict with up to 80% accuracy the targeting of TA 
proteins. Furthermore, using this prediction tool, we tested the targeting of 
several uncharacterised proteins (Figure 3.7B). Two of them, ACBD4 and 
PPP1R3F were targeted as predicted to peroxisomes and ER, respectively. A 
third one, ATP5J2, was targeted to peroxisomes and mitochondria but strongly 
predicted as peroxisomal (91.4% vs 5.9% to mitochondria) (Appendix 1). This 
result illustrates some of the weaknesses of a prediction based analyses, since 
ATP5J2 is part of the ATP synthase complex which is localised to the inner 
mitochondrial membrane (IMM). It is possible that, since so far no other proteins 
have been identified in the IMM, our predictor lacks information to compute this 
possibility, and fails to predict it. However, it remains to be shown if this protein 
is targeted and stable on peroxisomes at endogenous levels, and if so, what is 
its role on this organelle. 
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Prediction based approaches should be employed with caution. In this case, it 
should be noted that the data used to create this classifier was itself obtained 
through indirect approaches. Furthermore, the diversity of parameters that can 
influence such a complex process as protein targeting cannot be computed by a 
simple two variable analysis. Other factors such as targeting information 
present at the N-terminus could also affect the localisation of these proteins. 
Although TA proteins lack any known targeting sequences, it is still possible that 
some proteins possess yet unidentified targeting sequences, or are bound by 
other proteins during translation, which could affect their targeting. 
Nevertheless, this predictor was able to classify correctly the tested proteins 
(since ATP5J2 was found on peroxisomes), and these and other proteins can 
be added to it to further improve its power. Moreover, if other variables such as 
tail length are proven to affect targeting, these could be included, adding an 
extra dimension to the classifier. Finally, creating a similar predicting tool for 
yeast and plants, or integrating data from these organisms in the existing 
predictor, could in principle enable the analysis of other databases. 
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Chapter 4 – Results 
 
MIRO1 is a regulator of peroxisome motility and 
dynamics in mammalian cells 
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4.1. Introduction 
The regulation of organelle positioning within eukaryotic cells is crucial for the 
maintenance of cellular homeostasis, allowing cellular movement and 
polarisation, and facilitating metabolic and physical interactions between 
organelles (Jongsma et al., 2015; Knoblach and Rachubinski, 2016). 
Conversely, defects in organelle motility are associated with the development of 
severe neurodegenerative disorders such as Alzheimer’s and Parkinson’s 
disease (Devine et al., 2016; Mattson et al., 2008).  
In mammalian cells, peroxisomes are found associated with the microtubule 
cytoskeleton and move bidirectionally by associating with kinesin and dynein 
motors (reviewed in Neuhaus et al., 2016). Compared with other organelles, 
only a small proportion of peroxisomes (5-15%) show fast directional movement 
(Rapp et al., 1996; Schrader et al., 2000; Wiemer et al., 1997), which helps 
maintain a uniform distribution at optimal energy expenditure (Bonekamp et al., 
2012). However, little information is known on the molecular complexes 
regulating peroxisome motility. Recent studies have focused on identifying the 
protein linkers between peroxisomes and molecular motors. Dietrich and 
colleagues have shown a direct interaction between PEX1 and the minus-end 
directed motor KIFC3, proposing a role for these proteins in peroxisome 
tethering to microtubules and motility regulation (Dietrich et al., 2013). 
Additionally, PEX14 has been shown to interact directly with tubulin, revealing a 
possible role for this peroxin in the anchoring of peroxisomes to microtubules 
(Bharti et al., 2011). 
As established in chapter 3, several TA proteins are targeted to more than one 
organelle (Figure 3.1), and are particularly prone to be dually targeted to 
mitochondria and peroxisomes. Interestingly, MIRO1 and MIRO2, which were 
initially identified on the outer mitochondrial membrane (Fransson et al., 2003), 
are also targeted to peroxisomes when expressed in COS-7 cells (Figure 3.1A, 
B). Miro proteins form a family of Ras GTPases highly conserved throughout 
eukaryotes, known to play key roles in mitochondrial motility, homeostasis, 
inheritance and ER tethering (reviewed in Yamaoka and Hara-Nishimura, 
2014). Mammalian MIRO1 and MIRO2 share 60% similarity and an analogous 
structure containing two GTPase domains intercalated by two calcium binding 
EF hand motifs. Studies on mammalian MIRO proteins have focused mainly on 
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MIRO1 due its clear role in mitochondrial motility, particularly in neurons 
(MacAskill et al., 2009b; Wang and Schwarz, 2009). Here we show that 
endogenous and myc-tagged MIRO1 is localised to both mitochondria and 
peroxisomes, and that dual targeting depends on the C-terminal tail. 
Overexpression of wild-type and mutated MIRO1 alters peroxisome distribution 
either to the cell periphery or to the perinuclear area, and this effect is inhibited 
by microtubule depolymerising drugs. Live-cell imaging of peroxisomes in cells 
expressing an exclusively peroxisomal MIRO1 fusion protein revealed an 
increase in microtubule-dependent peroxisome motility, and suggests a role for 
motor forces on the formation of new peroxisomes. These findings support a 
mechanism in which MIRO1 bridges the interaction between peroxisomes and 
kinesin (plus-end) motors, and provides us with a tool to further analyse 
peroxisome dynamics in different cell types. 
 
4.2. Results 
4.2.1. MIRO1 is targeted to peroxisomes and interacts with the 
peroxisomal chaperone PEX19 
As shown in chapter 3, expressed myc-tagged MIRO1 is targeted to both 
peroxisomes and mitochondria in COS-7 cells (Figure 3.1A). To confirm these 
results, we analysed the endogenous localisation of MIRO1 in different cell 
types by IMF and immunoblotting using two antibodies. Interestingly, each 
antibody recognized different organelles in HepG2 cells. As shown in Figure 
4.1A, MIRO1 is recognized on mitochondria when using the HPA010687 
antibody, and on peroxisomes when using the PSI-8027 antibody. Both 
antibodies show some unspecific background staining in HepG2 cells. Although 
endogenous MIRO1 had been previously identified on mitochondria (Fransson 
et al., 2003; Saotome et al., 2008), no prior studies have shown its presence on 
peroxisomes, raising the possibility that our second antibody could be 
recognizing an unspecific protein on peroxisomes. While both antibodies are 
raised against N-terminal peptides of MIRO1, the immunogen sequence for 
PSI-8027 is not available, and therefore we do not know if both immunogens 
have sequence overlap. Furthermore, MIRO1 and MIRO2 share 69% sequence 
similarity at the N-terminus, raising the possibility that these antibodies could 
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Figure 4.1 – MIRO1 is targeted to peroxisomes and mitochondria in 
mammalian cells. (A) HepG2 cells were fixed and stained using two different 
antibodies against MIRO1 – HPA010687 (Sigma-Aldrich) and PSI-8027 
(ProSci), as well as antibodies against TOM20 (mitochondrial marker), PMP70 
and catalase (peroxisomal markers). Arrows point to the presence (n-p) or 
absence (f-h) of signal co-localisation with peroxisomes. (a-h) are confocal and 
(i-p) are epifluorescence microscopy. Scale bar: overview 20 µm, overlay 5 µm. 
(B) Detection of endogenous MIRO1 in subcellular fractions isolated from rat 
liver. Equal amounts of protein were separated by SDS-PAGE and 
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immunoblotted using both anti-MIRO1 antibodies, anti-ATP synthase α 
(mitochondrial marker), anti-GAPDH (cytosolic marker), anti-Cyclophilin (ER 
marker) and anti-PMP70 (peroxisomal marker). In accordance with (A), MIRO1 
was detected in the mitochondrial fractions (heavy and light) by the HPA010687 
antibody, and in the peroxisomal fraction (as well as light mitochondrial fraction) 
by PSI-8027. (C) Immunoblot of cell lysates from MIRO1 KO and control MEFs 
stained against MIRO1 (PSI-8027) and γ-tubulin. The PSI-8027 antibody 
specifically recognises MIRO1 in these cells. (D) Co-immunoprecipation from 
COS-7 cell lysates expressing HA-PEX19 and myc-MIRO1WT, using myc-
tagged agarose beads. HA-PEX19 was only co-immunoprecipitated in the 
presence of myc-MIRO1WT. Higher band in α-myc blot is unspecific and 
characteristic for this antibody. Input – 10% of total cell lysates. PNS – post 
nuclear supernatant, Mito – mitochondria, PO – peroxisome, IP – 
immunoprecipitation. 
 
recognise both proteins. To complement our observations, we tested both 
antibodies in subcellular fractions of rat liver (Figure 4.1B). While the 
HPA010687 antibody recognizes a protein in the heavy and light mitochondrial 
fractions, the PSI-8027 antibody recognizes a protein in the   light   
mitochondrial   and the highly purified peroxisome fractions.  Both proteins have 
similar sizes around 80 kDa, suggesting that each antibody could be 
recognizing different isoforms of MIRO1. Additionally, the PSI-8027 antibody 
recognizes two bands between 75 and 100 kDa in cell lysates from WT mouse 
embryonic fibroblasts (MEFs) but none in MIRO1 knockout (KO) MEFs (Figure 
4.1C), demonstrating that this antibody is recognizing MIRO1, and that 
endogenous MIRO1 is targeted to peroxisomes. Further experients should be 
performed to strengthen these observations, such as testing the HPA010687 
antibody on similar MEF WT and MIRO1 KO cell lysates, and performing 
depletion studies, to confirm that the antibodies are recognising MIRO1. 
Several TA proteins require PEX19 binding for targeting and insertion into the 
peroxisomal membrane, making it likely that MIRO1 is also bound and delivered 
to peroxisomes by this pathway. Evidence of this interaction was initially found 
by searching the BioGRID database (Stark et al., 2006), an interaction 
repository that compiles data from published literature. In particular, PEX19’s 
interaction with MIRO1 was identified in a high-throughput interaction study with 
PEX19 as bait (Huttlin et al., 2015). To confirm this, myc-MIRO1WT was co-
expressed with HA-PEX19 in COS-7 cells, and processed for co-
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immunoprecipitation using myc-tagged agarose beads. Similarly to other shared 
TA proteins (e.g. FIS1, GDAP1), PEX19 was bound to MIRO1 (Figure 4.1D), 
suggesting a role for this protein in the targeting of MIRO1 to peroxisomes.  
 
4.2.2. MIRO1 expression alters peroxisomal distribution in COS-7 cells 
MIRO1 has been shown to play a key role on mitochondrial motility in 
mammalian cells (MacAskill et al., 2009b; Saotome et al., 2008; Wang and 
Schwarz, 2009). To assess its role on peroxisomes we expressed WT and four 
mutated versions of myc-tagged MIRO1 in COS-7 cells, and analysed their 
effect on peroxisome dynamics (Figure 4.2). As previously described (Fransson 
et al., 2003, 2006), the expression of myc-MIRO1WT and mutants resulted in 
several mitochondrial phenotypes such as formation of perinuclear aggregates 
(Figure 4.2B i, m), highly elongated networks (Figure 4.2B e) and fragmented 
organelles (Figure 4.2B k). Conversely, expression of myc-MIRO1WT and 
mutants did not induce peroxisome elongation or network formation. Instead, 
depending on the expressed protein, peroxisomes accumulated at the cell 
periphery (Figure 4.2B a-d, i-j) or in intracellular inclusions (Figure 4.2B k-n), 
suggesting an effect on organelle motility. Expression of myc-Miro1WT induced 
the formation of peroxisome accumulations at the cell periphery in ~25% of 
transfected cells (Figure 4.2B, C), as shown at higher magnification (Figure 
4.2B b-d). Expression of the V13 mutant, which is constitutively active at the 
first GTPase domain, also induced the accumulation of peroxisomes at the cell 
periphery but to a lower extend than the WT protein (Figure 4.2B i-j, C). 
Additionally, expression of this mutant, as well as of myc-MIRO1N18 (dominant 
negative for the first GTPase domain) and myc-MIRO1KK (unable to bind 
calcium) led to the formation of peroxisome aggregates scattered through the 
cell (Figure 4.2B k-n, C). Finally, cells expressing myc-MIRO1ΔTM (lacking the 
TMD and tail sequence) showed a cytoplasmic distribution of this protein and 
had no visible effects on the peroxisomal network (Figure 4.2B o-p, C).  
As the expression of these constructs had severe effects on the mitochondrial 
network and, as result, on cellular homeostasis, we created an exclusively 
peroxisomal set of MIRO1 proteins. For this, two different strategies were 
developed by exchanging the TMD and tail of MIRO1 for new targeting  
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Figure 4.2 – Myc-MIRO1 is targeted to peroxisomes and alters their 
distribution. (A) Schematic view of MIRO1 domains and mutation sites. (B) 
COS-7 cells were transfected by turbofect with myc-MIRO1WT (a-h), myc-
MIRO1V13 (i-j), myc-MIRO1N18 (k-l), myc-MIRO1KK (m-n) and myc-
MIRO1ΔTM (o-p). Fixed cells were labelled with anti-myc, anti-PEX14 
(peroxisomes) and anti-TOM20 (mitochondria). Expressed myc-MIRO1WT 
localizes to peroxisomes and mitochondria, and alters their distribution (a-h). All 
of the expressed mutants show peroxisomal (and mitochondrial) localisation, 
except for the myc-MIRO1ΔTM which shows a cytosolic staining. All images are 
confocal. Scale bars: overview 20 µm, magnification 5 µm. (C) Quantitative 
analysis of peroxisomal distribution in control cells (no plasmid) and cells 
expressing different myc-MIRO1 plasmids. Cells with peroxisome 
accumulations in the periphery or scattered were counted. Values represent 
mean ± SEM of three independent experiments (100 replicates per experiment 
– total 300 cells per condition; ** p<0.01; *** p<0.001; one-way ANOVA with 
post hoc Tukey test against control cells).  
 
information (Figure 4.3A). Our first strategy was to insert MIRO1 into the GFP-
ACBD5TMD-T plasmid (see chapter 3), creating a GFP-tagged MIRO1 (GFP-
MIRO1WT-PO). Additionally, we exchanged the GFP-tag with the myc-MIRO1 
protein, creating myc-MIRO1WT-PO. Expression of both proteins led to a re-
distribution of peroxisomes to the cell periphery, confirming our previous results 
(Figure 4.3B). However, dual targeting to mitochondria and peroxisomes was 
still observed in several cells, particularly in cells with higher expression. 
Additionally, an increase in elongated peroxisomes was observed with the 
expression of GFP-MIRO1WT-PO, suggesting that the N-terminal tag could be 
affecting peroxisome membrane dynamics (Figure 4.3B).  
To overcome these issues, a second strategy was employed using a previously 
described PEX26/ALDP construct (Halbach et al., 2006). This fusion protein 
contains two PEX19 binding domains and two TMDs, and it has been shown to 
target GFP exclusively to peroxisomes (Figure 4.3A). Expression of the 
resulting myc-MIRO1WT-Pex protein in COS-7 cells revealed an exclusively 
peroxisomal targeting, with no effects on mitochondrial morphology and 
distribution (Figure 4.3C). In agreement with the dually targeted versions, 
expression of the myc-MIRO1WT-Pex and myc-MIRO1V13-Pex induced the 
accumulation of peroxisomes in the cell periphery, and expression of myc-
MIRO1N18-Pex and myc-MIRO1KK-Pex led to the formation of scattered 
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aggregates in the cell (Figure 4.3D, E). This effect was much more pronounced 
with the myc-MIRO1-Pex proteins than with the dually targeted myc-MIRO1 
(Figure 4.2C and Figure 4.3E). Additionally, peroxisomal proliferation was 
observed in some cells expressing myc-MIRO1WT-Pex and myc-MIRO1V13-
Pex, whereas others expressing myc-MIRO1N18-Pex and myc-MIRO1KK-Pex 
had lower number of peroxisomes. Organelle quantification was hindered by the 
overlap of peroxisomes at the periphery and in intracellular aggregates, but 
examples of these can be seen in figure 4.3D (e.g. myc-MIRO1V13-Pex and 
myc-MIRO1N18-Pex). These effects suggest that, similarly to the role on 
mitochondria, MIRO1 could be affecting peroxisome motility and as a result the 
position of this organelle in the cell. 
 
4.2.3. MIRO1 expression regulates peroxisome distribution in a 
microtubule-dependent manner 
MIRO1 is part of a protein complex that includes both kinesin and dynein 
motors and promotes mitochondrial movement through the microtubule 
cytoskeleton (reviewed in Devine et al., 2016). To test if the effect of MIRO1 
expression on peroxisome distribution is due to microtubule-dependent motility, 
COS-7 cells were transfected with myc-MIRO1WT-Pex and treated with the 
microtubule-depolymerizing drug nocodazole. After a 1 hour treatment, the 
majority of cells expressing myc-MIRO1WT-Pex no longer presented 
peroxisome accumulations at the cell periphery. After 4 hours no cells could be 
found with these accumulations (Figure 4.4A), suggesting that microtubule 
stability is necessary for the formation and maintenance of peroxisome 
accumulations at the cell periphery. Additionally, microtubule depolymerisation 
induced peroxisome elongation in several cells, as exemplified in the control 
cells (Figure 4.4A) and as previously described (Schrader et al., 1996). 
To quantify the effect of MIRO1 expression on peroxisome motility, live-cell 
imaging experiments were performed to track peroxisome movement over time. 
For this, COS-7 cells were dually transfected with myc-MIRO1V13-Pex and 
GFP-SKL (peroxisome marker) and imaged using a spinning disc microscope. 
This system allowed us to improve time resolution compared with previous 
studies. To analyse this data systematically, a tracking algorithm was developed  
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Figure 4.3 – Myc-MIRO1-Pex is exclusively targeted to peroxisomes and 
alters their distribution in COS-7 cells. (A) Cloning strategies to target 
MIRO1 exclusively to peroxisomes. The TMD and tail region of MIRO1 was 
substituted by i) the TMD and tail of the peroxisomal TA protein ACBD5, or ii) a 
PEX2626/ALDP fusion domain which has been previously shown to target GTP 
to peroxisomes (Halbach et al., 2006). (B-D) COS-7 cells were transfected with 
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GFP- or myc-tagged MIRO1 using turbofect and fixed after 24h. Cells were 
stained against myc, PEX14 and TOM20. (B) GFP- and myc-MIRO1WT-PO 
were targeted to peroxisomes in all cells and altered peroxisome distribution. 
However, weak mitochondrial staining was present in several cells, and 
increased peroxisome elongation was observed with the expression of GFP-
MIRO1-PO. (C) Myc-MIRO1WT-PEX was exclusively targeted to peroxisomes 
and induced their re-distribution to the cell periphery without affecting 
mitochondrial morphology and distribution. (D) Mutated myc-MIRO1-Pex 
proteins were exclusively targeted to peroxisomes and induced the formation of 
peroxisomes accumulations in the cell periphery (V13) or scattered (V13, N18 
and KK). (B) is epifluorescence and (C-D) are confocal microscopy. Scale bars: 
overview 20 µm, magnification 5 µm (E) Quantitative analysis of peroxisomal 
distribution in cells expressing different myc-MIRO1-Pex plasmids. Cells with 
peroxisome accumulations in the periphery or scattered were counted. Values 
represent mean ± SEM of three independent experiments (100 replicates per 
experiment – total 300 cells per condition; * p<0.05; ** p<0.01; *** p<0.001; one-
way ANOVA with post hoc Tukey test against control cells).  
 
by Jeremy Metz (Biomedical informatics hub analyst) to identify and follow 
individual peroxisomes, providing us with information on the speed of motile 
organelles. The myc-MIRO1V13-Pex plasmid was used due to its strong 
induction of peroxisome accumulations in the cell periphery. Figure 4.4 B shows 
the cumulative distribution function (CDF) for each group of cells. This function 
shows the distribution of the total population of peroxisomes (1.0), and each 
value of the curve corresponds to a single organelle movement. The total 
number of movements is aligned by increasing speeds to give the CDF. For this 
analysis, all speed values above 0.24 µm/s were considered microtubule 
dependent-movements as previously described (Bonekamp et al., 2012). A 
clear increase in the number of fast moving peroxisomes can be observed in 
cells expressing myc-MIRO1V13-Pex (Supp. Movie S1 and S2). Whereas in 
control cells the mean number of peroxisomes moving via microtubules was 
5.23 ± 0.66 %, in cells expressing myc-MIRO1V13-Pex this number increased 
to 13.99 ± 2.04 % (Figure 4.4C). The variation observed between cells 
expressing MIRO1 is likely a result of different levels of protein expression. 
Additionally, a close analysis of the peroxisomes accumulated at the cell 
periphery revealed that while the organelles seem to be confined to a relatively 
restricted area of the cell, peroxisomes regularly move within these structures, 
revealing very dynamic interactions (Supp. Movie S3).  
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Figure 4.4 – MIRO1 expression increases microtubule-dependent 
peroxisome motility in COS-7 cells. (A) COS-7 cells were transfected with 
myc-MIRO1WT-Pex and, after 24 hours, treated with 10 µM nocodazole or 
DMSO (control), for 4 hours. Fixed cells were stained against myc (green) and 
TUBULIN (red). Cells expressing myc-Miro1WT-Pex no longer showed 
aggregates at the cell periphery after treatment with nocodazole. (B-C) COS-7 
cells were transfected with myc-Miro1V13-Pex and GFP-SKL and seeded in 
glass-bottom dishes prior to imaging. For each cell analysed, 500 stacks of 5 
planes were obtained over time, and peroxisomes were detected and tracked 
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using an automated algorithm and manually checked. (B) Cumulative 
distribution function (CDF) of control (blue line) and myc-MIRO1V13-Pex 
expressing cells (red line), plotted against peroxisome speed. A threshold of 
0.24 µm/s was defined for microtubule dependent-motility (Bonekamp et al., 
2012). There is a clear increase in the number of peroxisomes moving in a fast 
directed motion, suggestive of microtubule-dependent motility. (C) Percentage 
of fast moving peroxisomes per cell in control (5.23 ± 0.66) and myc-
MIRO1V13-Pex cells (13.99 ± 2.04). Values represent mean ± SEM of 20 to 30 
cells obtained in three independent experiments (*** p<0.001; two-tailed 
unpaired t-test against control cells). (D) Silencing of MIRO1 in HepG2 cells 
after 72 hours transfection with lipofectamine 3000. (E) Control and MIRO KO 
MEFs were transfected by microporation with GFP-SKL and fixed after 24 
hours. No differences in peroxisome morphology and distribution were 
observed. (F-G) Control and MIRO1 KO MEFs were transfected with GFP-SKL 
and seeded in glass-bottom dishes prior to imaging. For each cell analysed, 250 
stacks of 9 planes were obtained over time. (F) CDFs of control (blue line) and 
MIRO1 KO cells (red line), plotted against peroxisome speed. No changes in 
peroxisome motility were observed in the absence of MIRO1. (G) Percentage of 
fast moving peroxisomes per cell in control (5.54 ± 0.95) and MIRO1 KO cells 
(5.28 ± 0.93). Values represent mean ± SEM of 8 to 12 cells obtained in 1 
experiment. (H) Percentage of fast moving peroxisomes per cell in control (5.57 
± 0.74) and calcimycin treated cells (6.54 ± 1.44). Values represent mean ± 
SEM of 13 to 17 cells obtained in 2 experiments (A-E) All images are from 
epifluorescence microscopy. Scale bars: 20 µm.  
 
To further analyse the effects of MIRO1 on peroxisome motility, we aimed to 
silence this protein in HepG2 cells (Figure 4.4D). However, after several 
attempts using two different pools of MIRO1 siRNA (see table 2.7) and different 
concentrations, we were unable to silence this protein. As a control for the 
silencing procedure, additional proteins were successfully silenced using the 
same procedure (not shown). To overcome this issue, we examined 
peroxisome distribution and motility in MIRO1 KO MEFs (Figure 4.4E-G). These 
cells, which were initially described by the Nguyen et al., have an altered 
mitochondrial distribution but no alterations of peroxisome morphology and 
distribution (Nguyen et al., 2014). In agreement, we did not find any alterations 
in peroxisome distribution (Figure 4.4E) nor motility (Figure 4.4F-G) (Supp. 
Movie S4 and S5). Finally, as MIRO1 has been described as a calcium sensing 
protein, inhibiting mitochondrial motility in conditions of high cytosolic Ca2+ 
concentrations, we tried to verify if the same was true for peroxisomes. To test 
this, we treated COS-7 cells with the calcium ionophore calcimycin for 10 
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minutes prior to imaging, which should lead to an influx of calcium from the 
growing medium to the cells (Huber et al., 1997; Wang and Schwarz, 2009). 
However, we were unable to see any changes of peroxisome motility in COS-7 
cells using this method (Figure 4.4H). Furthermore, treatment with this 
ionophore, even at low concentrations, increased cell death, as observed during 
live-cell imaging. 
 
4.2.4. MIRO1 expression in fibroblasts induces organelle proliferation 
Protein expression and regulation can vary between different cell types, 
stressing the need to test different conditions when characterising protein 
function. For example, whereas early studies on MIRO1 in COS-7 cells 
suggested a role for it in apoptosis (Fransson et al., 2003), later studies 
identified its role in mitochondrial motility in cardiomyocytes and neuronal cells 
(MacAskill et al., 2009b; Saotome et al., 2008; Wang and Schwarz, 2009). To 
further analyse MIRO1 and its function at peroxisomes, we expressed myc-
MIRO1WT-Pex in primary human skin fibroblasts (C109) and looked at its effect 
after 24 hours (Figure 4.5A). Surprisingly, in these cells peroxisomes did not 
accumulate at the cell periphery but instead proliferated, presenting a 
significantly higher number of peroxisomes when compared with control cells 
(Figure 4.5A, B). Additionally, peroxisome motility was also significantly higher 
(Figure 4.5C, D) (Supp. Movie S6 and S7), suggesting that organelle 
proliferation could be a result of increased motility. As the mean peroxisome 
motility in control fibroblasts is lower than in control COS-7 cells (4.51 ± 0.43 vs 
5.23 ± 0.66 %), this could also point to the presence of stronger peroxisomal 
tethers in fibroblasts or differences in motility regulation. To further analyse this, 
we expressed myc-MIRO1WT-Pex in two patient cell lines with altered 
peroxisome number, size and motility. ΔPEX5 and ΔPEX14 fibroblasts lack 
matrix protein import, and have less and larger peroxisomes. Additionally, 
ΔPEX14 patient fibroblasts have been described as lacking peroxisome motility 
(Bharti et al., 2011). Expression of myc-MIRO1WT-Pex in both ΔPEX5 and 
ΔPEX14 cells induced peroxisome proliferation (Figure 4.5B, E, F), creating a 
mixed population of large and small peroxisomes. Similarly to C109 cells, 
MIRO1 expression also significantly increased organelle motility (Figure 4.5D) 
(Supp. Movie S8-11), most prominently in the smaller peroxisomes. It should be 
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Figure 4.5 – MIRO1 expression induces peroxisome proliferation in human 
skin fibroblasts. (A) C109 cells were transfected with myc-MIRO1WT-Pex by 
microporation and fixed after 24 hours. Cells were stained against PEX14, 
TOM20 and myc. Expression of myc-MIRO1WT-Pex significantly increased the 
number of peroxisomes. (B) Quantitative analysis of peroxisome number in 
C109, ΔPEX5 and ΔPEX14 cells. In all tested fibroblast cell lines, expression of 
myc-MIRO1WT-Pex significantly increased peroxisome number: C109 – 741 ± 
53 vs 1040 ± 101, ΔPEX5 – 304 ± 27 vs 710 ± 51, and ΔPEX14 – 268 ± 18 vs 
457 ± 58. Values represent mean ± SEM of 24 to 29 cells obtained from three 
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independent experiments. (C-D) Human skin fibroblasts were transfected with 
GFP-ACBD5TMD-T (peroxisome membrane marker) on its own, or co-transfected 
with myc-MIRO1WT-Pex, and seeded in glass-bottom dishes prior to imaging. 
For each cell analysed, 250 stacks of 9 planes were obtained over time, and 
peroxisomes were detected and tracked using an automated algorithm and 
manually checked. (C) Cumulative distribution function (CDF) of control (blue 
line) and myc-MIRO1WT-Pex expressing (red line) C109 cells, plotted against 
peroxisome speed. Microtubule dependent-motility was defined above 0.24 
µm/s (Bonekamp et al., 2012). There is a clear increase in the number of 
peroxisomes moving in a fast directed motion, suggestive of microtubule-
dependent motility. (D) Percentage of fast moving peroxisomes per cell in 
control and myc-MIRO1WT-Pex expressing fibroblasts. In all tested cell lines, 
peroxisome motility was significantly increased upon MIRO1 expression: C109 
– 4.51 ± 0.43 vs 11.05 ± 1.32, ΔPEX5 – 1.61 ± 0.20 vs 8.25 ± 1.17, ΔPEX14 – 
3.36 ± 0.30 vs 8.30 ± 1.59. Values represent mean ± SEM of 14 to 26 cells 
obtained in three independent experiments. (E-F) ΔPEX5 and ΔPEX14 cells 
were transfected with myc-MIRO1WT-Pex by microporation and fixed after 24 
hours. Cells were stained against PEX14, PMP70, TOM20 and myc. Expression 
of myc-MIRO1WT-Pex significantly increased the number of peroxisomes. All 
images are from epifluorescence microscopy. Scale bars: overview 20 µm, 
magnification 5 µm. (B-D) * p<0.05; ** p<0.01; *** p<0.001; one-way ANOVA 
with post hoc Tukey test against control cells. 
 
noted that, since these fibroblasts have defects in matrix protein import, a 
different organelle marker was used to observe peroxisomes by live-cell 
imaging. For these experiments we expressed GFP-ACBD5TMD-T in both patient 
and control fibroblasts. Although expression of this membrane marker had no 
effects on peroxisome motility when compared to GFP-SKL in C109 fibroblasts 
(not shown), some peroxisomal proliferation was observed, particularly in 
ΔPEX5 and ΔPEX14 patient fibroblasts. 
 
4.2.5. MIRO1 expression in patient fibroblasts induces the formation of 
organelle elongations 
In addition to its effect on peroxisome number and motility, MIRO1 expression 
in patient fibroblasts induced the formation of peroxisome elongations (Figure 
4.6). As shown in figure 4.6A, expression of myc-MIRO1WT-Pex in ΔPEX5 cells 
induced the formation of long peroxisomal structures, usually following straight 
lines with sporadic bends, suggestive of an organelle following one or several 
120 
microtubules. To test this hypothesis, ΔPEX5 cells expressing myc-MIRO1WT-
Pex were fixed with methanol and paraformaldehyde, and co-stained with 
tubulin to mark microtubules (Figure 4.6B). In these conditions, several of the 
observed elongations were co-localising with microtubules, suggesting that their 
formation could be a result of a motor force pulling peroxisomes by moving 
through microtubules. Furthermore, whereas myc-MIRO1WT-Pex appears 
homogeneously distributed over the length of the elongation, PEX14 is more 
strongly accumulated at one of the extremities, suggesting that these 
elongations extend from a large peroxisome, and might give rise to new 
organelles (Figure 4.6A). To verify this, we re-analysed the data obtained for the 
motility analysis and examined the formation of these structures. A time-lapse 
analysis of this motility showed that peroxisome elongations originate from large 
peroxisomes, can grow at varying speeds and generally form relatively straight 
lines in a single direction (Figure 4.6C, D) (Supp. Movie S12 and S13). These 
elongations can sometimes quickly retract, suggesting that the peroxisomal 
membrane has elastic properties (Figure 4.6C, D). A meticulous analysis of all 
the videos previously acquired showed that these elongations are formed both 
in ΔPEX5 and ΔPEX14 patient fibroblasts, albeit more frequently in ΔPEX5 
(Figure 4.6E). Additionally, expression of myc-MIRO1WT-Pex significantly 
increased the length of these elongations in ΔPEX5 cells but not in ΔPEX14 
cells, suggesting that the PEX14 absence could be interfering with the stability 
of elongated peroxisomal structures.  
 
4.3. Discussion 
Organelles move within (and between (Ahmad et al., 2014)) cells in order to 
perform localised functions, communicate with other organelles, and to enable 
segregation during cell division (Jongsma et al., 2015; Sheng and Cai, 2012). 
Whereas peroxisome motility is a well described process in yeast, showing its 
importance for organelle inheritance, little is known about its function and 
regulation in mammalian cells (Knoblach and Rachubinski, 2016; Neuhaus et 
al., 2016). Having a clear picture of how peroxisome motility is regulated in 
mammalian cells would not only contribute to our understanding of this 
organelle, but also provide us with tools to further analyse peroxisomes and 
their role in the cellular environment. Here we show that the Ras GTPase 
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Figure 4.6 – Expression of MIRO1 increases the length of peroxisomal 
elongations in ΔPEX5 patient fibroblasts. (A-B) ΔPEX5 patient fibroblasts 
were microporated with myc-MIRO1WT-Pex and fixed after 24 hours. (A) Cells 
were stained against myc and PEX14. The majority of observed elongations in 
fixed cells show an evenly distributed myc-MIRO1 signal, likely originating from 
a large peroxisome as shown by the strong PEX14 staining at one of the 
extremities. (B) ΔPEX5 cells were fixed using methanol (see 2.5) and stained 
against PEX14 and TUBULIN. Elongated peroxisomal structures were usually 
found overlaying microtubules. (C-D) ΔPEX5 patient fibroblasts were 
transfected with GFP-ACBD5TMD-T (peroxisome membrane marker) and myc-
MIRO1WT-Pex, and seeded in glass-bottom dishes prior to imaging. (C) Time 
lapse of peroxisome elongation forming and retracting in a ΔPEX5 cell 
expressing GFP-ACBD5TMD-T and myc-MIRO1WT-Pex. (D) Kymograph of 
peroxisome elongation observed in (C). Scale bars: 20 seconds (vertical), 5 µm 
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(horizontal). (E) Quantitative analysis of peroxisome elongation length in ΔPEX5 
and ΔPEX14 cells. Expression of myc-MIRO1WT-Pex significantly increased 
the length of peroxisomal elongations in ΔPEX5 cells (1.62 ± 0.08 vs 2.21 ± 
0.15), but not in ΔPEX14 cells (1.44 ± 0.07 vs 1.47 ± 0.09). Values represent 
mean ± SEM of measurements made in 22 to 29 cells obtained from three 
independent experiments (*** p<0.001; two-tailed unpaired t-test against control 
cells). (A) is epifluorescence, (B) confocal and (C) spinning disc microscopy. 
Scale bars: overview 20 µm, magnification 5 µm. 
 
MIRO1 is a peroxisomal TA protein, and that it plays a role in peroxisome 
microtubule-dependent motility. Furthermore, we propose that peroxisome 
motility contributes to the formation of new peroxisomes, likely playing an 
important role in peroxisome inheritance in mammalian cells. 
 
4.3.1. Where is MIRO1 targeted to? 
Reports have shown that Miro proteins are targeted to mitochondria in several 
organisms from yeast, to plants and mammals, and play key roles in this 
organelle’s motility and homeostasis (reviewed in Yamaoka and Hara-
Nishimura, 2014). Due to its topological grouping within the TA proteins, we 
expressed and analysed the localisation of MIRO1. Interestingly, expressed 
myc-MIRO1 was not only targeted to mitochondria but also to peroxisomes (see 
Figure 3.1). Analysis of the localisation of the endogenous protein in both 
HepG2 cells and highly purified peroxisome fractions from rat liver confirmed 
these results (Figure 4.1). Strangely, the two antibodies used in these 
experiments recognised difference subcellular structures in HepG2 cells. This 
could be due to the existence of two (or more) protein isoforms localised to 
different organelles, each of which is recognized by one antibody. However, 
both antibodies recognize partly overlapping sequences at the N-terminus, and 
should be able to recognize all of the currently identified MIRO1 isoforms (not 
shown). Another hypothesis could be that one of the antibodies is specifically 
recognizing a post-translationally modified isoform specific to one of the 
organelles. It would be interesting to clone and express different isoforms of 
MIRO1 to test if all are dually targeted to peroxisomes and mitochondria, and if 
they are differently recognised by each antibody. Furthermore, MIRO1 was 
found to interact with the peroxisomal chaperone PEX19 by co-
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immunoprecipitation. It should be noted that, similarly to previous PEX19-TA 
protein co-IP experiments (Delille and Schrader, 2008), a cross-linking reagent 
was used to stabilise the PEX19-MIRO1 interaction. Further experiments to 
confirm this interaction should be performed, in particular in the absence of 
cross-linker. Nevertheless, this result further strengthens the hypothesis that 
endogenous MIRO1 is targeted to peroxisomes, and that peroxisomal TA 
proteins are targeted to this organelle by the same pathway as several other 
peroxisomal membrane proteins (Giannopoulou et al., 2016). It would be 
interesting to further investigate the biochemical interaction of PEX19 and 
MIRO1, and to see if the same domains that are responsible for the recognition 
and targeting of PMPs also interact with MIRO1.  
 
4.3.2. What is MIRO1’s role at peroxisomes? 
Several studies have characterised the role of MIRO1 on mitochondrial motility 
in mammalian cells (reviewed in Devine et al., 2016). However, other roles in 
mitochondrial homeostasis and calcium regulation have also been suggested 
(Chang et al., 2011; Frederick et al., 2004). Furthermore, MIRO1 has been 
shown to interact with several proteins such as MFN1, MFN2 and ARMC3, 
without clear functions associated with these interactions (López-Doménech et 
al., 2012; Misko et al., 2010). As shown in figures 4.2 and 4.3, expression of 
myc-tagged MIRO1 in COS-7 cells had a clear effect on peroxisome 
distribution, leading to peroxisome accumulations both at the cell periphery and 
within the cell, depending on which version of the protein was expressed. Since 
the expression of myc-MIRO1 had strong effects on mitochondrial morphology 
and cellular homeostasis, we created an exclusively peroxisomal version of 
MIRO1 (myc-MIRO1-Pex), which enabled us to clearly analyse the effects of 
MIRO1 expression on peroxisomes. This was done by substituting the TMD and 
tail of MIRO1 by a PEX26/ALDP construct, with two TMDs and two PEX19 
binding sites. This strategy altered the topology of MIRO1, which could have an 
effect on the protein’s function or ability to interact with other proteins. 
Furthermore, despite the effects observed on peroxisome motility, which are in 
agreement with a cytosolic orientation of MIRO1 in the Pex constructs, an 
analysis of protein topology should be performed to confirm the localisation of 
the N and C terminus of this protein.   
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Our attempt to maintain MIRO1 as a TA protein by changing its C-terminus to 
that of the peroxisomal ACBD5 led to a high number of cells with mitochondrial 
targeting. This could be due to: 1) the presence of additional targeting 
information in MIRO1 that enables some of the expressed protein to target 
mitochondria; 2) ambiguity in the targeting information present at ACBD5’s TMD 
and tail fragment, as observed by the expression of GFP-ACBD5TMD-T, which is 
dually targeted to peroxisomes and mitochondria in ~15% of cells (see Figure 
3.4); 3) an overload of the targeting system due to protein overexpression, 
which could allow mistargeting to other organelles. As a mechanism for the 
degradation of mistargeted TA proteins at mitochondria has been described 
(see 1.2.2) (Chen et al., 2014b; Okreglak and Walter, 2014), it would be 
interesting to test if expression of ATAD1 in these cells would induce the 
degradation of myc/GFP-MIRO1WT-PO at mitochondria.  
Since expression of myc-MIRO1WT-Pex led to the accumulation of 
peroxisomes at the cell periphery, this would suggest that MIRO1 plays a 
similar role at peroxisomes as that of mitochondria, increasing microtubule plus-
end directed motility. In agreement with this, similar peroxisome accumulations 
have been previously observed using an inducible cargo assay where kinesin 
motors are artificially tagged to peroxisomes in a regulated and inducible 
manner (Kapitein et al., 2010). Expression of a mutated MIRO1 protein, which is 
constitutively active at the first GTPase domain (myc-MIRO1V13-Pex), further 
increased the number of cells with peroxisome accumulations at the cell 
periphery (Figure 4.3E). Although still poorly understood, as MIRO1’s first 
GTPase domain enables its interaction with TRAK proteins (Fransson et al., 
2006), expression of WT and a constitutively active protein might favour the 
activity of the motility complex.  
Concurrently, expression of a dominant negative mutant for the first GTPase 
domain (myc-MIRO1N18-Pex) led to the formation of peroxisome 
accumulations within the cell, and at times closer to the nucleus. This could 
point to either a defect/loss of motility, or an increase in minus-end directed 
motility (dynein-dependent), which has also been previously shown to depend 
on the MIRO1/TRAK complex (Morlino et al., 2014; van Spronsen et al., 2013). 
Since several cells expressing this protein also appeared to have less 
peroxisomes, it might be that an inactive MIRO1 at the first GTPase inhibits 
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peroxisome motility, which could either prevent peroxisome growth and division, 
or signal for peroxisome degradation. This can to some extent mimic the 
phenotypes present in some peroxisome patient fibroblasts, where a reduced 
number of peroxisomes and altered distribution has been associated with 
motility defects (Nguyen et al., 2006).  
Lastly, expression of myc-MIRO1KK-Pex, a mutant for both calcium binding EF-
hands, had a very similar phenotype to myc-MIRO1N18-Pex, suggesting that 
the proteins inability to bind calcium could also inhibit organelle motility. These 
two mutants were also previously shown to induce similar phenotypes on 
mitochondria in COS-7 cells (Fransson et al., 2006). Further studies should be 
performed to analyse the effect of these mutants on peroxisomes in neuronal 
cells. In these, expression of the WT and dominant negative mutant induces a 
similar phenotypes on mitochondrial motility and distribution in these cells, 
whereas the expression of constitutively active MIRO1 appears to decrease the 
number of moving mitochondria in axonal processes (MacAskill et al., 2009a). 
To confirm that the changes observed on peroxisome distribution were due to 
microtubule-dependent motility, we treated cells expressing myc-MIRO1WT-
Pex with nocodazole (Figure 4.4). In these cells, peroxisomes were no longer 
accumulated at the cell periphery, confirming that this effect in dependent on 
the microtubule cytoskeleton. Similar experiments should be performed using 
myc-MIRO1N18-Pex and KK-Pex, to test if the peroxisome accumulations 
observed in these cells start to disperse after a few hours or if, for example, 
peroxisomes proliferate. Furthermore, a live-cell imaging approach was used to 
track the movement of individual peroxisomes. Expression of myc-MIRO1-V13-
Pex in COS-7 cells induced a significant increase in the number of fast-moving 
peroxisomes, strengthening the view that organelle accumulation at the 
periphery is due to an increase in anterograde transport. To complement these 
observations, we tried to knockdown MIRO1 in HepG2 cells and analyse if there 
were any changes in peroxisome distribution and motility. Unfortunately, despite 
our attempts (using two different pools of MIRO1 siRNA and different 
concentrations), we were unable to decrease the levels of this protein (Figure 
4.4D). To overcome this issue, we obtained MEFs of MIRO1 KO mice and 
analysed both peroxisome distribution and motility in these cells (Figure 4.4E-
G). As previously reported, despite the changes in mitochondrial distribution 
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observed in MIRO1 KO MEFs, no alterations of peroxisome distribution were 
observed (Figure 4.4E) (Nguyen et al., 2014). Furthermore, we did not detect 
any changes of peroxisome motility by live-cell imaging. Although unexpected, 
and to some degree conflicting with our previous results, it should be noted that 
only a small proportion of peroxisomes present microtubule-dependent motility. 
If other motility complexes are present at peroxisomes, these could be sufficient 
to compensate for the absence of MIRO1. For example, MIRO2 also localises 
to peroxisomes when expressed in COS-7 cells (see Figure 3.1), and might play 
a similar role on peroxisome motility. Additionally, alternative motility complexes 
yet unidentified might also contribute to peroxisome motility. An alternative way 
to analyse the effect of endogenous MIRO1 on peroxisome motility might be to 
overexpress PEX19. If this protein is the de facto chaperone responsible for 
MIRO1 targeting to peroxisomes, an increase in its availability might shift a 
higher pool of MIRO1 to peroxisomes and, similarly to the results obtained with 
myc-MIRO1WT expression, increase plus end directed motility.    
MIRO1 has also been described as a calcium sensing protein, inhibiting 
mitochondrial motility in response to increases in intracellular Ca2+ 
concentration (MacAskill et al., 2009b; Wang and Schwarz, 2009). Additionally, 
peroxisome motility has been previously shown to cease upon treatment with 
calcium ionophores, which induce an increase in intracellular calcium (Huber et 
al., 1997). As this could be due to Ca2+ binding by MIRO1, we tried an 
experimental set up to test the effects of calcium on peroxisome motility in 
COS-7 cells. Unfortunately, after several tries, we were unable to replicate the 
previously published results. Further experiments should be performed testing 
different calcium ionophores, as well as calcium indicator dyes for microscopy.  
 
4.3.3. How does peroxisome motility regulate organelle dynamics? 
As previously established, peroxisomes are highly dynamic organelles 
responding to changes in the cellular environment by adapting their shape, 
number, localisation and size (Schrader et al., 2016). However, the role of 
motility in several processes such as peroxisome proliferation, degradation and 
inheritance is still poorly understood in mammalian cells (Neuhaus et al., 2016). 
In yeast, motility plays an essential role in peroxisome segregation to the 
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budding cell, with the inheritance of peroxisomes proteins 1 and 2 (Inp1 and 
Inp2) playing crucial roles in the maintenance of peroxisomes in the mother cell 
(Inp1), and the myosin-dependent transport of peroxisomes to the daughter cell 
(Inp2) (Fagarasanu et al., 2010). Although no homologs for the Inp proteins 
have been found in mammalian cells, it is likely that peroxisome partitioning 
during the cell cycle also relies on a cytoskeleton-dependent reorganization of 
the peroxisomal network, as suggested by observations of peroxisome clusters 
at spindle poles during metaphase (Knoblach and Rachubinski, 2016; Kredel et 
al., 2009). However, unlike in yeast, this distribution likely relies on microtubules 
and associated motor proteins. In line with this, Kanfer et al. have recently 
described a role for MIRO1 in mitochondrial distribution during the cell cycle, by 
interacting with the microtubule growing tip associated protein CENP-F (Kanfer 
et al., 2015). It would be interesting to see if a similar mechanism is regulating 
peroxisome distribution during the cell cycle.  
Another likely role for peroxisome motility is in the formation of new 
peroxisomes. Although peroxisomes are still able to elongate and divide in the 
absence of microtubules, as observed when cells are treated with microtubule 
depolymerising drugs, they are unable to uniformly disperse, forming clusters 
(Schrader et al., 1996; Wiemer et al., 1997). The peroxisome proliferation 
observed after myc-MIRO1-Pex expression in human fibroblasts, and to a 
lesser extent in COS-7 cells, points to a likely role for peroxisome motility in 
organelle growth and division (Figure 4.5). In these cells, the increase in 
peroxisomal linkers (i.e. myc-MIRO1WT-Pex) for motor proteins, likely 
increases the pulling forces exerted on the peroxisomal membrane, leading to 
its bending and likely facilitating division (Zimmerberg and Kozlov, 2006). This is 
further strengthened by the observation of peroxisome elongations in ΔPEX5 
and ΔPEX14 fibroblasts, which could facilitate peroxisome division by forming 
narrow tubules for DLP1-dependent division. In these cells, peroxisomes are 
usually larger and less frequently, likely due to changes in metabolism that alter 
membrane composition, and peroxisomes ability to divide (Itoyama et al., 2012). 
This process would explain how these patient fibroblasts can be maintained for 
several generations while keeping a low but constant pool of peroxisomes. It 
should be noted that similar peroxisomal elongations have also been observed 
in plant cells, known as peroxules (Barton et al., 2014). These can form in 
response to hydroxyl ROS and exposure to UV light (Sinclair et al., 2009), and 
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have been suggested to play a role in organelle growth and division (Jedd and 
Chua, 2002), as well as organelle tethering, since peroxule formation allows two 
organelles to keep interacting despite opposing pulling forces (Gao et al., 2016). 
Another interesting observation is the lack of peroxisome accumulations at the 
cell periphery in human fibroblasts in comparison with COS-7 cells. This 
suggests that peroxisome motility is differently regulated between cell types. In 
this case, since peroxisome motility in control fibroblasts appears to be lower 
than in COS-7 cells, it is possible that peroxisomes are more tethered to 
microtubules or other organelles in fibroblasts. One such tether could be PEX14 
due to its ability to directly interact with TUBULIN (Bharti et al., 2011). In line 
with this, we saw less elongations in ΔPEX14 cells in comparison to ΔPEX5, 
suggesting that in the absence of this protein peroxisomes might be less 
attached to microtubules and consequently less likely to be pulled. When 
MIRO1 was expressed in these cells, we also did not see an increase in the 
length of elongations, suggesting that a strong tether is necessary for an 
opposing motor force to enable the formation of an elongation. Further 
experiments should be performed with fixed cells to test if elongated 
peroxisomes in ΔPEX14 cells are also co-localising with microtubules (as 
performed for ΔPEX5 cells). Nevertheless, expression of MIRO1 still increased 
peroxisome motility in ΔPEX14 cells, most significantly in small peroxisomes, 
showing that these organelles are still able to move and their motility can be 
increased by higher motor recruitment to the organelle.  
129 
 
 
 
 
 
 
 
 
Chapter 5 – Results 
 
Investigating the role of TRAK1 in peroxisome 
motility in mammalian cells 
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5.1. Introduction 
As previously described, MIRO proteins are part of a protein complex that 
regulates mitochondrial (and peroxisomal) motility in mammalian cells. TRAK1 
and/or TRAK2 are essential elements of this complex which enable MIRO’s 
interaction with kinesin and dynein motors (van Spronsen et al., 2013), and 
regulate motility in response to cellular cues, such as an increase in intracellular 
glucose (Pekkurnaz et al., 2014). 
Both TRAK1 and TRAK2 are cytoplasmic proteins which lack any obvious 
domain structure apart from an N-terminal coiled-coil region homologous to the 
huntingtin-associated protein 1 (HAP1) domain (Stowers et al., 2002), which 
can be found in several motor-interacting proteins. These proteins interact 
directly with the kinesin heavy chain (KHC) to enable cargo transport (Brickley 
et al., 2005). In addition to mitochondria, TRAK proteins have also been shown 
to regulate the endocytic traffic of γ-aminobutyric acid type A (GABAA) 
receptors in mice (Gilbert et al., 2006) and early endosomes (Kirk et al., 2006). 
Both proteins also interact with β O-linked N-acetylglucosamine transferase, 
which post-translationally modifies TRAK proteins by glycosylation (Pekkurnaz 
et al., 2014). 
TRAK proteins were initially described in Drosophila, where the deletion of their 
orthologue, dMilton, strongly affects neuronal development by altering 
mitochondrial motility, with mitochondria accumulating in neuronal cell bodies 
and being absent from axons and synapses (Glater et al., 2006; Stowers et al., 
2002). Additionally, TRAK1 silencing in hippocampal mouse neurons also led to 
a decrease in mitochondrial motility in the axons (Brickley and Stephenson, 
2011). This effect was not observed for TRAK2, pointing to differences in 
motility regulation between these proteins. 
In chapter 4, we showed that MIRO1 is targeted to peroxisomes and plays a 
role in this organelle’s motility. Since TRAK1 forms a complex with MIRO 
proteins and regulates mitochondrial motility, we looked at its localisation in 
COS-7 cells and its possible role in peroxisome motility. 
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5.2. Results 
5.2.1. TRAK proteins are targeted to peroxisomes in cells expressing 
MIRO1 
The adaptor protein TRAK1 interacts with KHC, enabling the transport of 
several cargoes such as mitochondria and endosomes (Brickley and 
Stephenson, 2011; Kirk et al., 2006). Due to its role in MIRO1-dependent 
mitochondrial motility, we decided to examine its subcellular localisation in 
mammalian cells and possible role in peroxisome motility. To do this, GFP-
TRAK1 was expressed in COS-7 cells on its own or co-expressed with myc-
MIRO1WT and myc-MIRO1WT-Pex (Figure 5.1). As previously described, 
expression of TRAK1 proteins induced the formation of bulbous and thread-like 
mitochondria, as well as perinuclear mitochondrial clusters in COS-7 cells 
(Figure 5.1) (Fransson et al., 2006). When expressed on its own, GFP-TRAK1 
was not detected on peroxisomes (Figure 5.1 a-e) and had no effect on 
peroxisome morphology and distribution. However, when co-expressed with 
myc-Miro1WT and myc-MIRO1WT-Pex, TRAK1 was targeted to both 
mitochondria and peroxisomes (Figure 5.1 f-j and p-t). In these cells peroxisome 
morphology and distribution was identical to that of cells expressing MIRO1 
alone, making it difficult to discern any TRAK1-dependent phenotype on 
peroxisomes. Similar results were obtained upon expression of GFP-TRAK2 in 
these cells (not shown). 
 
5.2.2. TRAK1 patient fibroblasts have an altered mitochondrial 
distribution but no effect on peroxisome distribution/motility 
TRAK1 appears to play an essential role in mitochondrial motility and, as a 
result, in neuronal health. Both TRAK1 knockout in Drosophila and knockdown 
in mouse hippocampal neurons had severe effects on mitochondrial distribution 
and impaired synaptic activity (Brickley and Stephenson, 2011; Stowers et al., 
2002). Recently, a patient with a TRAK1 mutation has been identified, who 
presents severe neurodevelopmental defects (unpublished data). As part of a 
collaboration with Dr. Yair Anikster (Sheba Medical Center, Israel), we received 
primary skin fibroblasts from this patient for analysis. Control and patient 
fibroblasts were fixed and stained using antibodies against PEX14 (peroxisomal 
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Figure 5.1 – TRAK1 is targeted to peroxisomes when co-expressed with 
MIRO1. COS-7 cells were transfected by turbofect with GFP-TRAK1 (all), myc-
MIRO1WT (f-o) or myc-MIRO1WT-Pex (p-t), and stained with antibodies 
against myc, TOM20 (mitochondrial marker) and PEX14 (peroxisomal marker). 
Arrows point to the presence (g-I, q-s) or absence (b-d) of signal co-localisation 
with peroxisomes. Expressed GFP-TRAK1 is targeted to mitochondria and 
induces the formation of elongated, globular or clustered networks. GFP-TRAK1 
is targeted to peroxisomes in the presence of MIRO1. All images are confocal 
microscopy. Scale bar: overview 20 µm, overlay 5 µm.  
  
marker) and TOM20 (mitochondrial marker). As shown in figure 5.2A, 
peroxisomes from patient fibroblasts had a normal morphology and distribution 
when compared with control cells. Furthermore, no changes in peroxisome 
number were observed (Figure 5.2B). In contrast, the majority of cells presented 
an altered mitochondrial distribution, with clustered mitochondria around the 
nucleus, resembling the phenotype of MIRO1 KO MEFs (Nguyen et al., 2014). 
To analyse peroxisome motility, control and patient fibroblasts were 
microporated with GFP-SKL and imaged using a spinning disc microscope.  
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Figure 5.2 – TRAK1 patient fibroblasts maintain normal peroxisome 
distribution and motility. (A) Control and TRAK1 patient fibroblasts were fixed 
and stained with antibodies against PEX14 and TOM20. Peroxisomes are 
uniformly distributed in control and patient cells, reaching the periphery, 
whereas mitochondria cluster near the nucleus. Representative images 
depicting organelle distance from the nucleus to the cell periphery. All images 
are epifluorescence microscopy. Scale bar: 20 µm. (B) Quantitative analysis of 
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peroxisome number in control and patient fibroblasts. No changes in 
peroxisome number were observed in patient fibroblasts (518 ± 34 vs 598 ± 33). 
Values represent mean ± SEM of 31 cells obtained from three independent 
experiments (C-D) Analysis of peroxisome motility in control and patient cells 
expressing GFP-SKL. (C) Cumulative distribution function (CDF) of control (blue 
line) and patient cells (red line), plotted against peroxisome speed. A threshold 
of 0.24 µm/s was defined for microtubule dependent-motility (Bonekamp et al., 
2012). No changes in peroxisome motility were observed between control and 
patient fibroblasts. (D) Percentage of fast moving peroxisomes per cell in 
control (2.75 ± 0.22) and patient cells (2.47 ± 0.17). Values represent mean ± 
SEM of 25 to 27 cells obtained in three independent experiments (ns: not 
significant; two-tailed unpaired t-test).  
 
Analysis of peroxisome motility revealed no differences in long range, 
microtubule-dependent motions between controls and patient fibroblasts, in 
agreement with the immunofluorescence results (Figure 5.2C-D). These 
observations reveal that a loss of TRAK1 function appears to specifically affect 
mitochondrial distribution and motility in fibroblasts. 
 
5.3. Discussion 
Several proteins have been shown to bind and regulate MIRO function. The 
most prominent of these, TRAK1 and TRAK2, form a complex with MIRO 
proteins and molecular motors to enable organelle motility (reviewed in Devine 
et al., 2016). Due to MIRO1’s newly discovered role in peroxisome motility, we 
decided to analyse if TRAK proteins are also targeted to peroxisomes and a 
possible role for TRAK1 in peroxisome motility.  Expression of either TRAK1 or 
TRAK2 revealed a mitochondrial localization as previously described (Fransson 
et al., 2006; MacAskill et al., 2009a). In these cells, no clear co-localization was 
seen with peroxisomes. This could be due to either a complete absence of 
TRAK proteins from peroxisomes, or a low abundance of MIRO binding 
partners at peroxisomes, which would limit the detection of this protein. Since 
COS-7 have been shown to express low levels of MIRO1 (Fransson et al., 
2003), additional studies could be perform using HepG2 cells which have a 
higher level of endogenous MIRO1. However, a clear peroxisomal localization 
was seen when GFP-TRAK1 was co-expressed with myc-MIRO1WT and myc-
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MIRO1WT-Pex. Co-expression of either MIRO1 plasmids induced the formation 
of peroxisome accumulations at the cell periphery, without any further 
observable changes on peroxisome morphology and distribution. Although 
these results show us that TRAK proteins can be targeted to peroxisomes in the 
presence of high levels of MIRO1, further studies should be performed to 
determine if these proteins are de facto peroxisomal proteins, or if additional 
proteins are regulating the MIRO1 motility complex at peroxisomes. 
Furthermore, we looked at peroxisome morphology, distribution and motility in 
TRAK1 patient fibroblasts. In contrast to mitochondria, all peroxisomal 
parameters analysed were similar to control cells. Although these results further 
point to the absence of endogenous TRAK1 at peroxisomes, it should be noted 
that no peroxisomal alterations were observed in MIRO1 KO MEFs. As 
previously suggested, it is possible that TRAK1 is present at peroxisomes but 
its role can be compensated for by either TRAK2, or a different motility complex. 
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Chapter 6 – General discussion  
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Peroxisomes were initially identified and characterised by Rhodin and De Duve 
more than 50 years ago (De Duve and Baudhuin, 1966; Rhodin, 1954), and 
over the past few decades numerous groups have strived to understand their 
functions and dynamics, regularly identifying new proteins and mechanisms 
associated with this essential organelle. Nevertheless, and as several recent 
studies have shown, there are still huge gaps in our understanding of basic 
peroxisome function. In this thesis, we set out to further characterise 
peroxisomes by investigating two specific questions: the targeting of TA 
proteins to this organelle and the regulation of peroxisome motility in 
mammalian cells. 
In chapter 3, using in vivo and in silico techniques, we were able to identify the 
biochemical parameters that direct the targeting of peroxisomal TA proteins, 
and to develop a tool to predict targeting of these proteins to peroxisomes, 
mitochondria and the ER. In chapter 4, we analysed one specific TA protein – 
MIRO1, which was found to be dually targeted to peroxisomes and 
mitochondria, and to play a key role in peroxisome motility and dynamics. 
One of the prevailing themes that we regularly came across was the close 
connection between peroxisomes and mitochondria. As seen in chapter 3, 
several TA proteins are shared between peroxisomes and mitochondria, and in 
the absence of peroxisomes, several of this organelle’s proteins are re-directed 
to mitochondria, pointing to a very permissible targeting system between these 
two organelles. Additionally, these shared proteins are responsible for several 
processes such as organelle division, antiviral signalling and organelle motility, 
implicating a synchronised response of both organelles to maintain cellular 
homeostasis. 
In this discussion we aim to integrate our results from an evolutionary point of 
view, highlighting the close interaction between peroxisomes and mitochondria. 
 
6.1. TA protein promiscuity and its role in organelle evolution 
Protein targeting is generally considered to be a tightly regulated process that 
enables any given protein to find its destination in order to perform its function. 
In line with this, cells have developed several mechanisms in order to regulate 
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gene expression, RNA localisation, protein import, amongst others, controlling 
every step of the way. Concurrently, defects in any of these steps or mutations 
on the protein itself which induce its mistargeting are associated with 
deleterious effects. However, when looking at the targeting of TA proteins, it 
appears that not all proteins in the cell follow these rules so strictly.  
Several TA proteins have been show to target more than one organelle, taking 
advantage of less stringent targeting information. Previous studies have found 
that TA protein targeting is not dependent on a conserved sequence or 
structural conformation, but on several physicochemical parameters (reviewed 
in Borgese and Fasana, 2011). Our own results support this by showing that a 
balance between high positive C-terminal charge and moderate TMD 
hydrophobicity enables peroxisomal targeting of TA proteins. But how does this 
bend the rules? In a hypothetical scenario of a shift in protein targeting from 
organelle A to B, it would take several localised and specific mutations to 
delete/create a targeting signal in order to change the proteins cellular 
localisation. In the case of TA proteins, a single mutation in the TMD or tail 
sequence could increase/decrease either TMD hydrophobicity or tail charge and 
slightly shift the targeting from one organelle to another, without completely 
depleting the original organelle of its necessary protein. This situation can be 
observed in our own results. As shown in figure 3.4, GFP-ACBD5TMD-T WT is 
targeted exclusively to peroxisomes in the majority of cells, with some cells 
presenting dual targeting to mitochondria and peroxisomes (~15%). Just two 
point mutations in the tail region, that replace charged residues for uncharged, 
were able to change this balance to ~35% of shared peroxisomal and 
mitochondrial targeting, and the majority of cells with exclusively mitochondrial 
targeting. This gradual change in protein localisation shows that, in the case of 
TA proteins, one single mutation is unlikely to completely inhibit targeting to the 
original organelle, therefore maintaining its function. Furthermore, the targeting 
to a new organelle is likely to be gradual, with lower levels of the protein being 
recognised by the new system’s chaperone, and possibly having minor 
deleterious effects. This could both promote a gain of function for the new 
organelle, but at the same time give it time to adapt to a new protein, offering 
the cell an evolutionary advantage.  
139 
One of the main advantages of such a system would be the organelle’s gain of 
function. If a single mutation is capable of transferring the basic component of, 
for example, a signalling process to a new organelle, this would likely strongly 
affect the homeostatic outcome of a cell. For example, MAVS is one of the core 
members of an antiviral signalling pathway (Dixit et al., 2010), and its dual 
targeting to mitochondria and peroxisomes effectively recruits cytosolic 
elements of this pathway to both organelles, but it also enables the existence of 
two signalling nixes that can play different roles in antiviral response, evolving 
additional levels of regulation.  
From a different point of view, we could question why would it be advantageous 
for a protein to be targeted to more than one organelle when, by definition, 
protein compartmentalization is considered an advantage to separate and 
regulate different cellular processes? One way to look at it would be to consider 
the advantage of sharing the division machinery, in particular MFF, FIS1, 
GDAP1 and DLP1. Taking into account the previously suggested hypotheses 
that 1) mitochondria appeared before peroxisomes in eukaryotic cells and 2) 
peroxisomes are derived from the ER (Bolte et al., 2015), we could reasonably 
suggest that this pathway originated to divide mitochondria that couldn’t 
otherwise form de novo to regenerate the organelle population. If so, the later 
acquisition of these proteins by peroxisomes would allow them to further 
distance themselves from the ER, enabling them to independently regenerate 
and become self-sustained. Whereas an obvious disadvantage would be that 
the loss of function of one protein would affect both organelles, we should 
consider that, so far, several TA proteins play essential roles in cellular viability 
(Schrader et al., 2014), so there shouldn’t be any selection against their 
sharing. Also, depending on the membrane to which they are targeted, each 
protein can be further regulated by organelle specific factors (e.g. MID49/MID51 
at mitochondria and PEX11 at peroxisomes) (Koch and Brocard, 2012; Palmer 
et al., 2011). 
 
6.2. MIRO1 and the evolution of motility pathways for peroxisomes 
As mentioned above, peroxisomes and mitochondria have a very close 
connection (Schrader et al., 2015a). Both organelles have long been shown to 
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share some metabolic functions, such as fatty acid β-oxidation and ROS 
degradation, and have more recently been shown to share components of their 
division, antiviral and motility machineries.  
As shown in chapter 4, the TA protein MIRO1 regulates peroxisome motility in 
mammalian cells. This protein has been previously shown to form a complex 
with TRAK proteins and KIF5 (also known as kinesin 1 and KHC) and dynein 
motors, enabling mitochondrial motility through microtubules (reviewed in 
Devine et al., 2016). Concurrently, peroxisome motility in mammalian cells has 
also been shown to rely on the microtubule network (Schrader et al., 1996; 
Wiemer et al., 1997), but until now no clear link between the organelle and 
motors had been identified.  
It is interesting to notice that, unlike the division machinery, which is partly 
conserved between yeast and mammals, the same does not appear to occur for 
the motility complex. In the budding yeast Saccharomyces cerevisiae, although 
both mitochondria and peroxisomes rely on the same myosin, Myo2, for actin-
dependent motility, they use different organelle-motor connectors: Mmr1 and 
Ypt11 for mitochondria, and Inp2 for peroxisomes (reviewed in Knoblach and 
Rachubinski, 2015). One clear difference between mammalian cells and 
budding yeast is the reliance on the microtubule cytoskeleton for the former and 
on actin filaments for the latter. This on itself justifies the existence of a different 
motility complex. Interestingly, additional forms of peroxisomal transport have 
been identified in other microorganisms. In the fission yeast 
Schizosaccharomyces pombe, peroxisomes exhibit a mix of slow erratic 
movements and fast directed motility, resembling microtubule-dependent 
motility. However, depolymerisation of the microtubule or actin cytoskeleton has 
no effect on peroxisome motility in these cells (Jourdain et al., 2008). Instead, 
peroxisome motility appears to rely on a close association of this organelle with 
the surface of mitochondria. Another interesting example of peroxisome motility 
occurs in the filamentous fungus Ustilago maydis. In this organism, peroxisomal 
motility relies on the microtubule cytoskeleton. However, instead of having a 
motility complex that interacts directly with microtubules, peroxisomes have 
been suggested to hitchhike on moving endosomes (Guimaraes et al., 2015; 
Salogiannis et al., 2016). How these different motility pathways have evolved is 
still unknown. 
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Furthermore, it would be interesting to investigating the targeting of MIRO1 in 
some of the organisms mentioned above. The yeast homolog of MIRO1, Gem1, 
is targeted to mitochondria and has been suggested to interact and regulate the 
mitochondria-ER tethering complex ERMES (Kornmann et al., 2011). If found 
on peroxisomes, this protein could likewise play a role on a peroxisome-ER 
tethering complex. Additionally, as both S. pombe and U. maydis rely on 
microtubule-dependent motility to move several organelles, it would be 
interesting to look for a MIRO1 homolog, analyse its localisation and possible 
role in these organisms. Concurrently, it would be interesting to investigate if 
peroxisome motility in mammalian cells is always dependent on a direct 
interaction with microtubules, or if they are also capable of hitchhiking with other 
organelles. 
 
6.3. Future work 
In this thesis we significantly improved the current knowledge on the targeting of 
TA proteins to cellular membranes and the regulation of peroxisome motility in 
mammalian cells. Nevertheless, several questions still remain regarding these 
two processes, such as: 
- Which additional factors regulate TA protein targeting to each organelle? 
Is it possible that posttranslational modification can favour/inhibit dual 
targeting of TA proteins to each organelle? 
- How are TA proteins recognised and targeted to mitochondria? 
- Which proteins regulate MIRO1 function on peroxisomes? 
Regarding TA proteins, it would be interesting to analyse the function and 
targeting of the several still uncharacterised TA proteins. This would potentially 
shed some light on additional factors regulating the targeting of these proteins. 
Furthermore, an extensive analysis of known mitochondrial chaperones and 
their affinity for mitochondrial TA proteins could further improve our knowledge 
of the mechanisms that regulate the targeting to this organelle. Finally, the 
identification of new TA proteins would allow us to further strengthen our current 
predictor, as well as improve it by adding additional physicochemical 
parameters. 
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Concerning peroxisome motility, the identification of MIRO1’s regulators at 
peroxisomes would improve our understanding of peroxisome motility and its 
function on peroxisomal homeostasis. To compliment this, the use of recently 
developed optogenetic techniques to regulate peroxisome motility in 
mammalian cells would facilitate the analysis of peroxisome positioning on 
organelle function. Optogenetics enables the regulation of protein dimerization 
using a light beam, allowing, for example, a tight temporal control of peroxisome 
motility by inducing the binding of a kinesin motor to a membrane anchor 
(Bergeijk et al., 2015). Despite the many advantages of this technique, the 
experimental set up necessary for its implementation hamper its general use. 
Additionally, it would be interesting to analyse MIRO2 and its role at 
peroxisomes and the ER. 
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